



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/00, C12N 1/15, 1/21, 5/10, 15/12, 15/63	A1	(11) International Publication Number: WO 99/43693 (43) International Publication Date: 2 September 1999 (02.09.99)															
(21) International Application Number: PCT/US99/03939 (22) International Filing Date: 24 February 1999 (24.02.99) (30) Priority Data: <table border="0"> <tr> <td>60/076,051</td> <td>26 February 1998 (26.02.98)</td> <td>US</td> </tr> <tr> <td>60/076,052</td> <td>26 February 1998 (26.02.98)</td> <td>US</td> </tr> <tr> <td>60/076,053</td> <td>26 February 1998 (26.02.98)</td> <td>US</td> </tr> <tr> <td>60/076,054</td> <td>26 February 1998 (26.02.98)</td> <td>US</td> </tr> <tr> <td>60/076,057</td> <td>26 February 1998 (26.02.98)</td> <td>US</td> </tr> </table> (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). FLORENCE, Kimberly [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). BREWER, Laurie, A. [US/US]; 410 Van Dyke Street #115, St. Paul, MN 55119-4321 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). DUAN,		60/076,051	26 February 1998 (26.02.98)	US	60/076,052	26 February 1998 (26.02.98)	US	60/076,053	26 February 1998 (26.02.98)	US	60/076,054	26 February 1998 (26.02.98)	US	60/076,057	26 February 1998 (26.02.98)	US	Roxanne, D. [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). (74) Agents: BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</i>
60/076,051	26 February 1998 (26.02.98)	US															
60/076,052	26 February 1998 (26.02.98)	US															
60/076,053	26 February 1998 (26.02.98)	US															
60/076,054	26 February 1998 (26.02.98)	US															
60/076,057	26 February 1998 (26.02.98)	US															
(54) Title: 36 HUMAN SECRETED PROTEINS (57) Abstract <p>The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.</p>																	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

36 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are less than 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of the coding sequence, but do not comprise all or a portion of any intron. In another embodiment, the nucleic acid comprising the coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene in the genome).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence

of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42°C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress

background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or

without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.

Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: HSSLPHFSSRI (SEQ ID NO:85). Polynucleotides encoding

these polypeptides are also encompassed by the invention. Contact of cells with supernatant expressing the product of this gene induces the expression of osteocalcin in human SOAS-2 osteoblastic cells. Osteocalcin is a protein attributed to influencing the bone mineralization of skeletal tissue, and is also thought to be useful in inhibiting osteoblast function. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, inducing the expression of osteocalcin.

This gene is expressed primarily in B-cell lymphoma, and to a lesser extent in brain tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the hematopoietic system and brain, including cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, central nervous system, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in B-cell lymphoma and brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of disorders of the hematopoietic system and the central nervous system, as well as cancers thereof. The expression of this gene in B-cell lymphoma indicates that this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Alternatively, the tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1427 of SEQ ID NO:11, b is an integer of 15 to 1441, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

25

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RDSNGRGDSSLLKFVCPVPLKK (SEQ ID NO:86). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 2. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 2.

30

This gene is expressed primarily in brain and embryonic tissues, and to a lesser extent in several other tissues and organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and developmental diseases and cancers. Similarly,

35

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and developing systems, expression of this gene at significantly higher or lower levels may
5 be routinely detected in certain tissues or cell types (e.g., neurological, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not
10 having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:49 as residues: Ile-35 to Lys-40.

The tissue distribution in brain and embryonic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the
15 diagnosis, treatment, and/or prevention of disorders of the neural system, as well as cancer. The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania,
20 dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein
30 may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ
35 ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2146 of SEQ ID NO:12, b is an integer of 15 to 2160, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

10 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IPEYTFRRRWFH (SEQ ID NO:87). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in breast lymph nodes, brain tissue, hematopoietic cells and cancerous tissues.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancer and diseases of the hematopoietic and central nervous systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
20 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neurological, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample
25 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in hematopoietic and neural tissues indicates that
30 polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of disorders of the hematopoietic system, the central nervous system, and cancers thereof, particularly leukemias. Expression of this gene product in normal and cancerous lymph nodes indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all
35 hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other

processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Alternatively, the tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1188 of SEQ ID NO:13, b is an integer of 15 to 1202, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LCVSMKIEWGRESCEKK (SEQ ID NO:88). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in leukemia cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases of the hematopoietic system and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in leukemia cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of disorders of the hematopoietic system and cancers thereof, particularly leukemia, as well as cancers of other tissues where expression has been observed. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1540 of SEQ ID NO:14, b is an integer of 15 to 1554, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

10 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RLKTTRAYSSQFWRPEVQNQGVKRV (SEQ ID NO:89). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in CD-34 Positive cord blood cells.

15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, diseases and disorders of the immune and hematopoietic system, in addition to developing cells and tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above
20 tissues or cells, particularly of the immune and hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a
25 disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in CD34 (+) cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of disorders of the hematopoietic and immune systems, including cancers
30 thereof. Furthermore, expression of this gene product in CD34 (+) cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by
35 boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor

marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1526 of SEQ ID NO:15, b is an integer of 15 to 1540, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LTLCLPRSLYALPQCPGPHVHPCALLWDRAGLPLPLPG CIHGRSQVPWHELHSPA AFNQGMGMCTYPTPLGRVMLRCGFLTVPRLSQA WVVWVPTVGAGVISYLRRPFLPVLCAPTPTLELPRFSVFVKELTLCCLPLSQCP CHSCEPAAGEVGADLCVAG (SEQ ID NO:90), LTLCLPRSLYALPQCPGPHVHPC ALLWDRAGLPLPLPGCI (SEQ ID NO:91), HGRSQVPWHELHSPA AFNQGM GMCTYPTPLGRVMLR (SEQ ID NO:92), CGFLTVPRLSQA WVVWVPTVGA GVISYLRRPFLPVLCAPT (SEQ ID NO:93), and/or PTLELPRFSVFVKELTLCCL PLPLSQCPCHSCEPAAGEVGADLCVAG (SEQ ID NO:94). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in lymph nodes, thymus and chronic synovitis tissues, and to a lesser extent in several other tissues and organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, immune and inflammatory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, musculo-skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of inflammatory and hematopoietic disorders. Furthermore, expression of this gene product in thymus and lymph nodes indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1043 of SEQ ID NO:16, b is an integer of 15

to 1057, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 7

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IRHETFRVRGCSISRALSPFPLPFPHPGRSGWSGPEAK (SEQ ID NO:95). Polynucleotides encoding these polypeptides are also encompassed
10 by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in embryonic, placental and umbilical vein
15 tissues, and to a lesser extent in several other tissues and organs, including cancerous tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, disorders of developing organs, growth disorders, and cancer(s).
20 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing and fetal systems, highly vascularized tissues and cancer, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues
25 or cell types (e.g., embryonic, placental, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution in placental and embryonic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of diseases of developing, embryonic, and/or fetal systems, as well as growth disorders and cancer(s). Furthermore, the tissue distribution in placental tissue indicates that polynucleotides and polypeptides
35 corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function.

Alternatively, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Likewise, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2066 of SEQ ID NO:17, b is an integer of 15 to 2080, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

This gene is expressed primarily in the hematopoietic system, the central nervous system, and developing systems, as well as in cancer(s), and to a lesser extent in several other tissues and organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic diseases, developmental disorders, central nervous system, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, hematopoietic system, and cancer, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neurological, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:55 as residues: Lys-37 to Ile-45.

The tissue distribution in immune and neurological tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment, and/or prevention of disorders of the hematopoietic system, the central nervous system, and cancer(s). This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Alternatively, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders

associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 588 of SEQ ID NO:18, b is an integer of 15 to 602, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

This gene is expressed primarily in fetal skin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, growth and skin abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of epithelial structures, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., epithelial, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal epithelium indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of growth and skin disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine

syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e., wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma.

Moreover, such disorders may predispose an individual (i.e. increase an individuals susceptibility) to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athletes foot, and ringworm). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 615 of SEQ ID NO:19, b is an integer of 15 to 629, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

When tested against sensory neuronal cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates sensory neuron cells, and to a lesser extent other neuronal cells, through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in epileptic frontal cortex tissue of the brain, and to a lesser extent in fetal heart tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurological and cardiovascular abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and vascular systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neurological, vascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:57 as residues: Pro-43 to Pro-50, Asn-65 to Gly-70.

The tissue distribution in frontal cortex tissue of the brain and fetal heart tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of nervous system and cardiovascular disorders. The tissue distribution in frontal cortex tissue, in conjunction with the observed biological activity data, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the brain and nervous system. Elevated expression of this gene product within the frontal cortex of the brain indicates that it may be involved in neuronal survival; synapse formation; conductance; neural differentiation, etc. Such involvement may impact many processes, such as learning and cognition. It may also be useful in the treatment of such neurodegenerative disorders as schizophrenia; ALS; or Alzheimer's.

Alternatively, the tissue distribution in fetal heart tissue indicates that the protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis, and wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2053 of SEQ ID NO:20, b is an integer of 15 to 2067, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The translation product of this gene shares sequence homology with the polypeptide sequence of a novel protein ETI-1, which has cytostatic activity. ETI-1 is thought to be useful as an anti-tumor agent. Based on the sequence similarity, the translation product of this clone is expected to share biological activities with cytostatic proteins. Such activities are known in the art and described elsewhere herein. When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent other immune cells, through the Jak-STAT signal transduction pathway.

The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PDSRPEAR GDH VVRPSRGLRVTGATRSIMGPWGEP ELLVWRPEAVASEPPVPV GLEVKLGALVLLLVL TLLCSLVPICVLR RPGANHEGSASRQKALSLVSCFAGGVFLATCLLDLLPDYLA AIDEALAALHVTLQFPLQEFILA (SEQ ID NO:96), PDSRPEAR GDH VVRPSRGLRVTGATRSIMGPWGEP (SEQ ID NO:97), ELLVWRPEAVASEPPVPV GLEVKLGALVLLLVL TLLC (SEQ ID NO:98), SLVPICVLR RPGANHEGSASRQKALSLVSCFAGGVF (SEQ ID NO:99), and/or LATCLLDLLPDYLA AIDEALAALHVTLQFPLQEFILA (SEQ ID NO:100).

Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

35

This gene is expressed primarily in endocrine organs and cancerous tissues, such as pancreas and endometrial tumors, as well as neuroblastomas, and to a lesser extent in various normal and transformed cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hormonal abnormalities and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders
10 of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endocrine, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,
15 relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:58 as residues: Lys-17 to Glu-27, Gln-40 to Gly-47.

The tissue distribution in cancerous tissues such as pancreatic and endometrial
20 tumors, in conjunction with the observed biological activity data and the homology to a protein known to have cytostatic activity, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of tumors of various tissue types, such as pancreas and endometrium, as well as cancers of other tissues where expression has been observed. Protein, as well as, antibodies
25 directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present
30 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 983 of SEQ ID NO:21, b is an integer of 15 to
35 997, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: KYILSSPLLDLSLAEHKNLVWKSFLPRNF (SEQ ID NO:101).

5 Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in leukemic spleen tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, leukemia and other cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution in leukemic spleen tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of immune disorders and neoplasias, as well as cancers of other tissues where expression has been observed. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1369 of SEQ ID NO:22, b is an integer of 15 to 1383, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

In specific embodiments, polypeptides of the invention comprise the following
5 amino acid sequence: YGKVVDLAPLHLDARISLSTLQQQLGQPEKALEALEPM
YDPDTLAQDANAAQXELKLLLHRSTLLFSQ GK (SEQ ID NO:102).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is thought to reside on chromosome 2.

Accordingly, polynucleotides related to this invention are useful as a marker in linkage
10 analysis for chromosome 2.

This gene is expressed primarily in hematopoietic tissues such as fetal
liver/spleen, and to a lesser extent in several other normal and transformed cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
15 biological sample and for diagnosis of diseases and conditions, which include, but are
not limited to, immune and growth abnormalities. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing immunological probes
for differential identification of the tissue(s) or cell type(s). For a number of disorders
of the above tissues or cells, particularly of the immune system, expression of this gene
20 at significantly higher or lower levels may be routinely detected in certain tissues or cell
types (e.g., immune, liver, cancerous and wounded tissues) or bodily fluids (e.g.,
lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell
sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
25 individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID
NO:60 as residues: Ser-31 to Arg-36, Ser-44 to Glu-55, Asp-112 to Glu-119, Lys-132
to Asn-139, Asn-148 to Leu-154, Thr-214 to Leu-220, Gly-260 to Ser-265.

The tissue distribution in immune tissues such as fetal liver/spleen indicates that
30 polynucleotides and polypeptides corresponding to this gene are useful for the study
and/or treatment of immune disorders. Expression of this gene product in fetal
liver/spleen tissue indicates a role in the regulation of the proliferation; survival;
differentiation; and/or activation of potentially all hematopoietic cell lineages, including
blood stem cells. This gene product may be involved in the regulation of cytokine
35 production, antigen presentation, or other processes that may also suggest a usefulness
in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1499 of SEQ ID NO:23, b is an integer of 15 to 1513, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DFMETFPDFCLPLAPHYLGKAALWAMCPGRAWAGCGPV LRTSHLGPHSALPSWCNICXQAIVGAGRQRGLSEDPTCASHWDTKTGLVPSCG AGKGI (SEQ ID NO:103), DFMETFPDFCLPLAPHYLGKAALWAMCPGRAWAG CGPVLRTSHL (SEQ ID NO:104), and/or GPHSALPSWCNICXQAIVGAGRQRGL SEDPTCASHWDTKTGLVPSCGAGKGI (SEQ ID NO:105). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in cerebellum tissue, and to a lesser extent in fetal liver, synovial sarcoma and glioblastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative diseases and brain tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., nervous, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and in cerebellum tissue and fetal liver tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of immune, neurodegenerative and cognitive disorders and neoplasias. The tissue distribution in cerebellum tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Alternatively, expression of this gene product in fetal liver indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have

commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.
- 10 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1030 of SEQ ID NO:24, b is an integer of 15 to 1044, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

- 20 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RLPQRGQWAWVLQDALGIAFCLYMLKTIRLPTFKACTL LLLVLFLYDIFFVFITPFLTKSGSSIMVEVATGPSDSATREKLPMVLKVPRLNSSP LALCDRPFSLGFGDILVPGLLVAYCHRFDIQVQSSRVYFVACTIAYGVGLLVTF VALALMQRGQPALLYLPCTLVTSCAVALWRRELGVFWTGSGFAKVLPPSPW APAPADGPQPPKDSATPLSPQPPSEEPATSPWPAPAEQSPKSRTSEEMGAGAPMRE
- 25 PGSPAESEGRDQAQPSPTQPGASA (SEQ ID NO:106), RLPQRGQWAWVLQD ALGIAFCLYMLKTIRLPTFKACTLLLLVL (SEQ ID NO:107), FLYDIFFVFITPF LTKSGSSIMVEVATGPSDSATREKLPMVLKV (SEQ ID NO:108), PRLNSSPL ALCDRPFSLGFGDILVPGLLVAYCHRFDIQVQSSR (SEQ ID NO:109), VYFV ACTIAYGVGLLVTFVALALMQRGQPALLYLPCTLVTSC (SEQ ID NO:110),
- 30 AVALWRRELGVFWTGSGFAKVLPPSPWAPAPADGPQPPKD (SEQ ID NO:111), SATPLSPQPPSEEPATSPWPAPAEQSPKSRTSEEMGAGAPMRE (SEQ ID NO:112), and/or PGSPAESEGRDQAQPSPTQPGASA (SEQ ID NO:113). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 19. Accordingly,
- 35 polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in brain and placental tissue, and to a lesser extent in various other normal and transformed tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, placental, neurological and cancerous abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the placenta and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neurological, placental, lung, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:62 as residues: Gly-127 to Asp-134, Gly-194 to Arg-201, His-205 to Glu-217, Pro-275 to Arg-280, Pro-287 to Gln-294, Arg-315 to Arg-325.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of central nervous system disorders and neoplasias. Furthermore, the tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioral disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Alternatively, the tissue distribution in placental tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by

the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus.

Moreover, expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in
5 endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body.
10 Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present
15 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2561 of SEQ ID NO:25, b is an integer of 15
20 to 2575, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 16

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ESSGLPALGPRRRPWEQRWSDPITLK (SEQ ID NO:114), and/or LTLALDEIRLLKKDLGLIEMKKTDSEKRFGSVSFG RSCRLIPHALASWL QTLILCFCCRIC (SEQ ID NO:115). Polynucleotides encoding these polypeptides are
30 also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

This gene is expressed primarily in placental and embryonic tissues and PHA activated T-cells.

35 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, growth and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing and immune systems,

5 expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developing, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue

10 or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:63 as residues: Arg-21 to Leu-26.

The tissue distribution in placental and embryonic tissues, as well as in T-cells, indicates that polynucleotides and polypeptides corresponding to this gene are useful for

15 the study and/or diagnosis of growth and immune disorders. Furthermore, the tissue distribution in placental and embryonic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental

20 function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus.

Moreover, expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in

25 endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body.

30 Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein

35 may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy.

Alternatively, expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 704 of SEQ ID NO:26, b is an integer of 15 to 718, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

30

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GRPTRPVMAIQSLHPCPSELCCRACVXFYHWA (SEQ ID NO:116). Polynucleotides encoding these polypeptides are also encompassed by the invention.

35

This gene is expressed primarily in activated monocytes, primary dendritic cells, and GM-CSF stimulated macrophages, and to a lesser extent in activated T-cells and adult brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune regulation and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:64 as residues: Thr-24 to Gly-42, Glu-53 to Gly-58.

The tissue distribution in immune cells and leukocytes such as monocytes, macrophage, primary dendritic cells, and T-cells, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and/or treatment of immune dysfunction and other immune disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in T cells and primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present

invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of
5 a-b, where a is any integer between 1 to 640 of SEQ ID NO:27, b is an integer of 15 to 654, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

10 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The translation product of this gene shares sequence homology with NADH ubiquinone oxidoreductase B15 complex, which is thought to be important in cellular respiration and metabolism. In specific embodiments, polypeptides of the invention
15 comprise the following amino acid sequence: NSKNTRNERSFLKLFRNIHDIPLTV LENK (SEQ ID NO:117). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal liver/spleen and infant brain tissues, and to a lesser extent in fetal kidney and adipose tissues.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, growth and developmental disorders, and adult metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
25 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developmental and metabolic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, renal, neurological, metabolic, cancerous and wounded tissues) or bodily fluids (e.g.,
30 lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in a number of fetal and infant tissues, as well as the
35 homology to NADH ubiquinone oxidoreductase B15 complex, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and/or treatment of various developmental and growth disorders, and adult

metabolic disorders, such as Tay-Sachs disease, phenylketonuria, galactosemia, hyperlipidemias, porphyrias, and Hurler's syndrome.

Furthermore, the tissue distribution in adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of obesity and other metabolic and endocrine conditions or disorders. Furthermore, the protein product of this gene may show utility in ameliorating conditions which occur secondary to aberrant fatty-acid metabolism (e.g. aberrant myelin sheath development), either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1431 of SEQ ID NO:28, b is an integer of 15 to 1445, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The translation product of this gene shares sequence similarity with neuronal olfactomedin-related ER localized protein isolated from the rat (Genbank accession no. gil442370). In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PRVRGEGNRCWTQGALCHRM (SEQ ID NO:118). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is thought to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

This gene is expressed primarily in synovial sarcoma tissue, and to a lesser extent in fetal dura mater, adipose, and Hodgkin's lymphoma tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are

not limited to, cancers and other metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., musculo-skeletal, metabolic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:66 as residues: Tyr-76 to Lys-81, Glu-92 to Asp-99, Glu-125 to Ile-132, Asp-197 to Arg-204, Gln-241 to Glu-246, Pro-310 to Ala-316, Thr-332 to His-338, Pro-361 to Ser-366, Leu-392 to Thr-399.

The tissue distribution in musculo-skeletal and metabolic tissues, and the sequence similarity to neuronal olfactomedin-related ER localized protein, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and/or treatment of cancers and other metabolic disorders. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes.

Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the

scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2006 of SEQ ID NO:29, b is an integer of 15 to 2020, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The translation product of this gene shares sequence homology with tissue plasminogen activator gene enhancer element which is thought to play a role in blood clotting. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: FPCICLSGLLDLLIWRPFSEELTKTFG (SEQ ID NO:119).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in rhabdomyosarcoma and to a lesser extent in lymphocytic leukemia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cancers and clotting disorders, such as hemophilia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and blood clotting systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, developmental, metabolic disorders, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:67 as residues: Cys-38 to Cys-45, Leu-49 to Ala-54.

The homology to the conserved tissue plasminogen activator gene enhancer element indicates that the protein product of this gene is useful for the study, treatment and diagnosis of cancers and blood clotting disorders. The protein is useful for the treatment, detection, and/or prevention of metabolic and developmental disorders which

include, but are not limited to diabetes, or placental aberrations. The protein is also useful for the treating and ameliorating cardiovascular conditions such as coronary artery disease, atherosclerosis, or arteriosclerosis.

Moreover, the protein is useful in the detection, treatment, and/or prevention of
5 vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. Alternatively, the expression within lymphocytic leukemia cells, combined with its homology to tissue plasminogen activator indicates this gene product may be involved in the regulation of cytokine production, antigen presentation, or other
10 processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such
15 as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus
20 erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

Furthermore, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury (i.e. through modulating integrin function). In addition, this gene product
25 may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
30 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more
35 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1069 of SEQ ID NO:30, b is an integer of 15

to 1083, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 21

The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

10 This gene is expressed primarily in fetal liver, fetal spleen and infant brain and to a lesser extent in human epididymus tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are
15 not limited to, developmental, hematopoietic, immune, CNS, and/or reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of
20 the reproductive, developmental, and central nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, hematopoietic, immune, CNS, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, bile, synovial fluid and spinal fluid) or another tissue or cell sample taken from
25 an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:68 as residues: Pro-29 to Pro-35.

The tissue distribution in fetal liver, fetal spleen and infant brain indicates that
30 the protein product of this gene is useful for the study, diagnosis and treatment of reproductive, developmental, and CNS disorders. Moreover, this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

Similarly, developmental tissues rely on decisions involving cell differentiation
35 and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired

immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may
5 modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
10 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more
15 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1566 of SEQ ID NO:31, b is an integer of 15 to 1580, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The translation product of this gene shares sequence homology with human beta-casein which is thought to be important as a milk component. This sequence
25 encodes a homolog of the human milk protein, beta-casein. This sequence can be used in the production of recombinant human beta- casein for use as a constituent of infant formulae. Beta-casein is a phosphorylated protein which is present in milk of several species including humans in which it is the major casein subunit.

This protein is believed to enhance calcium absorption by chelating calcium to
30 its phosphorylated residues and thereby keeping it in an adsorbable form. Human beta-casein is easily digestible by newborn infants and the digestive products have been found to play an important part in calcium uptake, and thus in the mineralisation of the skeleton. A digestion product of human beta-casein has been found to have opiod activity and may be involved in the sleeping patterns of breast-fed infants.

35 In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: KDTCTRMXIAALFTIAKIWNQPKX (SEQ ID NO:120), RHM

HTYVYCGTIHNSKDLEPTQM XDXIKKMWHLYTTKYAAIKKD (SEQ ID NO:121), RKCPTYIPRNTMQP (SEQ ID NO:122), and/or KRTEFMSFXGTWM KLEAILSKLTQEEKTKHLMFSLISGS (SEQ ID NO:123). Polynucleotides encoding these polypeptides are also encompassed by the invention.

5 This gene is expressed primarily in adult heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive and/or vascular disorders and diseases, particularly
10 deficiency in milk production, atherosclerosis, or coronary artery disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system and mammary glands, expression of this gene at significantly higher or lower
15 levels may be routinely detected in certain tissues or cell types (e.g., reproductive, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the
20 disorder.

The homology to human beta-casein indicates that the protein product of this gene is useful as a constituent of infant formulae. Moreover, the protein is useful for the detection, treatment, and/or prevention of aberrant mammary gland function and diseases, in addition to a possible use in the developmental of novel protein expression
25 for the isolation of heterologous proteins using the beta-casein enhancer, promoter, and encoding nucleotide sequences. Alternatively, the expression in adult heart indicates the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, and/or
30 atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present
35 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 782 of SEQ ID NO:32, b is an integer of 15 to 796, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The translation product of this gene shares sequence homology with a rat protein, dendrin, which is distributed in the dendrites of neurons of the forebrain. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PKSDTSPASSR (SEQ ID NO:124), PKSDTSPASSRLCWD (SEQ ID NO:125), YVPSFLPKATGSIPSRKGGVGSEKPEVPLQTYKEIVHCCEEQVLT LATEQTYAVEGETPINRLSLLSGRVRVSQDGQFLHYIFPYQFMDSPEWESLQP SEEGVFQVTLTAETSCSYISWPRKSLHLLLT KERYISCLFSALLGYDISEKLYT LNDKLFKFGRLRFDIRLPSLYHVLGPTAADAGPESEKGDEEVCEPAVSP PQATP TSLQQTPPCSTPPATTNFPAPPTRARLSRPDSGILASRIPLQSYSQVISRGQAP LAPHTPEL (SEQ ID NO:126), ATGSIPSRKGGVGSEKPEVPL (SEQ ID NO:127), IVHCCEEQVLT LATEQTYAVEGETP (SEQ ID NO:128), QDGQFLHYIFPYQFM DSPEWESL (SEQ ID NO:129), TLTAETSCSYISWPRKSLHLLLT (SEQ ID NO:130), DISEKLYTLNDKLFKFGRLRFDIRL (SEQ ID NO:131), SLYHVLGPTA ADAGPESEKGDEEVCE (SEQ ID NO:132), and/or TTNFPAPPTRARLSRPDSGILA SRIPLQ (SEQ ID NO:133). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in the heart and to a lesser extent, in tonsil.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, cardiovascular disorders and conditions, particularly congestive heart failure. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular and neural systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cardiovascular, vascular, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids

(e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:70 as residues: Met-1 to Ser-7, Asp-41 to Met-48, Pro-61 to Ser-67, Pro-121 to Trp-130, His-161 to Lys-181.

10 The homology to dendrin indicates that the protein product of this gene is useful for the detection, treatment, and/or prevention of neuronal diseases such as memory loss. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, 15 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception.

20 In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Alternatively, the expression in heart tissue indicates the protein is useful in the detection, treatment, and/or prevention of a variety 25 of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

35 Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1242 of SEQ ID NO:33, b is an integer of 15

to 1256, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 24

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: YFSHGICSHA (SEQ ID NO:134). Polynucleotides encoding these polypeptides are also encompassed by the invention.

10 This gene is expressed primarily in peripheral mononuclear cells, and to a lesser extent in other white blood cells such as neutrophils and lymphocytes from lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic or immune disorders and conditions, particularly leukemia and lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:71 as residues: Leu-41 to Pro-48.

The tissue distribution in blood cells indicates that the protein product of this gene is useful for diagnosis and treatment of blood diseases such as leukemia and lymphomas. Moreover, the tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy,

immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1050 of SEQ ID NO:34, b is an integer of 15 to 1064, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

The translation product of this gene was shown to have homology to a conserved ubiquitin thiolesterase (deubiquitinating enzyme) (See Genbank Accession No. sp|Q09738|UBPA_SCHPO) which is thought to be important in protein metabolism, processing, and/or regulation.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NSEDISQTRQELGLCISQ RCLSDRKKSRSGVWVRACT MQFMKHVFPRLISPRP (SEQ ID NO:135), PTRHFCGTSSCLTGTAVRCRAP APVWSVRCPHCFRSSDAWVDPGIPDRYLQ AYLL (SEQ ID NO:136), GEAMDA EXAVAPPGCSHLGSFKVDNWKQNLRAIYQCFVWSGTAEARKRKAKSCICHVC GVHLNRLHSCLYCVFFGCFTKKHIHEHAKAKRHNLAIDL MYGGIYCFLCQDYI YDKDMEIIAKEEQRKAWKMQGVGEKFSTWEPTKRELELLKHNPKRKITSNC TIGLRGLINLGNTCFMNCIVQALHTHTPLLRDFFLSDRHRCMQSPSSCLVCEMS SLFQEFGRVGRPGNSGPVAGVPSIV SPE (SEQ ID NO:137), VAPPGCSHLGS FKVDNWKQNLRAI (SEQ ID NO:138), TAEARKRKAKSCICHVC GVHLNR (SEQ ID NO:139), FTKKHIHEHAKAKRHN LAIDL MY (SEQ ID NO:140), YDKDMEIIA KEEQ RKAWKMQG (SEQ ID NO:141), ELLKHNPKRKITSNCTIGLRGLINLGN (SEQ ID NO:142), GNTCFMNCIVQALHTHTPLLRDFFLSD (SEQ ID NO:143),

and/or EFGRVGRPGNSGPVPAGVPS (SEQ ID NO:144). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in L428 cells, and to a lesser extent, in osteoblasts.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, skeletal diseases and disorders, particularly osteosarcoma or other bone diseases. Similarly, polypeptides and antibodies directed to these polypeptides are
10 useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, metabolic, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
15 plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in osteoblasts indicates that the protein product of this
20 gene is useful for diagnosis and treatment of bone disorders such as osteoporosis. Moreover, the homology to the ubiquitin thiolesterase indicates the protein can be used to arrest proliferation of haematopoietic cells for treating or preventing e.g. cancer especially leukaemias or lymphomas (in addition to other proliferative conditions in other cells or cell types). The protein can also be used to stimulate haematopoietic cell
25 proliferation e.g. to produce blood cells for replacing blood cell depletion due to disease or condition e.g., immune suppression from AIDS or therapy such as chemotherapy or dialysis. The protein may also be used to suppress the immune system e.g. during organ or cell transplantation.

The polynucleotides of the present invention can be used to transform cells for
30 screening agents which inhibit DUB enzyme activity. Furthermore, the protein is useful for the detection and treatment of disorders and conditions affecting the skeletal system, in particular bone cancer, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis,
35 lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal

chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 741 of SEQ ID NO:35, b is an integer of 15 to 755, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

This gene is expressed primarily in cells from Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, hematopoietic or immune diseases and conditions, particularly Hodgkin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:73 as residues: Arg-47 to His-52, Gly-64 to Leu-71.

The tissue distribution in Hodgkin's lymphoma indicates that the protein product of this gene is useful for diagnosis and treatment of hematopoietic and immune disorders and conditions. Moreover, polynucleotides and polypeptides corresponding

to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 590 of SEQ ID NO:36, b is an integer of 15 to 604, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 27

The translation product of this gene shares sequence homology with 'AP2' tumor-specific DNA, which is thought to be important in detecting insertions or deletions in DNA sequences in tumor cells. Such mutations are markers of cancer and can be used in the diagnosis of cancer, esp. colorectal, stomach or pancreatic tumors. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: AFPWPTS (SEQ ID NO:145). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in breast lymph nodes from a breast cancer patient, and to a lesser extent in adrenal gland and tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive and/or immune diseases and disorders, particularly cancers, such as breast cancer, colorectal cancer, and pancreatic cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:74 as residues: Ile-25 to Trp-30.

The tissue distribution breast lymph nodes, combined with the homology to 'AP2 tumor-specific DNA sequence' indicates that the protein product or the DNA sequence of this gene is useful for detecting insertions or deletions in DNA sequences in tumor cells. Such mutations are markers of cancer and can be used in the diagnosis of cancer, esp. colorectal, stomach and pancreatic tumors. Expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases, particularly those of the immune and/or hematopoietic systems. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more

- 5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 798 of SEQ ID NO:37, b is an integer of 15 to 812, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

The translation product of this gene was shown to have homology to a conserved reverse transcriptase homolog which may implicate this protein as playing a
15 role in various DNA processing and modulatory activities (See Genbank Accession No.bbsl80120).

- In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ESNFFYPYDSQLALLSSVTCSAS (SEQ ID NO:146), KTKMF
AFYVQVLNQSKSIFVYSRNLIFFIHMIVSWPSFLQLPAVHQCHQSSVHICGVSGL
20 FPSSNYQCL SLCQNHTVLIITTL (SEQ ID NO:147), SILNVIPNLSKQSFEEDRLI
LKYMQKSKSKRIA KILLSNKKTCPTKY (SEQ ID NO:148), LPQILRWLKYHQSVW
VWVGKQTPVTLHYLTLDLIQEFTP (SEQ ID NO:149), and/or IFVYSRNLIFFIHMIV
SWPSFLQLPAVHQCHQS (SEQ ID NO:150). Polynucleotides encoding these
polypeptides are also encompassed by the invention.

- 25 This gene is expressed primarily in B-cell lymphoma.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune or hematopoietic disorders and conditions, particularly B-cell
30 lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic,
35 developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 The tissue distribution in B-cell lymphoma tissue indicates that the protein product of this gene is useful for diagnosis and treatment of immune or hematopoietic disorders. Moreover, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

10 Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, 15 hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

20 Furthermore, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. In addition, the homology to a 25 reverse transcriptase protein indicates the protein may play a vital role in DNA metabolism, processing, and/or regulatory roles which would have utility in treating or detecting developmental and proliferative disorders and conditions. The protein is useful in, but not limited to, the inhibition or enhancement of apoptosis, transcription, translation, trafficking, and other cellular functions. Protein, as well as, antibodies 30 directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present 35 invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more

polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1135 of SEQ ID NO:38, b is an integer of 15 to 1149, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PTGNDLVYVFPCLLSVFSRMEEPSVFCLFFPLSILISSASRT
 10 FPGTQQVFSIVHGVTDVSAKKVQSQGRMTSTGLDFNLLPAWFPSPTSLQPTE
 DLFQTGSLSRSFCSKAFSSSPLSPGGSPNALTSVKEHLVSPAFLASHSCTAE
 SFPRVDVIHAVPIAWIPAPLHPIQLINSWFFFFFFFFF (SEQ ID NO:151), DLVY
 VFPCLLSVFSRMEEPSVFCL (SEQ ID NO:152), ISSASRTFPGTQQVFSIVH
 15 GVTDV (SEQ ID NO:153), FNLLPAWFPSPTSLQPTEDL (SEQ ID NO:154),
 FCSKAFSSSPLSPGGSPNALTSVKE (SEQ ID NO:155), and/or TAESFPRVDVIHA
 VPIAWIPAPL (SEQ ID NO:156). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in B-cell lymphoma.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune or hematopoietic disorders, particularly B-cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
 25 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,
 30 synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID
 35 NO:76 as residues: Glu-16 to Arg-21.

The tissue distribution in B-cell lymphoma tissue indicates that the protein product of this gene is useful for diagnosis and treatment of immune or hematopoietic

disorders and conditions. Moreover, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

Furthermore, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1073 of SEQ ID NO:39, b is an integer of 15 to 1087, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

The translation product of this gene was shown to have homology to histone family of proteins. Based on the sequence similarity, the translation product of this gene is expected to share biological activities with histone proteins, in addition to other proteins having DNA binding activity. Such activities are known in the art and described elsewhere herein.

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: FSFLKPLCAPRAPWLWLPPSSKSR VHVGP GDFRS (SEQ ID NO:157), VCGTGGLEPNLAWVRVDNGSFPSSSPSVPLEHPGCGCLLHPRAESMLGQETSDPCPGAASGFVFPQWAGLGLLVHLYPSLSY AALACCVSGLYSLPFT QALGNQPSFXQERQRRSMPLWAS (SEQ ID NO:158), HAGRKT VK (SEQ ID NO:159), SFYAKMPMERKALEMVEKCLDKYFQHLCDDLEVFAAHAGRKT VK PEDLELLMRRQGLVTDQ (SEQ ID NO:160), PMERKALEMVEKCLDKYFQ (SEQ ID NO:161), EVFAAHAGRKT VK PEDLELLMR (SEQ ID NO:162), SFPSSSPSVPLEHPGCGCLLHPRAESMLGQE (SEQ ID NO:163), and/or YPSLSYAALACCVSGLYSLPFTQALGN (SEQ ID NO:164). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

This gene is expressed primarily in epididymus and, to a lesser extent, in placenta and fetal liver/spleen .

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive, hematopoietic, and/or immune disorders and conditions, particularly male infertility. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, hematopoietic, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, seminal fluid, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:77 as residues: His-44 to Pro-50, Glu-90 to Glu-96, Gln-111 to Glu-117, Ser-143 to Gly-151, Ala-154 to Leu-166, Pro-199 to Ala-216, Gly-264 to Asp-272.

5 The tissue distribution in epididymus and placental tissue indicates that the protein product of this gene is useful for diagnosis and treatment of various reproductive disorders and conditions which include, but are not limited to infertility. Moreover, the protein is useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of impotence, and could
10 be useful as a contraceptive, either directly or indirectly. Considering the homology to histone proteins, this gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents.

Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that
15 may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor
20 marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the
25 scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1262 of SEQ ID NO:40, b is an integer of 15 to 1276, where both a and b correspond to the positions of nucleotide residues shown
30 in SEQ ID NO:40, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

35 The translation product of this gene was shown to have homology to serine/threonine phosphatase proteins. Based on the sequence similarity, the translation product of this gene is expected to share biological activities with proteins involved in

signal transduction and/or the cell cycle. Such activities are known in the art and described elsewhere herein. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: APGGVNSEGRGQHLPPPXL AVCLKLHL (SEQ ID NO:165). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

This gene is expressed primarily in breast and infant brain and, to a lesser extent, in neutrophils, fetal spleen, and activated monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive, developmental, immune, and/or hematopoietic disorders, particularly breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and metabolic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, developmental, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, breast milk, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:78 as residues: Pro-37 to Ala-42, Leu-44 to Cys-53, Glu-57 to Leu-65, Pro-79 to Pro-85.

The tissue distribution in breast tissue and neutrophils indicates that the protein product of this gene is useful for diagnosis and treatment of certain cancers including those of reproductive and immune cell origin. Similarly, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy,

immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within various fetal and infant tissues
5 indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to
10 control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue
15 differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
20 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more
25 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2069 of SEQ ID NO:41, b is an integer of 15 to 2083, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

30

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NSAEPWVPVCARGGGAGCGRRRGRRFCAAGAVPAAE
35 RGGENG (SEQ ID NO:166), SLVPALKEVVVLWRRQMVLVLVWAFIPESWLN
SLGLTYWPQKYWAVALPVYLLIAIVIGYVLLFGINMMSTSPLDISIHTTIDNY
AKNQQQKKYQEEAIPALRDISISEVNQMFFLA AKELYTKN (SEQ ID NO:167),

MVLYLVWAFIPESWLNSLGLTYWPQKYW (SEQ ID NO:168), YWAVALPVYLLI AIVIGYVLLFGIN (SEQ ID NO:169), and/or QQQKKYQEEAIPALRDISISEV (SEQ ID NO:170). Polynucleotides encoding these polypeptides are also encompassed by the invention.

5 This gene is expressed primarily in fetal liver/spleen.

 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune, hematopoietic, and/or developmental disorders and conditions, particularly haemopoiesis, leukemias, and lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred epitopes include those comprising a sequence shown in SEQ ID NO:79 as residues: Asn-28 to Pro-34.

 The tissue distribution in fetal liver/spleen indicates that the protein product of this gene is useful for diagnosis and treatment of disorders involving haemopoiesis. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

35 Moreover, expression within fetal tissue indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment

of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1002 of SEQ ID NO:42, b is an integer of 15 to 1016, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LSPRLFDAGILLWGASVNVTTWEVRXAQSSAS (SEQ ID NO:171). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

This gene is expressed primarily in Jurkat T-cell G1 phase and to a lesser extent in 12 Week Old Early Stage Human.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune, hematopoietic, and/or developmental diseases and conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in Jurkat cells indicates that the protein product of this gene is useful for diagnosis and treatment of certain immune disorders, especially involving Jurkat cells. Moreover, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

The protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of

apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2183 of SEQ ID NO:43, b is an integer of 15 to 2197, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NLTSDPRPLALPPCGDFIKVTSFSPGLETHT (SEQ ID NO:172), EQQLRDRETQTGXDSRAKTQRGEDGESERGRWRLREGEDGDSERE EDGDSERWRLRSMESQRGEDGHSGGWVRMRMETHRKGRMESQERLETGEGI ETQRGEDGDSEGGRWRLKEDGNPGERRTEMRQRLGEAG (SEQ ID NO:173), GHGVAGXCLPQPLLPPSPPDYDERSHLHDTFTQMTHALQELAAAQGSFEVAFP DAAEKMKKVFTQLKEAQACIPPCEGLQEFARRFLCSGCYSRVCDLPLDCPVQD VTVTRGDQAMFSCIVNFQLPKEEITYSWKFAGGGLRTQDLSYFRDMPRAEG YLARIRPAQLTHRGTFCVQKQDQRPLARLYFFLNVTGRPRGRRQSCRPRSGK CCAGRRGMPS (SEQ ID NO:174), and/or GDHPHFISVLGKVQREGRRGPEGQA EGQTERNSQRRKAQRP (SEQ ID NO:175). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in uterine cancer and, to a lesser extent, in macrophage and adult testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive diseases and conditions, particularly uterine and testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:81 as residues: Ser-54 to Arg-64, Lys-70 to Thr-77, Gly-88 to Ser-96.

The tissue distribution in uterine and testis tissue indicates that the protein product of this gene is useful for diagnosis and treatment of certain cancers, including uterine cancer. Moreover, the tissue distribution in testis tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents.

Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more
5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1985 of SEQ ID NO:44, b is an integer of 15 to 1999, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MLVYQNQAQFSSN (SEQ ID NO:176). Polynucleotides
15 encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are
20 not limited to, neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues
25 or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 The tissue distribution in cerebellum indicates that the protein product of this gene is useful for the diagnosis and treatment of neurodegenerative disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to
35 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction,

aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1505 of SEQ ID NO:45, b is an integer of 15 to 1519, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

This gene is expressed primarily in cerebellum and whole brain and to a lesser extent in pineal gland, fetal liver/spleen, and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, endocrine, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:83 as residues: His-3 to Phe-11, Pro-35 to Arg-40.

5 The tissue distribution in cerebellum and whole brain indicates that the protein product of this gene is useful for the diagnosis and treatment of neurodegenerative disorders involving the cerebellum or other brain regions. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or
10 inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive
15 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception.

In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is
20 involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
25 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more
30 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1175 of SEQ ID NO:46, b is an integer of 15 to 1189, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HCEIQ30	209626 02/12/98	Uni-ZAP XR	11	1441	1	1441	137	137	48	1	30	31	55
2	HAGBP70	209626 02/12/98	Uni-ZAP XR	12	2160	163	2142	360	360	49	1	34	35	40
3	HBCAY27	209626 02/12/98	Uni-ZAP XR	13	1202	447	1202	580	580	50	1	18	19	93
4	HCACU58	209626 02/12/98	Uni-ZAP XR	14	1554	1	1554	137	137	51	1	30	31	83
5	HCWLD74	209626 02/12/98	ZAP Express	15	1540	1	1540	138	138	52	1	21	22	65
6	HDPFP29	209626 02/12/98	pCMVSPORT 3.0	16	1057	1	1057	293	293	53	1	30	31	52
7	HDPFH47	209626 02/12/98	pCMVSPORT 3.0	17	2080	105	2080	116	116	54	1	35	36	540

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HFEAN33	209626 02/12/98	Uni-ZAP XR	18	602	1	602	25	55	1	26	27	177
9	HFEAT91	209626 02/12/98	Uni-ZAP XR	19	629	1	629	21	56	1	32	33	83
10	HFPAO71	209626 02/12/98	Uni-ZAP XR	20	2067	364	2067	414	57	1	33	34	131
11	HLWAA17	209626 02/12/98	pCMVSPORT 3.0	21	997	246	997	436	58	1	15	16	187
12	HLYCQ18	209626 02/12/98	pSport1	22	1383	1	1383	126	59	1	34	35	40
13	HOSFG70	209626 02/12/98	Uni-ZAP XR	23	1513	203	1513	257	60	1	23	24	338
14	HSSAJ29	209626 02/12/98	Uni-ZAP XR	24	1044	1	1044	103	61	1	25	26	47
15	HUSIF44	209626 02/12/98	pSport1	25	2575	1	2575	27	62	1	25	26	336

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HUSIF44	209626 02/12/98	pSport1	47	2584	1	2584	29	29	84	1	28	29	132
16	H6EDX46	209626 02/12/98	Uni-ZAP XR	26	718	1	718	128	128	63	1	20	21	84
17	HABAG37	209626 02/12/98	pSport1	27	654	1	639	97	97	64	1	31	32	62
18	HACBD91	209626 02/12/98	Uni-ZAP XR	28	1445	1	1445	117	117	65	1	42	43	49
19	HADEH21	209626 02/12/98	pSport1	29	2020	1	2020	61	61	66	1	25	26	401
20	HAGHD57	209626 02/12/98	Uni-ZAP XR	30	1083	97	1083	402	402	67	1	24	25	57
21	HAGHR69	209626 02/12/98	Uni-ZAP XR	31	1580	1	1450	11	11	68	1	21	22	72
22	HAHDB16	209626 02/12/98	Uni-ZAP XR	32	796	1	796	93	93	69	1	20	21	50

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
23	HAHDR32	209626 02/12/98	Uni-ZAP XR	33	1256	365	1256	435	435	70	1	25	26	181
24	HAJAW93	209626 02/12/98	pCMVSPORT 3.0	34	1064	45	1064	218	218	71	1	30	31	48
25	HAJBR69	209626 02/12/98	pCMVSPORT 3.0	35	755	1	755	262	262	72	1	19	20	53
26	HAMGO32	209626 02/12/98	pCMVSPORT 3.0	36	604	1	604	119	119	73	1	22	23	74
27	HATBR65	209626 02/12/98	Uni-ZAP XR	37	812	1	812	252	252	74	1	16	17	64
28	HBJLD29	209626 02/12/98	Uni-ZAP XR	38	1149	1	1149	142	142	75	1	29	30	43
29	HBJNB13	209626 02/12/98	Uni-ZAP XR	39	1087	1	1087	12	12	76	1	17	18	52
30	HCE2F54	209626 02/12/98	Uni-ZAP XR	40	1276	19	1256	166	166	77	1	19	20	319

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
31	HCE3C52	209626 02/12/98	Uni-ZAP XR	41	2083	119	2074	236	236	78	1	33	34	171
32	HCEEA88	209626 02/12/98	Uni-ZAP XR	42	1016	1	1016	134	134	79	1	23	24	60
33	HCEFE96	209626 02/12/98	Uni-ZAP XR	43	2197	1	2197	121	121	80	1	26	27	100
34	HCEIF12	209626 02/12/98	Uni-ZAP XR	44	1999	1	1999	198	198	81	1	15	16	97
35	HCEOR67	209626 02/12/98	Uni-ZAP XR	45	1519	1	1519	155	155	82	1	27	28	52
36	HCEVB76	209626 02/12/98	Uni-ZAP XR	46	1189	1	1189	105	105	83	1	37	38	40

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988).

10 Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

15 Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1
20 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

25 In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results
30 shown in Table 1.

35 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

10 Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions,
5 interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be
10 determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and
15 subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window
20 Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity.
25 For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of
30 the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are
35 considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid

substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a

larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein

molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983).)

- 5 Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

 In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to
10 about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

 Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al.,
15 supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However,
20 immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

 As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example,
25 Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library.
30 Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

 Any polypeptide of the present invention can be used to generate fusion
35 proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein

by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

5 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino
10 acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of
15 polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example
20 describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the
25 monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a
30 fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for
35 example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D.

Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein.

Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

15 **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance

genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein

after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

5 In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and
10 which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al.,
15 Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

20

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes
25 known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention
30 can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic
35 cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping
5 strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This
10 technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to
15 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the
20 physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University
25 Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.
30 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and
35 the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this

technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

5 Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to
10 identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

15 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type.
20 In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences
25 in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

30 Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et
35 al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay

(ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and
5 biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit
10 detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with
15 an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety
20 needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of
25 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves
(a) assaying the expression of a polypeptide of the present invention in cells or body
30 fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an
35 effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to

activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

5 Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

10 At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the
15 polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

20 The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

25 A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red
30 blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune
35 system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or

polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to:

5 blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

10 Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood

15 coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

20 A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the

25 present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia,

30 antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation,

35 Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

5 A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The
10 administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may
15 inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute
20 rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

25 A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

30 For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may
35 also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

15 Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps,

Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

- 5 Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*,
10 *Norcardia*), Aspergillosis, Bacillaceae (e.g., Anthrax, *Clostridium*), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (*Klebsiella*,
15 *Salmonella*, *Serratia*, *Yersinia*), *Erysipelothrix*, *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, Mycoplasmatales, Neisseriaceae (e.g., *Acinetobacter*,
20 *Gonorrhea*, *Menigococcal*), Pasteurellacea Infections (e.g., *Actinobacillus*, *Heamophilus*, *Pasteurella*), *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease,
25 (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

- Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not
30 limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery,
35 giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide

of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

10 Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized

neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

5

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell
5 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

10 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,
15 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

20 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The
25 molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which
30 bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if
35 a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5 A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

10 A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity),
15 hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical
25 to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the
30 Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the
35 Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
5 sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500
contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

10 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical
15 to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method
20 comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences
25 comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said
30 group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from
35 the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA

clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide
5 sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein
10 identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide
15 sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least
20 two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a
25 panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the
30 deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

35 Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted

Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a

sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For

example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
5	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
10	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR®2.1	pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the

phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation

at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence
5 by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known
10 in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set
15 containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with
20 phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction
25 leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to
30 the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a 35 **Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

5 **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system
10 (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or
15 human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

20

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of
25 conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is
30 determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified
35 using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA

sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the

protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After
5 renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively
10 linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin
15 of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with *NdeI* and *XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA
20 insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or *Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to
25 express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified,
30 all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount
35 of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50

mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

5 The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel
10 electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

 Five μg of a plasmid containing the polynucleotide is co-transfected with 1.0 μg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by
15 Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μg of BaculoGold™ virus DNA and 5 μg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection
20 mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

25 After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture
30 and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in
35 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV I, HIV I and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991);
5 Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

10 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,
15 with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate
20 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the
25 naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

30 The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

35 Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 is cotransfected with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo

contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

15 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

30 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated

by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

5 If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

10 GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAACC
CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
15 AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
20 GAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCA
GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

25

Example 10: Production of an Antibody from a Polypeptide

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera
30 containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are
35 monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.

Immunol. 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in
5 any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma
10 cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells
15 obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is
20 possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide.
25 Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such
30 fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use
35 "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies

described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

10 The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a
15 working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be
20 poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

25 The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a
30 multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

35 Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of

cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

- 5 While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄·5H₂O; 0.050 mg/L of Fe(NO₃)₃·9H₂O; 0.417 mg/L of FeSO₄·7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄·H₂O; 71.02 mg/L of Na₂HPO₄; 10 .4320 mg/L of ZnSO₄·7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D- 15 Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L- 20 Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of 25 Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 30 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene 35 conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

5 On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

10 It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

15 **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

20 GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

25 The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

30 The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two

groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a
5 WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

10 Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be
15 identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
<u>IFN family</u>							
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
<u>gp130 family</u>							
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>							
20	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
25	IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>							
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
30	GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>							
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
35	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>							
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
40	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCG
AAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGTCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATG
ATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC
CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGC
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
TGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final
5 concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

10 On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

15 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12
20 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples
25 from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

30 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells.

5 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

10 To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

15 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37°C for 45 min.

20 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

25 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

30 Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

35

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

- 5 The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

- 10 Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

15

Example 16: High-Throughput Screening Assay for T-cell Activity

- NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by
20 expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

- In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B
25 (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- Due to its central role and ability to respond to a range of stimuli, reporter
30 constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating

diseases. For example, inhibitors of NF- κ B could be used to treat those diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
5':GCGGCAAGCTTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCA
TCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTTCTCCGCCCATGGCTGACT
AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTC
CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6

23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours.

The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members

of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and
5 PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride,
10 pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM
15 EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-
20 phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the
25 absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying 30 **Phosphorylation Activity**

As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine
35 phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,

Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, C.v. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with

specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

- 5 The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

- 10 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

- 15 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

20 **Example 23: Formulating a Polypeptide**

- The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

- As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's

solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long
5 terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set
10 forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to
15 transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is
20 then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media,
25 containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is
30 required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.
35

Example 27: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) *Cardiovasc. Res.* 35(3):470-479, Chao J et al. (1997) *Pharmacol. Res.* 35(6):517-522, Wolff J.A. (1997) *Neuromuscul. Disord.* 7(5):314-318, Schwartz B. et al. (1996) *Gene Ther.* 3(5):405-411, Tsurumi Y. et al. (1996) *Circulation* 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and

biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, immune, hematopoietic, and/or developmental diseases and conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in Jurkat cells indicates that the protein product of this gene is useful for diagnosis and treatment of certain immune disorders, especially involving Jurkat cells. Moreover, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

The protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Furthermore, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of

apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2183 of SEQ ID NO:43, b is an integer of 15 to 2197, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NLTSDPRPLALPPPCGDFIKVTSFSPGLETHT (SEQ ID NO:172), EQQLRDRETQTGXDSRAKTQRGEDGESERGRWRLREGEDGDSERE EDGDSERWRLRSMESQRGEDGHSGGWVRRMETHRKGRMESQERLETGEGI ETQRGEDGDSEGGRWRLKEDGNPGERRTMRQRLGEAG (SEQ ID NO:173), GHGVAGXCLPQPLPPSPDYDERSHLHDTFTQMTHALQELAAAQGSFEVAFP DAAEKMKKVFTQLKEAQACIPCEGLQEFARRFLCSGCYSRVCDLPLDCPVQD VTVTRGDQAMFSCIVNFQLPKEEITYSWKFAGGGLRTQDLSYFRDMPRAEG YLARIRPAQLTHRGTFSCVIKQDQRPLARLYFFLNV TGRPRGRRQSCRPRSGK CCAGRRGMPS (SEQ ID NO:174), and/or GDHPHFISVLGKVQREGRRGPEGQA EGQTERNSQRRKAQRP (SEQ ID NO:175). Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in uterine cancer and, to a lesser extent, in macrophage and adult testis.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, reproductive diseases and conditions, particularly uterine and testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:81 as residues: Ser-54 to Arg-64, Lys-70 to Thr-77, Gly-88 to Ser-96.

The tissue distribution in uterine and testis tissue indicates that the protein product of this gene is useful for diagnosis and treatment of certain cancers, including uterine cancer. Moreover, the tissue distribution in testis tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents.

Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ

ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome.

Accordingly, preferably excluded from the present invention are one or more

- 5 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1985 of SEQ ID NO:44, b is an integer of 15 to 1999, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

10

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MLVYQNQAQFSSN (SEQ ID NO:176). Polynucleotides
15 encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the cerebellum.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are
20 not limited to, neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues
25 or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 30 The tissue distribution in cerebellum indicates that the protein product of this gene is useful for the diagnosis and treatment of neurodegenerative disorders. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to
35 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction,

aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1505 of SEQ ID NO:45, b is an integer of 15 to 1519, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

This gene is expressed primarily in cerebellum and whole brain and to a lesser extent in pineal gland, fetal liver/spleen, and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions, which include, but are not limited to, neurodegenerative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, endocrine, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO:83 as residues: His-3 to Phe-11, Pro-35 to Arg-40.

5 The tissue distribution in cerebellum and whole brain indicates that the protein product of this gene is useful for the diagnosis and treatment of neurodegenerative disorders involving the cerebellum or other brain regions. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or
10 inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive
15 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception.

In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is
20 involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available
25 and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more
30 polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1175 of SEQ ID NO:46, b is an integer of 15 to 1189, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HCE1Q30	209626 02/12/98	Uni-ZAP XR	11	1441	1	1441	137	137	48	1	30	31	55
2	HAGBP70	209626 02/12/98	Uni-ZAP XR	12	2160	163	2142	360	360	49	1	34	35	40
3	HBCAY27	209626 02/12/98	Uni-ZAP XR	13	1202	447	1202	580	580	50	1	18	19	93
4	HCACU58	209626 02/12/98	Uni-ZAP XR	14	1554	1	1554	137	137	51	1	30	31	83
5	HCWLD74	209626 02/12/98	ZAP Express	15	1540	1	1540	138	138	52	1	21	22	65
6	HDPFP29	209626 02/12/98	pCMVSPORT 3.0	16	1057	1	1057	293	293	53	1	30	31	52
7	HDPPH47	209626 02/12/98	pCMVSPORT 3.0	17	2080	105	2080	116	116	54	1	35	36	540

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HFEAN33	209626 02/12/98	Uni-ZAP XR	18	602	1	602	25	25	55	1	26	27	177
9	HFEAT91	209626 02/12/98	Uni-ZAP XR	19	629	1	629	21	21	56	1	32	33	83
10	HFP AO71	209626 02/12/98	Uni-ZAP XR	20	2067	364	2067	414	414	57	1	33	34	131
11	HLWAA17	209626 02/12/98	pCMV Sport 3.0	21	997	246	997	436	436	58	1	15	16	187
12	HL YCQ18	209626 02/12/98	pSport1	22	1383	1	1383	126	126	59	1	34	35	40
13	HOSFG70	209626 02/12/98	Uni-ZAP XR	23	1513	203	1513	257	257	60	1	23	24	338
14	HSSAJ29	209626 02/12/98	Uni-ZAP XR	24	1044	1	1044	103	103	61	1	25	26	47
15	HUSIF44	209626 02/12/98	pSport1	25	2575	1	2575	27	27	62	1	25	26	336

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HUSIF44	209626 02/12/98	pSport1	47	2584	1	2584	29	29	84	1	28	29	132
16	H6EDX46	209626 02/12/98	Uni-ZAP XR	26	718	1	718	128	128	63	1	20	21	84
17	HABAG37	209626 02/12/98	pSport1	27	654	1	639	97	97	64	1	31	32	62
18	HACBD91	209626 02/12/98	Uni-ZAP XR	28	1445	1	1445	117	117	65	1	42	43	49
19	HADEH21	209626 02/12/98	pSport1	29	2020	1	2020	61	61	66	1	25	26	401
20	HAGHD57	209626 02/12/98	Uni-ZAP XR	30	1083	97	1083	402	402	67	1	24	25	57
21	HAGHR69	209626 02/12/98	Uni-ZAP XR	31	1580	1	1450	11	11	68	1	21	22	72
22	HAHDB16	209626 02/12/98	Uni-ZAP XR	32	796	1	796	93	93	69	1	20	21	50

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
23	HAHDR32	209626 02/12/98	Uni-ZAP XR	33	1256	365	1256	435	435	70	1	25	26	181
24	HAW93	209626 02/12/98	pCMVSPORT 3.0	34	1064	45	1064	218	218	71	1	30	31	48
25	HABR69	209626 02/12/98	pCMVSPORT 3.0	35	755	1	755	262	262	72	1	19	20	53
26	HAMGO32	209626 02/12/98	pCMVSPORT 3.0	36	604	1	604	119	119	73	1	22	23	74
27	HATBR65	209626 02/12/98	Uni-ZAP XR	37	812	1	812	252	252	74	1	16	17	64
28	HBILD29	209626 02/12/98	Uni-ZAP XR	38	1149	1	1149	142	142	75	1	29	30	43
29	HBJNB13	209626 02/12/98	Uni-ZAP XR	39	1087	1	1087	12	12	76	1	17	18	52
30	HCE2F54	209626 02/12/98	Uni-ZAP XR	40	1276	19	1256	166	166	77	1	19	20	319

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
31	HCE3C52	209626 02/12/98	Uni-ZAP XR	41	2083	119	2074	236	78	1	33	34	171
32	HCEEA88	209626 02/12/98	Uni-ZAP XR	42	1016	1	1016	134	79	1	23	24	60
33	HCEFE96	209626 02/12/98	Uni-ZAP XR	43	2197	1	2197	121	80	1	26	27	100
34	HCEIF12	209626 02/12/98	Uni-ZAP XR	44	1999	1	1999	198	81	1	15	16	97
35	HCEOR67	209626 02/12/98	Uni-ZAP XR	45	1519	1	1519	155	82	1	27	28	52
36	HCEVB76	209626 02/12/98	Uni-ZAP XR	46	1189	1	1189	105	83	1	37	38	40

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).

It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

- 5 The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.
- 10

Signal Sequences

- Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.
- 15
- 20

- In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.
- 25
- 30

- As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely
- 35

uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

10 Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

15 By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are:

35 Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization

Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject-nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query

amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions,

5 interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be
10 determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and
15 subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window
20 Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity.
25 For subject sequences truncated at the N- and C-termini, relative to the the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of
30 the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are
35 considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.

Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after

deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid

substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a

larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding
5 region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the
10 mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted
15 from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by
20 structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
25 Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an
30 activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having
35 antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein

molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

- 5 Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

 In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to
10 about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

 Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al.,
15 supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However,
20 immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

 As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example,
25 Fab and F(ab')₂ fragments) which are capable of specifically binding to protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library.
30 Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

 Any polypeptide of the present invention can be used to generate fusion
35 proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein

by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

5 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino
10 acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of
15 polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example
20 describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the
25 monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a
30 fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for
35 example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D.

Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

15 Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance

genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein

after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

5 In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding
10 sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24,
15 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their
20 entireties).

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes
25 known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention
30 can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic
35 cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this

technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

5 Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to
10 identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

15 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type.
20 In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences
25 in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

30 Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-
35 3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay

(ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and
5 biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit
10 detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with
15 an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety
20 needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of
25 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves
(a) assaying the expression of a polypeptide of the present invention in cells or body
30 fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an
35 effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to

activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

5 Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

10 At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the
15 polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

20 The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

25 A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red
30 blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune
35 system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or

polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to:

5 blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

10 Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood

15 coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

20 A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the

25 present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia,

30 antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation,

35 Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

5 A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The
10 administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may
15 inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute
20 rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

25 A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

30 For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may
35 also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

15 Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps,

Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

5 Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*,
10 *Nocardia*), Aspergillosis, Bacillaceae (e.g., Anthrax, *Clostridium*), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (*Klebsiella*,
15 *Salmonella*, *Serratia*, *Yersinia*), *Erysipelothrix*, *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, Mycoplasmatales, Neisseriaceae (e.g., *Acinetobacter*,
20 *Gonorrhea*, Meningococcal), Pasteurellaceae Infections (e.g., *Actinobacillus*, *Haemophilus*, *Pasteurella*), *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease,
25 respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, *Gonorrhea*, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not
30 limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery,
35 giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide

of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

10 **Regeneration**

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized

neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

5

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell
5 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

10 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,
15 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

20 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The
25 molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which
30 bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b) determining if
35 a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5 A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, 10 utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), 15 hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional 20 components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical 25 to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the 30 Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the 35 Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
5 sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500
contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

10 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical
15 to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the
ATCC Deposit Number shown for said cDNA clone in Table 1; which method
20 comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences
25 comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said
30 group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from
35 the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA

clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide
5 sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein
10 identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide
15 sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least
20 two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a
25 panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the
30 deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

35 Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted

Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a

sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the
5 recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said
10 polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1;
15 and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased
20 level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily
25 understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample 30

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector
35 from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For

example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
5	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
10	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the

phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation

at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence
5 by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known
10 in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set
15 containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with
20 phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction
25 leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to
30 the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

35 Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

5 **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

20 **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

30 **Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA

35 using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA

sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the

protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After
5 renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively
10 linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin
15 of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA
20 insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to
25 express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified,
30 all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount
35 of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50

mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

5 The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel
10 electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five μ g of a plasmid containing the polynucleotide is co-transfected with 1.0 μ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by
15 Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μ g of BaculoGold™ virus DNA and 5 μ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μ l Lipofectin plus 90 μ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection
20 mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

25 After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture
30 and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in
35 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 μ Ci of 35 S-methionine and 5 μ Ci 35 S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991);
5 Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

10 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,
15 with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate
20 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the
25 naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

30 The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

35 Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo

contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

15 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

30 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated

by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

- 5 If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

- 10 GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGCC
CAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAACC
CAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGT
GGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG
GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
15 AGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT
GTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCT
GACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGA
20 GAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGG
ACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCA
GGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC
ACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGC
GACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

25

Example 10: Production of an Antibody from a Polypeptide

- The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera
30 containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

- In the most preferred method, the antibodies of the present invention are
35 monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J.

Immunol. 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in
5 any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma
10 cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells
15 obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is
20 possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide.
25 Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such
30 fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use
35 "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies

described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

10 The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a
15 working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be
20 poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

25 The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a
30 multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

35 Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of

cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

- 5 While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl_2 (anhyd); 0.00130 mg/L $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$; 0.050 mg/L of $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$; 0.417 mg/L of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 311.80 mg/L of KCl; 28.64 mg/L of MgCl_2 ; 48.84 mg/L of MgSO_4 ; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO_3 ; 62.50 mg/L of $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$; 71.02 mg/L of Na_2HPO_4 ;
- 10 .4320 mg/L of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine- H_2O ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- H_2O ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- H_2O ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na- $2\text{H}_2\text{O}$; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of
- 25 Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B_{12} ; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122
- 30 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene
- 35 conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

5 On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

10 It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

15 **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

20 GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

30 The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

35 The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two

groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a
5 WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

10 Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS
15 elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
<u>IFN family</u>							
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	IL-10	+	?	?	-	1,3	
<u>gp130 family</u>							
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>							
20	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
25	IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>							
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
30	GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>							
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
35	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>							
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
40	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCG
AAATGATTTCCTCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGTCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCGAAATG
ATTTCCTCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGC
CCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGC
CTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
TGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies)

with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final
5 concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

10 On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

15 Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12
20 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples
25 from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

30 As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells.

- 5 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

- 10 To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

- 15 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 1 mM MgCl_2 , and 675 uM CaCl_2 . Incubate at 37°C for 45 min.

- 20 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 25 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

- 30 Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

- 35 **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

- 5 The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

- 10 Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

15

Example 16: High-Throughput Screening Assay for T-cell Activity

- NF- κ B (Nuclear Factor κ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by
20 expression of certain viral gene products. As a transcription factor, NF- κ B regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

- In non-stimulated conditions, NF- κ B is retained in the cytoplasm with I- κ B
25 (Inhibitor κ B). However, upon stimulation, I- κ B is phosphorylated and degraded, causing NF- κ B to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κ B include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- Due to its central role and ability to respond to a range of stimuli, reporter
30 constructs utilizing the NF- κ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- κ B would be useful in treating

diseases. For example, inhibitors of NF- κ B could be used to treat those diseases related to the acute or chronic activation of NF- κ B, such as rheumatoid arthritis.

To construct a vector containing the NF- κ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- κ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCCCA
TCCCGCCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACT
AATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTC
CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:
3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF- κ B/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- κ B/SV40/SEAP cassette is removed from the above NF- κ B/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF- κ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- κ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 μ l of 2.5x dilution buffer into Optiplates containing 35 μ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 μ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 μ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6

23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

5 Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a
10 fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.;
15 catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours.

The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

5 A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension.
10 The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.
15

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular
20 signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

25 The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is
30 unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor
35 associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members

of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,

Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, C.v. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with

specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

- 5 The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

- 10 Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

- 15 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

20 **Example 23: Formulating a Polypeptide**

- The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of
25 administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

- As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 µg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject
30 to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 µg/kg/hour to about 50 µg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous
35 bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's

solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

5 pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

10 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to
15 transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is
20 then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media,
25 containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is
30 required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

35

Example 27: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and

connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is
5 similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression
10 may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body
15 weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being
20 treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries
25 during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or
30 linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is
35 injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization,

and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 μ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 28: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into

enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

5 The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. 10 (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to 15 be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that 20 cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant 25 gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue 30 samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or 35 crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines

in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening
5 of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides
10 of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 29: Knock-Out Animals.

15 Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide
20 of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate
25 knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson
30 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to
35 express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (*i.e.*,

animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing
5 submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>65</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>February 12, 1998</u>	Accession Number <u>209626</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") 	

For receiving Office use only <input checked="" type="checkbox"/> This sheet was received with the international application PERRY HACKLEY INTERNATIONAL DIVISION 703/309/6517 PERRY HACKLEY@USPTO.GOV <i>Perry Hackley</i>	For International Bureau use only <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
--	--

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:X;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
 - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

- (g) a variant of SEQ ID NO:Y;
 - (h) an allelic variant of SEQ ID NO:Y; or
 - (i) a species homologue of the SEQ ID NO:Y.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
(b) recovering said polypeptide.
16. The polypeptide produced by claim 15.
17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.
18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 36 Human Secreted Proteins

<130> PZ025.PCT

<140> Unassigned

<141> 1999-02-24

<150> 60/076,051

<151> 1998-02-26

<150> 60/076,053

<151> 1998-02-26

<150> 60/076,054

<151> 1998-02-26

<150> 60/076,052

<151> 1998-02-26

<150> 60/076,057

<151> 1998-02-26

<160> 176

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaattct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttctctt	tcccccaaaa	acccaaggac	accctcatga	120
tctcccggac	tcttgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gacctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaag	tctccaacaa	agccctccca	acccccatcg	360
agaaaacat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctgggc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctt	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaagtgtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>
 <221> Site
 <222> (3)
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2
 Trp Ser Xaa Trp Ser
 1 5

<210> 3
 <211> 86
 <212> DNA
 <213> Homo sapiens

<400> 3
 gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
 cccgaaatat ctgccatctc aattag 86

<210> 4
 <211> 27
 <212> DNA
 <213> Homo sapiens

<400> 4
 gcggcaagct ttttgcaaag cctaggc 27

<210> 5
 <211> 271
 <212> DNA
 <213> Homo sapiens

<400> 5
 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
 aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120
 gccctaact cgcgccagtt ccgcccatc tccgccccat ggctgactaa ttttttttat 180
 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
 ttttgagggc ctaggctttt gcaaaaagct t 271

<210> 6
 <211> 32
 <212> DNA
 <213> Homo sapiens

<400> 6
 gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7
 <211> 31
 <212> DNA
 <213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c

31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc

12

<210> 9

<211> 73

<212> DNA

<213> Homo sapiens

<400> 9

gcgccctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg
ccatctcaat tag

60

73

<210> 10

<211> 256

<212> DNA

<213> Homo sapiens

<400> 10

ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct
caattagtca gcaaccatag tcccgcacct aactccgccc atcccgcccc taactccgcc
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg
cttttgcaaa aagctt

60

120

180

240

256

<210> 11

<211> 1441

<212> DNA

<213> Homo sapiens

<400> 11

ggcacgagtt ttatttatct tgcctagggt gtgttgggct tcataaatct gtggattgggt
atctttcgtc agttctgtaa aagtctcagg tactctttgt taacattcgt ctctgccccca
tttttcttct agaattatga tcaaaccatgc actaattaga ccttttattg tattctcttt
gcttcttagg ctatgctctg aaaatttatt ttgtcctaact actcagttta tagttctgtc
ttgtttccaa tctgttggtta aatccctcct ttcaatttta aatctcagtt actgtatttt
ttaattctag aaggctggtt gggtcttttca aatccactag atcaagtcac tctctgtgac
ttcctaagac ctatattcta gcctttgcct tttattattt ttttaacattg taagcaaagt
tggtttatag ttgataattc ttgtatctgt ggtctttgtc tcttcatact agctgttatt
tcttaacagt tttccctgat cccaccttac ttccctcatag atttgattat ctttgattat
gtgctgctta ttttttttaa agataattat ctgtattaat atgagacctt gattttaaga
tacttccct caggattgtg ctgtgtgcct gggcacattg caagtccaaa ttactttaaa
gtatcctaga acaccagagg tgaaaattca tgccattctc gtgcattctt accttatggg

60

120

180

240

300

360

420

480

540

600

660

720

tatagcccat	tgggaatcct	tagtgctcggg	agggagttct	attacacctt	ccacttcggg	780
cagatcctgg	gctttgacat	tcgtcctctt	catcataacc	aaatatcaga	cttgcctaata	840
gcgtaaatgc	ccttggggta	aagcatctgt	gttctgctta	cctctcaggg	ttcctgcttt	900
tcccttttagc	tttggttcca	tcacttggtg	gttcaaccag	tatgggaaac	tgctctaga	960
agcagtgttt	taaaatttta	gtctaaccat	aaaaatagag	aatgcttacc	ctctggatat	1020
aaatgccata	gcgataactt	tgaactccta	cattacatgc	cttttatgta	aggcaaacct	1080
cagtacacat	tgagagacag	tgtcataatac	ttattaagat	cacaggctct	aaaatcagac	1140
tgcttgtttt	aaatcctggc	cctgccatgt	agtagtaacc	tgtgttaatt	tatgcaagat	1200
acgtaatctc	tctgtgcctt	ggtttcttcg	tttaaaaagc	agaataatag	cttgcctcat	1260
gtgggtcatta	tgaaaaacaa	acaaggccgg	gcaccgtggc	ttacgcctgt	agtcctcagca	1320
ctttggggagg	ctgaggtggg	cagatgacct	gaggtcggga	gtttgagacc	agcctgccca	1380
acatggagga	accccgctctc	tactgaaaaa	aaaaaaagag	agagagagag	agagaactag	1440
t						1441

<210> 12

<211> 2160

<212> DNA

<213> Homo sapiens

<400> 12

ttttgaattc	tatagattgt	cttgggaagga	tactgtgtga	tgggtcaggc	acacagtaat	60
tggagacttt	taatgtatgt	aatatttcat	agattgcatg	ctattaatca	tctgtgaggg	120
tagtattttt	tgttttattg	taagtttccc	tcttttttta	taaattaaaa	gatgggttgt	180
attaggaatt	tcaaatgaat	gcagaaaatc	ttacatgctg	tgtactatta	atattataac	240
agacgatcca	agtccaaaat	ctgaccaata	aagcaaccat	tttatcaaga	tagagggatt	300
ctaattgggag	aggggattct	tccctcctga	agtttgtgtg	tccagtcccc	ttaaaaaaa	360
tgaatagtgt	tcttttcttg	tgcatattaa	tactcgaaaag	tgccatgggtg	gtattaatga	420
aagtacactt	tattgttgcc	tttgaactta	cggccaaggc	aataaatcag	aaacaaaaat	480
agtgccaatg	tgtcaaaaatc	gacatctgag	agattcagcc	tcccatttgg	aataaatatg	540
aatcttctaa	gctatcttgt	ttaatatattt	ccatcattta	gctacttctt	atctccctca	600
gagggcgctg	ctgttcccat	tttagagttg	acagtggcct	gctaattttg	ctatgttctt	660
aaaagttact	gggtgtgaga	cattttcctc	ccctcctttt	tcctactgct	gggtgtttatt	720
atccagctag	acaatatattt	atgcatattt	accgtgatgt	ctggaccgta	cctgtgctcc	780
ttggcagttt	atgttgaaga	taactaaaga	tttttctctt	tgggaggcat	caaatgatg	840
gtagtttgc	tttatctttt	tatgttcatt	ttcttttagt	aggtgacctt	tctgcattaa	900
gaactgtttt	tatctttttac	taccttttct	tttctccttt	gtggagacag	catgacatgt	960
cctgaagggtc	acctttgcct	ttgaaaaagg	tttgatggag	gaattcacag	gtgactgaca	1020
agtctttgaa	aagaatggga	tctgtctact	tctgggtctt	ttggccggga	actcctgatt	1080
ggtgttaagg	tggtaatattc	ccccatataa	gatttagaat	cactgagttt	gagctagatg	1140
aaatttttaa	aattttctgg	tgtctcatta	gactgatgag	gtgagttttc	ttcttcatat	1200
gaacagctag	ttaataacag	cagagttctc	actcagtgtc	cagtacttaa	ttttccactg	1260
caccacaact	gtcttaacta	aatgtgctgt	atttttcttt	aaaagttaag	agttctattt	1320
ggtgttttca	ggaatatatg	tgaaaagaca	tgccatgttt	tggtaaaatac	catcagagtt	1380
gtgtaaaggc	gtgtactaag	tgcaatctta	atltgtggaa	ataatcttca	tttaccctc	1440
ctaaaactac	actcagtata	aacactttcc	cataagggtgt	gtgcagtaaa	aatgttatat	1500
tactccaaca	ctggcaggag	cacagcacag	cagccttatt	ggagagagcc	ttataaaagt	1560
gattaaatgg	aggcattgag	ctcattacct	ttaagtttac	tttgtgctga	cctttgttcc	1620
tgttttgaga	atctcatata	attattaaaa	aaaaaaaaaca	attaaaacga	aacggcgggg	1680
cctagctgtg	tataaatgat	ccttgctgaa	tatcttaagg	ttttttgtaa	gaaaaaagaa	1740
aaaccaacaa	aaaaagctta	ttttcacatt	aaaatgaaac	ctcttttgca	acttaagaat	1800
tctatggaaa	agcagttttt	atcatatttt	gtgtccatgc	accatttttc	ttaaaatggc	1860
ttacaaaaaa	gaatgtaaac	aattttgtgat	ctggccagtt	gtacttttag	ctcccagagg	1920
gagagttggt	ggtattatga	gttgagtaaa	aaccatccag	gggaacttga	gggagcagtc	1980
tgttgccagt	aatgttccct	gtgtgccatt	aaaccacctc	cagatgagtg	gaggaacatc	2040

actttttaat tttttaattg tatttggaat tgttgccgtg tactaagaac ttgacctaaa 2100
 taaaatccca caaagtataa aaaaaaaaaa aaaaaaaaaa aagggcggcc gctcgcgac 2160

<210> 13
 <211> 1202
 <212> DNA
 <213> Homo sapiens

<400> 13
 ggggtcgaccc acgcgtccgg tttttttaga aatagaagtg cttacagatt tgtttgagca 60
 gaatagatac ccatgttcag agagagagag agagagccat tgagaggcas agagtgccga 120
 atgtgaattc tgtgtaaatt gaaaagttac ggtccccgtc cataaggaga tggctctggt 180
 tgtcttgaat ttagacagct ttccagagga ggaggttctc tcctgcagca gtgtgggaaa 240
 aaaatctacc agatttggac cagaatgact gcaatttagg tcagaacatg atacttagag 300
 ggaaaaaagt aatcatggct tgaatagctg ccctaaggcc agctacaggg ctgcagggtc 360
 tgtggacctt tcttgtcaga actcaggatc cttaggagtc ccacaaggg catggaggct 420
 gtggccatca tgagtgggaag aaccagcttc caaaggaacc taggattgtt ctggccctgg 480
 ctccagggtgc atatctctgc tttccgtgag cattgaatgg gaaatcacgt gttagcagaa 540
 taaatccag aatacacatt caggaggaga tggttccaca tggcacgtaa gtcctttgcc 600
 ttattgatgt ttgtctggca gatgtcetta agccttccca tcaagggtt tattctaagg 660
 gtggctaact ggctatttaa acctcatctc aatagtgtct gtctaggatg gcaaaatcac 720
 accaggttct gctgggcaaa tctcccaggt ggcgtattgc tagaggagag cgccactgca 780
 gaggacacac tgtcttggcc actggccttg caaaccatag tggaggagg agtctgggggt 840
 caccaaccac ttcctggctg actgcctgag ccacattata caagactgtt tgttgactta 900
 gtaatactga agccagagct caccaagatt ctgacatcaa gcatgaaagt gactaattct 960
 ttcawttccc agcactttga caaaggggac tctcttaaaa ctctcatcg gacgttagtg 1020
 gaagtcgact catgtatcta aacatgtagc cagcgtaagt tcttggtcag attgatctaa 1080
 tgactttttt agcgtgtgtg tgtgtgtgtg tgtgtgtgt taatcttttt aagtttgggt 1140
 gaagtttgac cttctagaat tctgtttat tctgagcaa aaaaaaaaaa aaaaaactcg 1200
 ag 1202

<210> 14
 <211> 1554
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (695)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (874)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1190)
 <223> n equals a,t,g, or c

<400> 14
 gctttaatat tgtacactta cacatctgga aggaagagag ttccatatgg cagggatgat 60

tgggacagga	gggatctttt	gataactttg	tgtgagcatg	aaaatcgaat	ggggaagggg	120
gagctgtgaa	aaaaaaatgt	tatctctttt	tttttgcttc	tggaaaccca	gcttttttgg	180
cagccgtctt	gtgatttggc	tgggcctggg	ttgtgggggt	cgctctctga	gttgggtagc	240
tcttggagaa	gattatctgg	gaactcccat	ccttatccca	aacatacacc	aaacctgccc	300
ccatccacca	ttatgggaat	tagtaccaga	gcatacctgc	agattagtgc	tcatttttctc	360
tctttgtgag	cacacacaca	tcaggtagag	ttccagaaac	ccagctttag	gacactgttc	420
acatatcaca	ggaggagcaa	ggacatgaat	acaagagagc	tctttcctga	ccagcagtgg	480
gargtggttg	tactatctat	ttawttgttt	attwatttat	ttattttttg	agatggartc	540
tccttctgtc	accagggtg	gagtgcagtg	gcatactctc	ggctcactgc	aatctctgcc	600
tcctgggttc	aagcagtcct	cctgcctcag	ccccccaagt	agctgsgatt	acaggctgca	660
ccaccatgcc	ccgetaattt	ttgtattttt	agtanagatg	gggtttcacc	atgttggcca	720
ggctgggtctg	taactcctga	mctcaggtga	tccacctgcc	ttagcctccc	aagggtgctgg	780
gattacaggt	gtgagccacc	gtgcccgsc	tggttccact	atttattaaa	atgtatatat	840
gtgttttyca	cttttttggg	aggcatttta	ttgntaataa	tttggaatt	aaaaaaattt	900
ctccacaagc	ttattttttg	tggagacaag	gtctccctgt	gttgccctagg	ctgggtcttga	960
attcctgggc	taagtgattg	gtctgccttg	gcctctcaaa	gtgctgggga	ttacaggcat	1020
aagtcacat	gccctgtttg	scagcaagkt	ttawackgct	ctttttggta	gggawwtkct	1080
maggtwcagt	gatagagaac	atgkagttgt	gggtgggawac	agtggctyat	gactgtatcc	1140
gcactttggg	aggctgaggc	aggaggattg	cttgaggctg	agagttgagn	acaggcctgg	1200
gcaacatagc	aagacacctt	ctctaaaatg	aaaaaaatta	gctggatgtg	gtgtcatgta	1260
cctgtagtcc	cagttgcttg	ggaggctgag	gcaggaggat	cacttgagcc	tgggtgttca	1320
agataggcct	ggtcaacaca	gcaagacccc	ttctctaaaa	atgaaaataa	aaaaattagc	1380
tggttgtggg	ggcatgtacc	tgtagtccca	gttacttggg	aggctgagac	aggaggattg	1440
cttgagccag	gggtttgagg	ctgcagtgag	ctatgactgc	tcccctgcac	cccaggctgg	1500
gtgacagagt	gagaccagc	ctctaaaata	aaaaaaaaaa	aaaaaaaact	cgta	1554

<210> 15

<211> 1540

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (651)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1124)

<223> n equals a,t,g, or c

<400> 15

agaattcggc	acgagggcat	attactttcc	taggactgcc	acaacaaact	attaccaact	60
agcggcttaa	aacaacaaga	gcttattcct	cacagttctg	gaggccagaa	gtccaaaacc	120
aagggtgcag	gaagggtcatg	ctctctccaa	agtctccaag	gatgctcctt	ccttgccctcc	180
tccagcctct	ggtcgtggcc	aacatcccg	gggttccttg	gcttgacagat	gaatcactta	240
atcccccccc	catcatcaca	tggcagtcct	cctgtgtagc	tcagctctgt	ccaaatttcc	300
cctttcctac	aaggacatta	gtcactggat	tatgacacag	ctcatcttaa	ctggattata	360
tctgcaaaga	ccctgttata	tctgcaaaga	cgagttaaca	ttcacatgtt	ccaggggaga	420
tatgaatttt	aaggggacag	tattggaccc	agtataggag	ggcaggcagc	agcaggggag	480
ccagggaggg	ctggcctgac	ttgagcctgt	ttgaaaagca	tcatacctcct	accaagactg	540
ggggctgctg	gttctgacaa	ggtttgagg	atcagctggg	atgatgggtt	scamccaytc	600
cttcgagyt	cgttggaccc	ctgggccac	ttacagcaag	gagcttgccc	ntyctgttag	660
ctctycgtca	gtgtgggaaa	atctgartga	gccagagaag	ggtgagattc	ccctgcaga	720

gcaggcagta	ctgagcaaat	ccaggatcca	gaactccagt	tctaatectg	gctcttgcct	780
gcttttctgt	gtgaccctgg	ggaagtgggt	ttccctctct	gagactctcc	ttccccatgt	840
gagtcacaag	ggctgggcct	agctgacccc	caaggccctt	acatgagtgg	atagttgcat	900
tttaaacctg	gtgctcccca	ggataaggga	gtcaacccca	aggagactgg	ggtttctcct	960
gagcctggcc	cctgggggatg	agcactcact	gtggaaaaag	ctggccactt	cttagccctt	1020
gtcatgggca	gaaaacatgc	ccctccagcc	ccaccagcac	caacacacag	ccaagctcac	1080
tgtttcat	ttagagagaa	atcagggcct	tgggtgcagc	tgantgacac	agacaagggg	1140
cggggggaca	tgaaaggag	cgggcaagga	cggaaattac	acttctccta	gcaacctggt	1200
tctgcagctc	ctaggcctgg	ggccgcgtga	tacatgccat	tcccaattaa	cgggatgtta	1260
aatatacccc	ggctcagcct	gccccatgct	gagccccgcc	tggggcagtg	cagggagcca	1320
tgtgatgggtg	tagagcactc	tgcaacaccc	catattcatg	ttcccactcc	tagggccccg	1380
ctcgggtcccc	aggaggccag	agcggtcctg	ccctctgcct	gagcatggct	cagctccagc	1440
ctccacttgc	cctccccctat	gctggccagc	tgggggtct	gcaggcagcc	tgtggggcag	1500
ggccagttgg	ccaaactctc	caagccagaa	gcccctcgag			1540

<210> 16

<211> 1057

<212> DNA

<213> Homo sapiens

<400> 16

tgcaccacg	cgtccgctga	gattacaggt	gtgagccacc	aggctcagcc	ccctaagatt	60
tgaaacactt	taaatggccc	atggtagggt	tcctgctagg	ataaaacatt	aagcggctgt	120
taaaagaaat	aaaaggagga	cacgtctctg	tgactgggtg	tggacaaatc	tccaagtcac	180
tgcaaaatgg	aaaaagtata	agatgctctt	tcctgaacc	tcaagggtcc	cgcccccttc	240
actttcaggt	ctctggacct	ctgactgaca	ctgtgcctgc	ccaggctcct	gtatgactg	300
ccacagtgcc	ctgggccccca	tgtccacccc	tgtcctgccc	ttctctggga	tagggctggc	360
cttctctctgc	ctctgcctgg	ctgcatccat	ggtcgatctc	aagtgccttg	gcatgaactc	420
cactctctctg	cagccttcaa	tcaaggaatg	atggggatgt	gtacataccc	caccccaccc	480
cttggcaggg	tgatgctgag	gtgtggattt	ttaacagttc	ccagactttc	ccaggaggct	540
tgggtttggg	tgcccacagt	gggagctggg	gtgatatcat	accttcgccg	gccgcctttc	600
cttctgttgc	tctgtgcccc	tactcccact	ctagagctgc	cccgtttctc	tgttttcgtg	660
aaagagctga	ccctgtgctg	cctcccactc	tcccaatgcc	cctgocactc	ctgtgagcct	720
gctgctgggtg	aggctcgggtg	tgacctctgt	gttgctggat	aatgagtcac	ctatctctgg	780
aggagaagaa	aggcaggtcc	tccacagccc	tgataaaatc	tccaagtctc	ccagtttcgg	840
gtccctctcc	tgggatgcag	acccactgcc	tgcccagctg	gtacgatcca	catgcccctc	900
tcttggaat	aggggcatgg	gaaagtgact	aaagatactg	ttctggctgc	tgtgttctact	960
gtgagtaata	aactgtccat	ttctccgaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaggg	cggccgc			1057

<210> 17

<211> 2080

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (145)

<223> n equals a,t,g, or c

<400> 17

aattcggcac	gagaccttta	gggtgcgcgg	gtgcagtata	tctcgcgctc	tctccccctt	60
ccccctcccc	tttccccacc	ccgggcgctc	aggttgggtct	ggaccggaag	cgaagatggc	120

gacttctggc	gcggcctcgg	cgganctggt	gatcggctgg	tgcataattcg	gcctcttact	180
actggctatt	ttggcattct	gctggatata	tgttcgtaaa	taccaaagtc	ggcgggaaag	240
tgaagttgtc	tccaccataa	cagcaatttt	ttctctagca	attgcactta	tcacatcagc	300
acttctacca	gtggatata	ttttggtttc	ttacatgaaa	aatcaaaatg	gtacatttaa	360
ggactgggct	aatgctaata	tcagcagaca	gattgaggac	actgtattat	acggttacta	420
tactttatat	tctgttatat	tgttctgtgt	gttcttctgg	atcccttttg	tctactttcta	480
ttatgaagaa	aaggatgatg	atgatactag	taaatgtact	caaattaaaa	cggcactcaa	540
gtatactttg	ggatttgttg	tgatttgtgc	actgcttctt	ttagttgggtg	cctttgttcc	600
attgaatgtt	ccaataaca	aaaattctac	agagtgggaa	aaagtgaagt	ccctatttga	660
agaacttggg	agtagtcatg	gtttagctgc	attgtcattt	tctatcagtt	ctctgacctt	720
gattggaatg	ttggcagcta	taacttacac	agcctatggc	atgtctgcgt	tacctttaaa	780
tctgataaaa	ggcactagaa	gcgctgctta	tgaacgtttg	gaaaacactg	aagacattga	840
agaagtagaa	caacacattc	aaacgattaa	atcaaaaagc	aaagatggtc	gacctttgcc	900
agcaagggat	aaacgcgcct	taaaacaatt	tgaagaaagg	ttacgaacac	ttaagaagag	960
agagagggcat	ttagaattca	ttgaaaacag	ctgggtggaca	aaattttgtg	gcgctctgcg	1020
tcccctgaag	atcgtctggg	gaatatTTTT	catcttagtt	gcattgctgt	ttgtaatttc	1080
tctcttcttg	tcaaattttag	ataaagctct	tcattcagct	ggaatagatt	ctggtttcat	1140
aattttttgga	gctaacctga	gtaatccact	gaatatgctt	ttgcctttac	tacaaacagt	1200
tttccctctt	gattatattc	ttataacaat	tattattatg	tactttattt	ttacttcaat	1260
ggcaggaatt	cgaaatattg	gcatatgggt	ctttttggatt	agattatata	aaatcagaag	1320
aggtagaacc	aggccccaag	cactcctttt	tctctgcatg	atacttctgc	ttattgtcct	1380
tcacactagc	tacatgattt	atagtcttgc	tccccaatat	gttatgtatg	gaagccaaaa	1440
ttacttaata	gagactaata	taacttctga	taatcataaa	ggcaattcaa	ccctttctgt	1500
gccaaagaga	tgtgatgcag	awgctcctga	agatcagtg	actgttacc	ggacatacct	1560
attccttcac	aagttctggt	tcttcagtg	tgcttactat	tttggttaact	gggcctttct	1620
tgggggtattt	ttgattggat	taattgtatc	ctggtgtaaa	gggaagaaat	cggttattga	1680
aggagtagat	gaagattcag	acataagtga	tgatgagccc	tctgtctatt	ctgcttgaca	1740
gccttctgtc	ttaaagggtt	tataatgctg	actgaatatc	tgttatgcat	ttttaagta	1800
ttaaactaac	attaggattt	gctaactagc	tttcatcaaa	aatgggagca	tggctataag	1860
acaactatat	tttattatat	gttttctgaa	gtaacattgt	atcatagatt	aacattttta	1920
attaccataa	tcatgctatg	taaatataag	actactggct	ttgtgagggg	atgtttgtgc	1980
aaaatttttt	cctctaattg	ataatagtgt	taaattgatt	aaaaatcttc	cagaattaaa	2040
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	gggcggccgc			2080

<210> 18

<211> 602

<212> DNA

<213> Homo sapiens

<400> 18

aattcggcac	agkttgtgtt	tctmatgttc	caggctccggc	caggctggca	gctcctgctg	60
gtcatgtttt	cctcatgtgc	tgtttccaac	cagctcttgg	tctgggtacc	agcaactgcc	120
ttagcagaca	acaaacctgt	agcacctgac	cgacgaatca	gtgggcatgt	gggcatcatc	180
ttcagcatgt	catacctgga	aagcaagggg	ttgctggcta	cagyttcaga	agaccgaagc	240
gttcgtatct	ggaagggtggg	cgacctgcga	gtgcctgggg	gtcgggtgca	gaatattggg	300
cactgctttg	ggcacagcgc	ccgtgtgtgg	caggctcaagc	ttctagagaa	ttaccttata	360
agtgcaggag	aggatttgtg	ctgcttgggtg	tggagccatg	aagggtgagat	cctccaggcc	420
tttcggggac	accaggatgt	gtaccgcggtt	gtagtaggag	ctgaaatcca	tgctgagctg	480
taccaggaac	ttgcataatc	agagacagag	actgagtcac	tggcccatct	ctttgctctt	540
gtccccaggc	cagaataaag	aatagagtgt	aaaaaaaaaa	aaaaaaaaaa	aaaaaactcg	600
ag						602

<210> 19

<211> 629
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (533)
 <223> n equals a,t,g, or c

<400> 19

gcacactttg	accacttgtg	atgagcctta	tttgggagca	aggtcttcaa	ctttgtgggt	60
tttgtttgtt	ttatttgggt	ttctgcttct	gcattagttc	acttaggggtg	atggctttca	120
gctgctycca	tggtgcttgc	tgcaaaggat	atgattttgt	ycctttttat	ggctgtgtag	180
tattccatgg	tgtatatgga	ccacattttc	tttatccaat	ccaccatata	tgggcaccta	240
ggttgattcc	atgtctttgc	tattgtgaat	agcactgtga	tgaacataga	agtggattaa	300
atttcttttt	cttgacagtc	tcctaattta	tgcttgtaga	tatatatttc	tctcatgcct	360
tgagggtttt	aaaagtcctc	tcctctttct	catggcaata	cttttactaa	agtacatttc	420
ctgggaatcc	ttagggttcc	ccttattttg	aataggctga	atattttcat	atgtttgggtg	480
atttttatct	tttaatcctt	taatagggtt	gaaagtctct	cttgatatgg	gtngctcaga	540
taggctccat	cgtagagtct	agaaatcatc	ctatgatttt	tttttgcca	ttcctaggtt	600
aaaaaaaaa	aaaaaaaaa	aaactcgag				629

<210> 20
 <211> 2067
 <212> DNA
 <213> Homo sapiens

<400> 20

aattcggcac	gaggaaaaac	aaaagttttt	taaaacaata	aaagttaaca	gtcaataatg	60
tgtttgtcgg	caagaagccc	tctgttaata	atgggtctaaa	caaataagac	attgtttttc	120
tccaataaag	aaatccagag	gcaggcagta	gctgggtttg	attcagcctc	tgactgtcac	180
tgtcagggcc	ccaggcccca	tgagcctttc	gtctttctctg	catgttggct	tatcttctca	240
tgcttgtgac	ttcctgggtg	caacacgggt	gctgcaacac	cagacatctt	gcctgtcttc	300
aaggcaggaa	ggagggggaa	actatcgctt	accagctatt	tttcttacct	tagctcctcc	360
atgtcttggg	tcaaaagcat	ctctttgaac	ctctccctca	ggcataccct	gaaatgctgt	420
ggactttaac	cttttttctg	ttgcaaaggt	cgctcacatc	tccttggttg	tttgggtctc	480
tcttctcttg	ctctagtaac	acagcagtct	gttgcttctt	aggacaactt	ataatgggac	540
ccaaagggga	aagaggattt	cccgggcctc	caggaagatg	tctttgtgga	cccactatga	600
atgtgaataa	cccttctctac	ggggaatctg	tgtatggggc	cagttccccg	cgagttcctg	660
tggttaaggct	ttctggggaga	agtctggggg	ggttatccgt	gaggacctct	cacctgatcc	720
ttatggggct	ttgtaaaatc	ctttcagtaa	aactaacttt	ttttcacgac	tctgagtaca	780
ccctcattat	aggaaattgg	aaaatatgag	aaaatcaaga	ggaaaaccaa	attgtccatt	840
tgattgtgag	tccatttttg	ggtattttct	ttgtcttatt	aaaatctaac	ttttatatgg	900
ttgagattat	attgtataaa	aatgtacttt	tggccgggca	tggtggctta	tgctgttaat	960
cccagcactt	tgggaggcca	aggtgggtgg	attataaggt	caggagtctg	agatcagcct	1020
ggccgataca	gtgaaacccc	atctctacta	aaaaatatat	ttaaaaaatt	agccggggcg	1080
ggtggtgcac	gcctgttgct	tcagctactt	gggaggctga	ggtggggaga	tcgcttgaac	1140
ccaggaggcg	gagattgcag	tgagctgaga	tagcaccact	gcactccagc	ctgggcaaca	1200
gagcgagact	ccgtctcaaa	aaaagttata	ctttgktatc	ttagttgaaa	tcctgccatg	1260
tttccacact	ctataaataa	catttttaaac	tttttattag	ggaaaatttc	aaatacatat	1320
aaaagcagaa	caaatagtgt	aatgaacccc	tgtgtaccct	tcacccaact	ttaataatga	1380
tcaactcatg	gcgagcctgt	gtccttggtt	tctctttatg	cctactcact	cctgccattt	1440
ctctgttgta	ttattttgaa	gtaaaccttg	gacatctgtt	catcataatc	atccatctag	1500
tgtggctgtg	ctacaattta	cttaaccagt	gttgggtgtt	aaccaaccta	ttgcttattg	1560

gccacccccca	agcttttttac	taatgtaa	aatgctgtaa	agaatatctt	tgagtaggat	1620
aattttaaga	atcacttcca	gatgtcaaat	tacttgacta	tatgacattg	ccttttaact	1680
taagtcttgg	gaacgtttta	aatattttaa	aatgttaa	ccgaggccgg	gcgcggtggc	1740
tcatgcctgt	aatcccagaa	ctttgggagg	ccgagggtgg	tggatcacct	tgaggtcagg	1800
agctcgcaac	cagcctggcc	aacatggcga	aaccctatct	ctactaaaaa	tacaaaagtt	1860
agccaggcat	tgtgggtgcac	acctgtaatc	ccacctactc	gagaggctga	ggcaggagaa	1920
ttgcttgaac	ccggggaggca	gagggtgcaa	tgagccgaga	tcacgctact	tcactccagc	1980
ctggggcaacc	gcgtgagact	ccatctcaaa	aacaaaagaa	aaaaaaaaaw	aaaaaaaccg	2040
gcacgagggg	gggcccgtac	ccaatcg				2067

<210> 21
 <211> 997
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (963)
 <223> n equals a,t,g, or c

cccgaactcta	ggccggaagc	gcgcggagac	catgtagtga	gaccctcgcg	aggtctgaga	60
gtcactggag	ctaccagaag	catcatgggg	ccctggggag	agccagagct	cctggtgtgg	120
cgccccgagg	cggtagcttc	agagcctcca	gtgcctgtgg	ggctggagggt	gaagttgggg	180
gccctggtgc	tgtgtgtggt	gtcaccctc	ctctgcagcc	tggtgcccat	ctgtgtgctg	240
cgccggccag	gagctaacca	tgaaggctca	gcttcccgcc	agaaagccct	gagcctagta	300
agctgtttcg	cggggggctg	ctttttggcc	acttgtctcc	tggacctgct	gcctgactac	360
ctggctgcca	tagatgaggc	cctggcagcc	ttgcacgtga	cgctccagtt	cccactgcaa	420
gagttcatcc	tggccatggg	cttcttctctg	gtcctggtga	tggagcagat	cacactggct	480
tacaaggagc	agtcaggggc	gtcacctctg	gaggaaacaa	gggctctgct	gggaacagtg	540
aatggtgggc	cgcagcattg	gcatgatggg	ccaggggtcc	cacaggcgag	tggagcccca	600
gcaacccct	cagccttgcg	tgcctgtgta	ctggtgttct	ccctggccct	ccactccgtg	660
ttcgaggggc	tggcggtagg	gctgcagcga	gaccgggctc	gggccatgga	gctgtgcctg	720
gctttgctgc	tccacaaggg	catectggct	gtcagcctgt	ccctgcggtc	gctgtgcagc	780
caccttaggg	cacagggtgt	ggctggctgt	gggatcctct	tctcatgcat	gacacctcta	840
ggcatcgggc	tgggtgcagc	tctggcagag	tcggcaggac	ctctgcacca	gctggccccag	900
tctgtgctag	agggcatggc	agctggcacc	tttytytata	tcaccttityt	ggaaatcctg	960
ctntttcatc	caaatttaa	gggggtttca	agaagaa			997

<210> 22
 <211> 1383
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (556)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (562)
 <223> n equals a,t,g, or c

<400> 22

```

ggtgcaaaga acatagaata ttttgaaaaa cataagactg aaaatacatt ctgagctcac      60
ctttgcttga tagtttggct gaacataaaa atctagtttg gaaatctttt ttgcctagaa      120
attttatgac attttcccca ttgtcttcta ctttctgggtg gtcttccaga tttcactgtg      180
aaatgctgtg gtttgtatct ttacttgtca cttttactgc aactcagtt gaatactctc      240
aatattaaag ctcatgccct ccagtttggg catattttga tgaatatttt gtgaaaattc      300
cttgccctttt ccaacttcta gaagctgcct ctacactttg attcttttggg ctctttcttt      360
ttttctccac cttcaaagcc agcagcatag cacttccaaa tttctctctg cttctgccct      420
agtactaata ttaagtgagg tctccttggt tcaaagaaaa tggatgtcaa taaagcactg      480
atgcatcagc aaatagtttt aaactccctg gakgwatata tagtcttcca gaatacctct      540
cttctctact agagtntaga tntattcatt tactcatcay tcmatcattt aamaaacatt      600
ttctaagaaa ctgcttttgcc tttgggactg ccctaggywc tggaaataaa tagtgagcat      660
gacattgttt gaacttttta agcagcttac agttaaatag gtgaaacaaa ccaatataca      720
aggacttgcc atataataca aatacttttg tagagctaag tatagaatgt aaaaqaaagg      780
aaatagctca gtcttggagg gggaaaggag atttctcagt gacctgggac acttgaagaa      840
taagtaggag tcatccaaac aaagaacagg caaagctatt gatatagcat gtacaaagac      900
ccagaagtga aagaagggtat agtattttca gagaaattac tcatgtaatc tgagacttag      960
acaagtagag acagagatga atctggagag gcaaagtaat gaaggacctt atgaattggg      1020
tgaccataga atatactatc caaacctata cacttttgaa aatgaaagag ataccgggt      1080
gcagtggctc atgcctgtaa tcccagcact ttgggaggcc aagcaagaca ggccgatcat      1140
ctgaggtcag gagtttgaga ccagcctgac caacatggtg aaaccccatc actactaaca      1200
ttacaaaatt agccaggcat ggtagctcac acctgtattc ccagctactc aggaggctga      1260
ggtagtagaa tcgcttgaac ccgggaagtg gaagttgtca gtgagccaag attgtgccat      1320
tgactctag cctgggtggc agagcgaac tctgtctcaa aaaaaaaaaa aaaaagggcg      1380
gcc

```

<210> 23

<211> 1513

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1502)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1512)

<223> n equals a,t,g, or c

<400> 23

```

gcagaatggt taaaggcctt aggtatatgg agcgagctgc tgaaastatg gcaaggtggt      60
tgatctggcc ccactccatt tggatgcaag gatttcaact tctacccttc agcagcagct      120
gggccagcct gagaaagctc tggaaagctc ggaaccaatg tatgatccag atacttttagc      180
acaggatgca aatgctgcac agcrghaact gaagttattg cttcatogtt ctactctggt      240
gttttcacaa ggcaaaatgt atggttatgt ggatacctta cttactatgt tagccatgct      300
tttaaaggta gcaatgaatc gagcccaagt ttgtttgata tccagttcca agtctggaga      360
gaggcatctt tatcttatta aagtatcgag agacaaaata tcagacagca atgaccaaga      420
gtcagcaaat tgtgatgcaa aagcaatatt tgctgtgctc acaagcgtct tgacaaagga      480
tgactgggtg aatcttctgt tgaaggccat atactcctta tgtgacctat cccgatttca      540
agaggctgag ttgctttag atctctcatt ggaatattac tcattttatg atgacaggca      600
aaaacgcaaa gaactagaat actttgggtc gtctgtctga attctggaca aaaatttcag      660

```

aaaggcatac	aactatatca	ggataatggt	aatggaaaat	gtcaataaac	cccagctctg	720
gaacattttc	aatcaagtta	ccatgcactc	ccaagatgta	cgacatcatc	gcttctgtct	780
ccgtttgatg	ctgaaaaacc	cagaaaatca	tgccctatgt	gtcttaaata	gacacaatgc	840
atttgtatct	ggtagtttta	agcatgcgct	tggacagtat	gtgcaagcct	ttcgcaactca	900
ccctgacgaa	cctctctata	gcttctgtat	aggcctaacc	tttattcata	tggcatctca	960
gaagtatgtg	ttacggagac	atgctcttat	tgtacagggc	ttttcctttc	ttaatcgata	1020
cctcagttta	cgtgggccct	gccaggaatc	attctacaat	ttggggccgtg	gccttcatca	1080
gttggggctg	attcatcttg	caatccacta	ttatcagaag	gccctggagc	tccctccact	1140
tgtggtagag	ggtatagaac	ttgaccagtt	agacttacga	agagatattg	cctacaactt	1200
gtctctcatc	tatcagagca	gtgggaatac	cgggaatggt	caaacgcttt	tgtataccta	1260
ttgttctata	taaagcaccg	caactgagaa	cagagcaatg	gcagctgctg	tgtgaggacc	1320
agtgtcttct	gtctcagggc	ttattatttg	taactccaaa	atagaaatga	caatttcaga	1380
attacctaac	aaacagtgtg	tttattttta	atatgtgata	atgatcttgt	ggtatatatg	1440
caaaattatt	cctacaaaaa	aaaaaaaaaa	aaactcgtag	ggggggcccg	gtacccaatc	1500
cnaatttttc	cnc					1513

<210> 24

<211> 1044

<212> DNA

<213> Homo sapiens

<400> 24

ggattttcag	agacaaaggt	ccaagttagg	agacgtaatt	actcagtgtc	ttgaaggagc	60
atccaaggtg	ctcactctta	gccatagccg	ttggtttctc	ggatgctgac	tgtgaagatt	120
ctaaagtgtc	tcctagggtg	ggcgggtggt	gcaggaggcc	ttggacggag	tcaggccaga	180
cccagcctcc	tgtttaatat	gctgagccca	agcgtccctc	agatgcgaat	ccaacagcct	240
tggtagattg	taagatttca	tggaaacttt	ccctgacttc	tgtctcccc	ttgctcccca	300
ttacctggga	aaggcagctt	tgtgggcat	gtgtcccgga	agggcctggg	ctggctgtgg	360
cccagtgtc	aggaccagcc	atcttggccc	tcacagcgcc	ctgcccagtt	ggtgtaatat	420
ttgtyttcaa	gccattgttg	gagcaggcag	gcaaaggggg	ctttctgagg	atccaacgtg	480
tgccagccac	tgggatacaa	agacaggcct	ggttcctagc	tgtggggctg	ggaagggtat	540
ctgacatcaa	tgggtggcacc	tggcagagga	cacacagaca	acagcaggca	gcatggactt	600
ttatgtttgt	agcttgagct	ggttttaatt	ggaagctctg	tgatttacat	aatcacttac	660
aatctctgta	aataaggaac	tatttatgag	gaattgtaaa	tttctctctc	cccccttctt	720
accctgtctg	tgatcttgtc	tgtgatgcag	taatgatatt	ccactctagg	ttcccatgat	780
cagtggtgaa	atatagtgat	tttcacctgt	gcttccatc	tgaagtctct	gaaagaagta	840
ctggatggac	tgaagtccag	gacaacgtyc	caaagaaagg	cagagtccag	gtaggccttg	900
aggaccaagc	cctggatgag	cactggaggg	cagaggcctc	agtgtccagc	actgtgccct	960
gcacatggaa	agccccctac	tttgtggaat	gaatgaataa	taaaaatgtt	ttcataagtg	1020
aaaaaaaaaa	aaaaaaaaact	cgag				1044

<210> 25

<211> 2575

<212> DNA

<213> Homo sapiens

<400> 25

ccacgcgtcc	gcgggacccg	gccgacatgg	cggcagcggg	ggcggctgcg	ctggcgcggc	60
ttttggcggc	ctttctgtct	ctcgcggccc	aggtggcctg	tgagtacggc	atgggtgcacg	120
tggctctcca	ggccgggggg	cccgaaggca	aagactactg	catcctctac	aaccgcagct	180
gggcccattc	tccgcacgac	ctcagcaagg	catctttcct	gcagctgcgc	aactggacgg	240
cctccctgtc	ctgtctcgca	gccgacctcc	ccgcccgtgg	cttcagcaac	cagatcccgc	300
tgggtggcgc	ggggaactgc	accttctatg	agaaagttag	gctggcccag	ggcagcggag	360

cacgcgggct	gctcatcgtc	agcagggaga	ggctgggtccc	cccggggggt	aataagacgc	420
agtatgatga	gattggcatt	cccgtggccc	tgctcageta	caaagacatg	ctggacatct	480
tcacgcgttt	cggccgcacg	gtgagggcgg	cgctgtatgc	gcctaaggag	ccggtgctgg	540
actacaacat	ggatcatcatc	ttcatcatgg	ctgtgggcac	cgctcgccatc	ggcggtact	600
gggcggggag	tggggacgtg	aagaaaaggt	acatgaagca	caagcgcgac	gatgggcccg	660
agaagcagga	ggacgaggcg	gtggacgtga	cgccgggtgat	gacctgctgt	tttgtggtga	720
tgtgctgctc	catgctgggt	ctgctctact	acttctacga	cctcctcgtg	tgcgtggtca	780
tcgggatctt	ctgcctggcc	tccgccaccg	gcctctacag	ctgcctggcg	ccctgtgtgc	840
ggcggtgccc	cttcggcaag	tgcaggatcc	ccaacaacag	cctgccctac	ttccacaagc	900
gcccgcaggc	cgatgctgtg	ctcctggcgc	tcttctgctg	ggcgcgcagc	gtgggtggtgg	960
gcgtcttccg	caacgaggac	agtgggacct	ggtcctccag	gatgccctgg	gcctgcctct	1020
ctgcctctac	atgctgaaga	ccatccgtct	gccaccttc	aaggcctgca	cgctgctgct	1080
gctgggtgctg	ttcctctacg	acatcttctt	cgtgttcac	acgcccttc	tgaccaagag	1140
tgggagcagc	atcatggtgg	aggtggccac	tgggcccctg	gactcagcca	cccgtgagaa	1200
gctgccccatg	gtcctgaagg	tggccaggct	gaactcctca	cctctggccc	tgtgtgaccg	1260
gcccttctcc	ctcctgggtt	tgggagacat	tttgtgtcca	gggctgctgg	tggcctactg	1320
ccacaggttt	gacatccagg	tacagtcttc	cagggtatac	ttcgtggcct	gcaccatcgc	1380
ctatggcggt	ggcctccttg	tgacattcgt	ggcactggcc	ctgatgcagc	gtggccagcc	1440
cgctctcttc	tacctggtgc	cctgcacgct	ggtgacgagc	tgcgctgtgg	cgctctggcg	1500
ccggggagctg	ggcgtgttct	ggacgggcag	cggttttgcg	aaagtcctac	ctccatctcc	1560
gtggggcccca	gcaccagccg	acggcccgcg	gcctcccaaa	gactctgcca	cgccactctc	1620
cccgcagccg	cccagcgaag	aaccagccac	atccccctgg	cctgctgagc	agtccccaaa	1680
atcacgcacg	tccgaggaga	tgggggctgg	agcccccatg	cgggagcctg	ggagcccagc	1740
tgaatccgag	ggccggggacc	aggcccagcc	gtccccggta	acccagcctg	gcgcctcggc	1800
ctagggggagg	ggtgagacgc	tcgctgcccgt	gcccgcacac	ccaagatggt	ggggctgcct	1860
ggcgcccatg	gagacagaca	gacagacgct	tgccccccgg	gaccgaggcc	tgtgccgtcc	1920
ccaccgcccc	caacatgggt	cttctccttg	ccgagacccc	tgcagtcgtg	cccgcgcccc	1980
gcccagctgc	cccggctgca	cgctgctgc	tcccagctcg	cccggctgcc	acaagctttc	2040
tgcgggtcca	tcctccccgc	aggaggagg	gtccgctcct	cgcaggcctt	gcccggcctc	2100
tctgcagacc	ctcaagcgtc	gtctgcatga	gtgagcaggc	gtgggtggac	tttggccggc	2160
gccacacttg	gtgctcacca	gctgcttcgg	ccttcagggt	acctccctcc	ccacggcacc	2220
ctgctctccg	ggtggaagag	cagctttttg	tctcccagaa	ggcatcgctt	ttccctcttg	2280
agcagatcgg	agcccctggg	aggtttgga	gctgcctcca	agcctaggac	acggaccggg	2340
ggccggggcg	gcctctggcc	cctgacgctg	gctgagacag	gcccgtgggg	cggggttttg	2400
gggcgtgaac	aaggctggca	gtaagtggac	aagctgctcc	cctggctaag	gccttgcctt	2460
gccctcagcc	agaggtgcct	ggccatgcct	gcacactcct	ccccatttta	ataaatgggtc	2520
gcaacttcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa	2575

<210> 26

<211> 718

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (21)

<223> n equals a,t,g, or c

<400> 26

aactagggat	ccccgggct	ncaggaattc	gccactggrg	ccaaagtgag	agtccagcgg	60
tcttccagcg	cttggggccac	ggcggcgccc	ctgggagcag	aggtggagcg	acccattac	120
gctaaagatg	aaaggctggg	gttggctggc	cctgcttctg	ggggccctgc	tgggaaccgc	180
ctgggctcgg	aggagccagg	atctccactg	tggagcatgc	agggtctctg	tggatgaact	240
agaatgggaa	attgcccagg	tggaccccaa	gaagaccatt	cagatgggat	ctttccggat	300

caatccagat	ggcagccagt	cagtgggtgga	ggtaactgtt	actgttcccc	caaacaaagt	360
agctcactct	ggcttttgat	gaaattcgac	tgcttaaaaa	ggaccttggt	ttaatagaaa	420
tgaagaaaac	agactcagaa	aaaagatttg	gctctgtctc	atgttgaaga	agctgcaggc	480
ttattcccca	tgcaacttgc	tcctggctgc	aaaccttaat	actttgtttc	tgctgtagaa	540
tttgtttagca	aacagggagt	cctgatcagc	acccttctcc	acatccacat	gactgggttt	600
taatgtagca	ctgtggtata	catgcaaaca	tccgttcaaa	atctgagtcg	gagctaaaaa	660
aaaaaaaaaa	aaaactcrag	ggggggcccg	agtacccaat	tsgccctaga	agaggcga	718

<210> 27

<211> 654

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (613)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (623)

<223> n equals a,t,g, or c

<400> 27

ggtcgacca	cgcgctcggg	catggccatc	cagagcctgc	acccttgccc	ctcagagctc	60
tgctgcagg	cctgcgtgas	yttttaccac	tgggcgatgg	tggtctgtgac	gggcggcgtg	120
ggcgtggccg	ctgcctgtg	tctctgtagc	ctcctgctgt	ggccgaccgg	cctgcgacgc	180
tcccaggcgg	gagaacaccg	aacacccagt	gaagggtgagg	ggatcagcac	ggcgccgcca	240
ccgtgctgga	acgagactca	gccacaagga	ggtgcgaagc	tctgacccag	gccacagtgc	300
ggatgcacct	tgaggatgtc	acgctcagtg	agagacacca	gacacagaag	ggtacgctgt	360
gatcccactt	ctatgaaatg	tccaggacag	accaatccac	agaatcaggg	agaggattcg	420
tgggtgccgg	gactggggag	ggggacctgg	gggtgactag	gtgacataat	ggggacaggg	480
ctgccttctg	ggtgatgaga	atgttcttga	atcagatggg	atggctgcac	ggcgtggtga	540
aggtactgaa	cgccacctca	ctgtaagacg	gtagattttg	tattttacca	caataaacia	600
aacaaaacia	aanmaaaaaa	aanmaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa	654

<210> 28

<211> 1445

<212> DNA

<213> Homo sapiens

<400> 28

ggcacgaggg	atgtgaacia	gatcattaga	attcaaaaaa	caccagaaat	gaaagatctt	60
tcctgaagct	gttttagaat	attcatgata	tacccttaac	tggtctagag	aacaaaatgc	120
gtctgtgtct	cttcacaaaa	gtccctatga	atgtgtttct	caatgtgac	cttcttaagt	180
tctataactt	tttgttttca	ttaatttttag	gaaaaatcctg	ccttgcttcg	ttgggcctat	240
gcaagaacia	taaatgtcta	tcctaatttc	agaccactc	ctaaaaactc	actcatggga	300
gctctgtgtg	gatttgggccc	cctcatcttc	atgtattata	ttatcaaaac	tgagagggta	360
agtattcaga	ccagatgttt	agtattttgag	tgataggttc	actttctagg	gaccagctgc	420
agctccttct	cttgaagatt	gccaccagtg	cccctcccac	cttggggctg	tcctctgcct	480
tccttctctc	tcttctttta	tctttattcc	tttccagcag	gagttaaaac	agaaagtttt	540
cagtcacctt	tgtctatttt	tgtagtttca	tttgtttttt	aaaaagatga	tgttttattgg	600
gttaagtatt	agcagaatac	ataaatcatt	tagtacgttt	cctgtttgcg	tgaattctat	660

ttatgttggg	cacattttgc	aaattaatgt	taaaacctat	taatactcta	cgggacagag	720
aagcacaagc	tgcctgtgtg	gggaatagct	gccgtcagca	gcctgggtat	atgattggag	780
agaaagtcaa	gctgatcttt	ggcaccaaac	cattccacat	ctgggtactaa	accctgagct	840
gcagccccc	ggcttgtgtt	gccactggag	cccactcgtc	tagctttgtc	tttaactggc	900
ccatctgcat	tcccattaga	gttcgtgtat	tttgattatc	tgggtgaatga	tctacttaac	960
agaaaggtag	tccacatttt	cccagaaagt	gtttgcattt	tgctttcaat	atatggtttt	1020
atgggataat	atattttctaa	tgactaaaat	gtgagtaaga	tgtttttgaa	taggagcatt	1080
ttcttactgt	gtcttttagtt	cctcggatta	ctgtttcttc	gcacactccc	tgggcttttag	1140
acagtgggat	tgcaattagg	tttgaggagt	ttcattctgt	ttgtcagttg	tacgggtgggt	1200
tgtgccaaaa	tgagttttt	cttacctttt	ttattttatt	atttttatct	aatatagcca	1260
actggcagaa	tatattgtct	ttaatgtact	ttttttctgt	ctttacagga	taggaaagaa	1320
aaacttatcc	aggaaggaaa	attggatcga	acatttcacc	tctcatatta	agtctggcaa	1380
tgatgactat	atgtattcct	gcctaaataa	atcatctatt	aatcattaaa	aaaaaaaaaa	1440
aaaaa						1445

<210> 29

<211> 2020

<212> DNA

<213> Homo sapiens

<400> 29

ccacgcgtcc	ggggtgaggg	caacagatgc	tggacccagg	gagctctctg	ccacaggatg	60
atgggtggccc	ttcgaggagc	ttctgcattg	ctgggtctgt	tccttgcagc	ttttctgccc	120
ccgccgcagt	gtacccagga	cccagccatg	gtgcattaca	tctaccagcg	ctttcgagtc	180
ttggagcaag	ggctggaaaa	atgtacccaa	gcaacgaggg	catacattca	agaattccaa	240
gagttctcaa	aaaatatatc	tgtcatgctg	ggaagatgtc	agacctacac	aagtgagtag	300
aagagtgcag	tgggttaactt	ggcactgaga	gttgaacgtg	cccaacggga	gattgactac	360
atacaatacc	ttcagagggc	tgacgagtgc	atcgaatcag	aggacaagac	actggcagaa	420
atgttgctcc	aagaagctga	agaagagaaa	aagatccgga	ctctgctgaa	tgcaagctgt	480
gacaacatgc	tgatgggcat	aaagtctttg	aaaatagtga	agaagatgat	ggacacacat	540
ggctcttgga	tgaaagatgc	tgtctataac	tctccaaagg	tgtacttatt	aattggatcc	600
agaaacaaca	ctgttttgga	atgtgcaaac	atacgggcat	tcattggagga	taacaccaag	660
ccagctcccc	ggaagcaaat	cctaacactt	tcctggcagg	gaacaggcca	agtgatctac	720
aaagggttttc	tattttttca	taaccaagca	acttctaatt	agataatcaa	atataacctg	780
cagaagagga	ctgtggaaga	tcgaatgctg	ctcccaggag	gggtaggccg	agcattgggt	840
taccagcact	ccccctcaac	ttacattgac	ctggctgtgg	atgagcatgg	gctctggggc	900
atccactctg	ggccaggcac	ccatagccat	ttggttctca	caaagattga	gccgggcaca	960
ctgggagtgg	agcattcatg	ggatacccca	tgcagaagcc	aggatgctga	agcctcattc	1020
ctcttgtgtg	gggttctcta	tgtggtctac	agtactgggg	gccagggccc	tcctgcctac	1080
acctgcatct	atgatccact	gggcactatc	agtgaggagg	acttgcccaa	cttgttcttc	1140
ccaagagac	caagaagtca	ctccatgatc	cattacaacc	ccagagataa	gcagctctat	1200
gcctggaatg	aaggaaacca	gatcattttac	aaactacaga	caaagagaaa	gctgactctg	1260
aagtaatgca	ttacagctgt	gagaaagagc	actgtggcct	tggcagctgt	tctacaggac	1320
agtgaggcta	tagccccctc	acaatatagt	atccctctaa	tcacacacag	gaagagtgtg	1380
tagaagtgga	aatacgtatg	cctcctttcc	caaatgtcac	tgccttaggt	atcttccaag	1440
agcttagatg	agagcatatc	atcaggaaag	tttcaacaat	gtccattact	cccccaaacc	1500
tcctggctct	caaggatgac	cacattctga	tacagcctac	ttcaagcctt	ttgttttact	1560
gtcctccagc	atctactgta	actctgccat	cttccctccc	acaattagag	ttgtatgcca	1620
gcccctaata	ttcaccactg	gctttttctc	cccctggcct	ttgctgaagc	tcttccctct	1680
ttttcaaata	tctattgata	ttctcccat	ttcactgccc	aactaaaata	ctattaatat	1740
ttctttcttt	tctttccttt	tttttgagac	aagggtctcac	tatgttgccc	aggctgggtc	1800
caaactccag	agctcaagag	atcctcctgc	ctcagcctcc	taagtacctg	ggattacagg	1860
catgtgccac	cacacctggc	ttaaaatact	atctcttatt	gaggtttaac	ctctattttc	1920
cctagccctg	tccttccact	aagcttggtg	gatgtaataa	taaagtgaag	atattaacat	1980

ttgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

2020

<210> 30

<211> 1083

<212> DNA

<213> Homo sapiens

<400> 30

aattcggcag	agccctgaac	cccgaccccc	accctcgagg	ccagaaatcg	gttgcctctg	60
gggacctgag	aagcgagacc	actcggcgcc	ctgacttgca	aagttggggg	ctttattggc	120
ctccgggatt	ctgctcctgg	cggtttctcc	aggctggtga	tgggcaagcc	gggtgtacca	180
agtccaggat	gcacatgagg	agcgtttgta	gcagtcactg	aatcacctca	tgactagcgg	240
ggcaggcctc	taattcaccg	caggatttcc	ggtagggttg	attgtggggg	tgggtgttgc	300
actccaaaga	gktgctgtga	tttccctgta	tctgtctttc	tggcttggtta	gatcttctca	360
tttggcgtcc	tttctccgaa	gagttaacca	agacgtttgg	catgggttcc	ttgctttcct	420
cctatctttt	gctgctagag	ctgcttttga	aaagaagtct	tttcttgtag	tgggtatctt	480
tctttggggt	acagtgttgt	tcacctcttc	tttgccgaaa	gaatgaatcc	cagtgtctca	540
caagggtaaa	ggaaagatct	gctggtagtg	tttagtcttt	gttctgagct	gatatgtgtt	600
agtagctttt	tgtttttaaa	ttttattagt	aaaatttcac	cagtgaacca	gaagctcttt	660
ttttctgttg	tgaatgcta	gctttaagat	ttctgagaac	tttgtgtcaa	agaaatcttt	720
gaaaagttac	tgaagtatac	agagagggtc	acaattttaa	atgtgcaggt	ggtccggggc	780
cggtagatca	cacctgtaac	cccagcactt	tgggacgcca	aggtggggcg	atcacttgag	840
cccaggattt	ccagaccagc	ctgggcaacg	tgccaaaacc	ctatctctac	taaaattaca	900
aaagttagct	gtgtgtggtg	gtgtgtgcct	gtagtcccag	ctacctggta	ggctgagggtg	960
ggaggatcac	cagagcccag	gaggttgaga	ttgcagttag	ccgtgatcat	ggcagtgcac	1020
tcccgcttgg	gtggcagagt	gagaccctgt	ctccaaaaaa	aaaaaaaaaa	aaaaaaactc	1080
gag						1083

<210> 31

<211> 1580

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1513)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1542)

<223> n equals a,t,g, or c

<400> 31

gctggggaag	atgctgcgtc	cagcgttacc	gtggctgtac	cttggcctct	gcagcctcct	60
ggtgggggag	gcagaggccc	cgagccccgt	ggatccgctg	gagcggagcc	ggccgtacgc	120
ggtgctgcga	gggcagaacc	tgggtgtgat	gggaaccatt	ttcagcatcc	tgctggtgac	180
tgctatcctt	atggcatttt	gtgtctacaa	gccattcggg	cgtcgggtgac	agccagacaa	240
gttcttcaat	gagtatttgg	gaataggata	agttgtgttg	cacacaggcc	agtggagaag	300
ttggaaccaa	aactttccta	cttggaatg	acctttgggtc	tggacagtgtg	gtaaatgcta	360
aatgaattag	aagaaaacat	gtactagaca	ttattttttc	ctaacactgt	agcgcaaata	420
attggccctt	gagtccgctt	ctcagtgttt	ctgactgtac	ttgttaaaag	taagacctga	480
aagctccaaa	ggtcagtgtg	aagatggagt	gttcatgaga	aagaaaacat	ggtaaccttg	540

tgagtgcctg	taagaaccac	actgtaaaga	actcatcatt	aatgcttgaa	aatgttatta	600
agaaggagac	ttaccatgca	gacattccct	atttaagaac	catttggtta	cagtggtgta	660
agaatcacag	atTTTTTTTT	ttaatctcac	ctgagttagc	ctagaatgcg	ctggttgcaa	720
agtgggtgca	gctgtgggga	tcttggggcc	tcgttcctca	cctgcaccc	gccctgcact	780
caggtgctcc	ccctgaagtc	agggtcacat	caggtagacc	tgttactata	tgacaccttg	840
gcctggaatg	ctctgaagtt	ggactggaaa	tgttactagg	ttggcctggt	acaaaaagga	900
ccccatcctg	cttaaacaca	ttgatctccc	ttgccctgca	tttgagtctt	tctagcccac	960
ggtctgaaac	ttgaggcagc	tttccagatt	tggaatgtaa	aaggctcagt	gggcactctg	1020
ttcatccctg	ggtggggagg	gcccagccaa	cagaagtgca	tgtccactgt	gcgggccagt	1080
gtgtgtttac	acaaatttca	tctcagcttt	gaaaatgctg	ctattagttt	ccactgttgg	1140
tgaactggat	tttttccctc	tattgaaatg	atactttcat	acttataaag	ctgtcgtcaa	1200
tatttatttc	aagggtgctag	atttaatttt	gttattaaat	tgaaatgctt	atcttgtgtt	1260
caagcacagc	actgatTTTT	acaacctgca	tttaatgtga	agtaaccgaa	gtaggatact	1320
gtaactgtgt	aaggatTTTT	tttgtaatct	tgtaacattg	aaccattgaa	atgttcagtt	1380
ctttgctttt	gagcaaaaacg	tcaattaaaa	ctaaagtaaa	atcctatata	ttgttttact	1440
ccaccagtta	tttcccaagt	gtttgaaatg	caggtgtgtg	tctgaatttg	gatctaatac	1500
acttaaagga	ggnctgtgga	ggggaaattc	cttttttgag	gncgggtttt	gggtcccctt	1560
gcccggggaa	agggttcccc					1580

<210> 32

<211> 796

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (748)

<223> n equals a,t,g, or c

<400> 32

tcggccccgag	aagaaatgtg	acgcactctc	accaagatgc	tgaagctgac	attcatcaat	60
aagcagctgt	gcatccacta	ggcatttggt	aaatgttaac	ttatctaccg	aggtgggtgtt	120
ttcttagcct	cccacctcct	tgctgtggag	cagcttcatg	taccatgatg	catattcaga	180
tcattcttaa	tactcatatt	ttgatagaga	ggtttttagg	ttttctttta	aaccaagttt	240
attgagataa	actacttttg	taggatattg	aacttaggaa	taatggtag	aaactagaca	300
gctttttttt	ttttattaca	ctttaagttc	tgggatattg	gttcagaaca	tgacagtttg	360
ttacataggt	atacacgtgc	catgggtggt	tgctgcaccc	atcaacctgt	catctgtatt	420
cgggtgtttc	cctaattcta	tcccwccctc	acccccctgc	ccccaaaaag	gccccagtgt	480
gtgatgggtc	cctccctgtg	tccatgtgtt	ctcattgttc	aactcccact	tatgagtggag	540
aacatgaggt	gtttgggttt	ttcttccctg	gttagtttgc	tgagaatgat	ggcttccagc	600
ttcatccatg	tcctkcaaaa	ggacatgaac	tcagtccttt	tttatggctg	catagtattt	660
cgtggatat	aagtgccaca	ttttctttat	ycagtctayc	atgtgggttg	gttccaaatc	720
tttgctattg	tgaatagtgc	cgcaatanac	atacgtgtgc	atgtgtcttt	aaaaaaaaaa	780
aaaaaaaaaa	ctcgag					796

<210> 33

<211> 1256

<212> DNA

<213> Homo sapiens

<400> 33

ctatgttcca	tcattccttc	ccaaagccac	cggaagcatt	ccttctagga	aagggtggagt	60
cggtagtgag	aagccggagg	tgcccctaca	gacatacaag	gagattgttc	actgctgyga	120


```

ggagcagggtc ttaactctgg ccaactgaaca gacctatgct gtggagggtg agacacccat 180
caaccgcctg tccctgctgc tctctggccg gggtcgtgtg agccaggatg ggcagtttct 240
gcactacatc tttccatacc agttcatgga ctctcctgag tgggaatcac tacagccttc 300
tgaggagggg gtgttccagg tcaactctgac tgctgagacc tcatgtagct acatttctctg 360
gccccggaaa agtctccatc ttcttctgac caaagagcga tacatctcct gcctcttctc 420
ggctctgctg ggatatgaca tctcggagaa gctctacact ctcaatgaca agctctttgc 480
taagtttggg ctgcgctttg acatccgcct tcccagcctc taccatgtcc tgggtcccac 540
tgctgcagat gctggaccag agtccgagaa gggatgatgag gaagtctgtg agccagctgt 600
gtcccctcct caggccacac ccacctctct ccagcaaaca ccccttgtt ctacccctcc 660
agctaccacc aactttctctg cacctcctac ccgggccagg ttgtccaggc cagacagtgg 720
catactggct tctagaattc ctctccagag ctactctcaa gttatatcca ggggacaggc 780
ccctttggct ccaaccacac cgcctgaact ttaaggatca ttggactatc ttctctgtgg 840
ccagcgcagc tctcttctgt gttcacagaa tggccactga taggcaygcc tcttttccca 900
cccactggaa ggctcacagg caagggtgaga gaggacacag aagggtgcaa cactgtcgtc 960
acagtaagga cctgaagtga ctttgagaaa ttcacctca caaaccttcc ttcaggagca 1020
ggcattggta gtgcagaggc acagattccg tcttttacca gctgcagaat cttgggcaag 1080
ttacatagcc tctgtgagcc tcatcggtaa acagtggggg ttatgaaacc cacctcacag 1140
ggttgttgtg aggatccaat gagttgattt aggtaagcac ctacgacatg ccgtggcacc 1200
aagtaagcac tcaataaatc actcaactcc ttaaaaaaaaa aaaaaaaaaa ctcgag 1256

```

<210> 34
 <211> 1064
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (462)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1047)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1048)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1050)
 <223> n equals a,t,g, or c

```

<400> 34
cttcagcctg ggcaacagag caagaacctg tctcagtcaa tcaataaatg tatgtatata 60
tatatatgta tatatgtcag accaccgtct gaaattgctg ttcattgattg gaaatcgaac 120
tggaaccccg aaggcaggag atgtgtgctc ccttgggatg tatggggaaa tcacacagag 180
ctgttagtac ttcagtcattg ggatttgctc tcatgctatg catatggggc tcacaacttg 240
taaagtccac tggaagatgg cttatctaag gttccttatt ttgtggtctt tcccccttag 300
ttctgcagtg agtggggcaa agcgtgtcac tgaccttttg aatggaaaac actggaagcc 360
ttagcgttct taattcctga aatgttcatt tttwcttcta agcaactggg cttcasagga 420
gattagggca ggcaataaca gtgttgacac caggggcaact gntttcycct gttatgggat 480

```

tatwcaacat	ctgctttctg	ctaagctcca	tggaaggcac	agaggaaaca	cagcagagtc	540
catgccttag	agactttgta	cctgatgaat	tgagtggat	caggacaatg	ctattttaatg	600
tttgatccat	ccctttctta	agcacatctc	agatttctgt	gctacctgat	tttaacccttt	660
cagttcatag	aaccagaag	gataagggtga	aaagatagac	cgggaaaagt	aatgcaagtg	720
gccaaagagta	gcttccactt	caaagtctct	catgtgtgtg	tgctaacatt	gtgacttctg	780
ttcagtcatt	gtcagtataa	actgtacatt	ggaatcattt	gtagcttttt	aaaaaatgcc	840
tatgcctcac	cctagacctt	ccacatcaaa	atctcaggat	agagtctcaa	gctaaaaagc	900
ctctatttga	gccaggctta	ttggcacctg	cctgtagtcc	cgtactcaga	aggctgaagt	960
gagaggatcg	cttgaactca	ggagttttaac	gccagcagag	gcaatagggc	aaaatagcga	1020
gatctcatct	ctttaaaaaa	aaaaaanntn	aaaagggcgg	ccgc		1064

<210> 35

<211> 755

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (733)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (734)

<223> n equals a,t,g, or c

<400> 35

natttcccgt	tcagttattc	cggtgacact	atagaaggta	cgctgcagg	taccggtecg	60
gaattcccgg	gtcgaccac	gcgtccgaac	tcctgaaaca	gtgaggacat	ctcacagacc	120
agacaggagc	tggggctctg	catctcacag	cggtgcctgt	cagacaggaa	gaagtcccgc	180
agaagtggcg	tgtgggtcag	ggcctgcacg	atgcagttca	tgaagcatgt	gttcccaagg	240
ttgatcagcc	cacgcagacc	tatggtgcag	ttcgagggtga	tctttctcct	tttcgggttg	300
tgcttcagca	gttcaagctc	ccgtttgggt	ggttcccaag	ttgaaaactt	ctctccaacg	360
ccttgcatth	tccaagctth	tcgtgtctcc	tccttgggca	ttatttccat	gtctttgtca	420
tagatgtagt	cctggcacag	aaaacagtag	atgcctccgt	acatcagatc	aatggccagg	480
ttgtgccgct	tcgccttcgc	atgctcgtga	atatgcttct	ttgtgaaaca	gccgaagaag	540
acacagtaga	ggcaggaatg	cagcctgttg	agggtggacgc	cacagacatg	gcagatacag	600
gacttggcct	tgcgcttgcg	ggcctcagcc	gtgccgctcc	acacgaagca	ctggtagatg	660
gcccgcaggt	tctgcttcca	gttgtccacc	ttgaagctgc	ccaggtgcga	gcagcccggc	720
ggcgctaccg	ccnctcggc	gtccatggcc	tcgcc			755

<210> 36

<211> 604

<212> DNA

<213> Homo sapiens

<400> 36

ggcctcccaa	agtgtctggga	ttacaggcgt	gagcaagatt	atattttcttt	aataaagaat	60
------------	-------------	------------	------------	-------------	------------	----

acgtgacttt	tatttaagtt	gtcagattta	ttggaaatgt	tggttcgtaat	atcttttgat	120
gtctgtggta	cctgtaatga	ttcctttttt	actactactg	ttttttttct	ctctctcttc	180
caccaccat	ccccatttac	tttatttttc	catctttata	ttttcaggct	ctttattggg	240
cagaattctt	agttgtagaa	aagagagttc	acaccaggta	ctcttaagca	gaaaatgttt	300
tattaagggg	cacagacagc	acagacagct	tacaaaagtg	taggggaccc	aaacagaaac	360
cctttaattt	tactgattag	aatggggagc	tcaacagagg	caactattaa	aatgtgcaga	420
aggtattcag	aagattgtga	gcaggcatat	atgagagatt	tcattacaag	ctctctacag	480
taaccaacca	taatgcagaa	tagaaattca	ttattttgga	cttttgctac	ctgtcaattt	540
aactgttacg	tttttacgga	cttggttaaaa	aagtgattag	atagactggt	ttagattttc	600
ctta						604

<210> 37

<211> 812

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (17)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (108)

<223> n equals a,t,g, or c

<400> 37

gaccattttt	agccaanctt	ggaattaacc	ctcacttaag	ggaacaaaag	ctggagcttc	60
caccgcgttg	gcggccgctc	tagaactagt	ggatcccccg	ggctgcanga	attcggccac	120
gagaggactt	ccccacctca	tgcagctatt	tgggcccgtg	cgtctgaaat	ttattatttc	180
agagtcaccc	ctttrratgac	cttggcagtg	ractgcagtc	atctgtttag	gcctttccat	240
ggccccacgtc	aatgccggtta	tttctgtttg	ttgcacattt	gatttccttg	ttgttggeat	300
ttagaaggcc	ccctgcttcc	cagatcacac	cacgggcatg	gaccacagag	attgcatctt	360
gtgagtctgt	agaaatggtc	aaggccttgt	cctctcttag	gtccagagct	caggtgaatg	420
cagattttcc	cggccatctg	tgctgaagtc	cctgtgggga	ggctcctggc	tggtttcctg	480
taggtagaca	gctacacgtc	ctgcccttca	ttggcttctt	ttcatgaagc	tcctgccatc	540
tacaaaacat	gtctcccttc	ttgaatcaca	tctctgttat	tgaagctctg	gaagtcaacc	600
gggcggtggtg	gctatgccta	taatcccagc	attttgggat	gccggggcgg	gtggatcacc	660
tgaggtcagg	agttcgggac	cagcctggcc	aacatggcga	aaccccgtct	ctaatacaag	720
tgcaaaaatt	ggccaggcgt	ggtggtcact	gtgctccagc	ctgggtgaca	gagcgagctc	780
cgtctcaaaa	aaaaaaaaaa	aaaaaactcg	ag			812

<210> 38

<211> 1149

<212> DNA

<213> Homo sapiens

<400> 38

gtaaaagtta	aaaatgtttg	ccttttatgt	tcaggtttta	aatcaatcta	aaagtatttt	60
tgtatacagt	aggaatctaa	ttttttttat	ccatatgata	gtcagttggc	cctcctttct	120
tcagttacct	gcagtgcatc	aatgtcatca	gtcaagtgtc	catatatgtg	gtgtttctgg	180
gcttttcccc	tcttccaatt	atcagtgttt	atccctgtgt	caaaatcaca	cagtattaat	240
tattacaact	ttatagtaag	tcttaatat	tagtagggca	agtcttttta	tttgataaga	300

gtatctttgc	tattctttta	cttttactct	tctgcatata	ttttagaatc	agcctgtcaa	360
attcctcaaa	agactgtttg	gataaatttg	gaattacatt	caatatagat	caatttggga	420
ataaccaaga	gttttgggat	attgagtctt	cattcattaa	catagctttt	ctcttcattt	480
atthaggtct	tattttttca	tagagcttta	aaaggtttac	tataaaatct	ttaaggggta	540
aactcttgaa	taaggtccag	agttaaatag	tggagagtta	caggtgtctg	tttgcccaa	600
acagactgat	ggtatttcag	ccatctcagg	atttggggaa	gtcagcacaa	ggatcaaaag	660
actgagaaag	tttaacttct	cctctaggat	gttttttagta	cacacattat	atttataagg	720
aaacatattg	taaataatag	agtgataatg	gccacttacc	tgagccttat	tataaacaga	780
aacaaatata	caaccaatgc	catagagcag	aagtacagcc	tgaaaccaag	aagaaaaaga	840
gcaattaaat	caggatctca	tctaggccaa	gcttgaaaag	gaagcttatt	tcctatttgt	900
cttctgccta	atgaatgtgt	cattactggg	gaccttacca	ataaagggtc	ttggatacat	960
tttccagcac	agaaacttaa	tttgcaggaa	catgatcttt	acttgtaaaa	ggatacatte	1020
ttaattcggg	atggttattt	gagctgattt	tcaaggcatt	tatttttaat	ttatttgtca	1080
gatgggaata	aaggtgggtt	ataattaaat	ttaaagata	gtttaaaaaa	aaaaaaaaaa	1140
aaactcgag						1149

<210> 39

<211> 1087

<212> DNA

<213> Homo sapiens

<400> 39

gcccactgga	aatgatcttg	tttatgtgtt	tccttgttta	ctgtctgtct	tcagtagaat	60
ggaagagcca	tcggtatttt	gtcttttttt	ccccttgctc	attcttatat	cctcagcttc	120
tagaacattc	cctggaacac	agcaagtgtt	cagtattgtt	catggagtga	cagatgtctc	180
agccaagaag	gtacaatcac	agggaagaat	gacttcaact	ggtcttgact	tcaacctgct	240
tcagcctgg	ttcccttctc	ccacctccct	acagcccaca	gaagatcttt	tccaaactgg	300
aagtctgtcc	aggtcattct	tctgctctaa	ggctttcagt	agctccccct	tatccccagg	360
aggaagtcca	aatgccttaa	caagtgtcaa	ggaacacttg	gtgagccctg	ctttccttgc	420
tagtcaactg	tgacacagctg	agtctttccc	cagagtggat	gtcattcatg	ctgttcccat	480
tgccctggatt	cctgctcctc	tccaccccat	tcaactgata	aactcgtggg	tttttttttt	540
tttttttttt	ttttgagack	gagtctcgat	ctatcaccca	cgctggagyg	cagaggttgc	600
tgtgagctga	ggtggtgcta	gtgccctcca	gcctggatga	cagagtggaga	ctcgggtctca	660
ataaataaat	aaataataaa	gaagaaacca	acccttttga	ccccggggtc	tcagactttt	720
agccaccaca	tcagcgagtt	atggtgtttg	ttatagcagc	tctgggaaac	taatgcatgt	780
tttcagtga	attttagccc	cttctgaatg	gtctggatgg	ctggttgaca	gctaagttca	840
gaccgatgc	aaaagcgcag	tctatgtagg	aatgtccctt	gtggacagct	gctgtgtagc	900
caaggtgggt	tacataactag	gaaagggccc	tgggggcccc	cacagggagc	taactctatt	960
gacgggggac	ccaggttaaca	gatgcaggca	tttgcgtgta	gtcacaagac	actgatgtgt	1020
gtttgcttgc	ctgggcaaca	tagtgagacc	ccgtctctat	taaaaaaaaa	aaaaaaaaaa	1080
actcgag						1087

<210> 40

<211> 1276

<212> DNA

<213> Homo sapiens

<400> 40

gtgagtgtgt	ggcactgggtg	gcctggagcc	aaatttagct	tgggtgagag	ttgacaatgg	60
tagttttcct	tcctcaagcc	cctctgtgcc	cctagagcac	cctggctgtg	gtgcctcct	120
tcacccaaga	gcagagtcca	tggtgggcca	ggagacttca	gatccatgtc	ctgggtgtgc	180
ctctggcttt	gtctttcctc	agtgggcagg	actgggtctg	ctgggtccatc	tttacccttc	240
tctgagctat	gcagccttgg	cctgctgcgt	ctccggcctg	tattctctcc	ccttcaactca	300

ggccctggga	aaccagccca	gtttctkgca	ggagaggcag	aggaggtcaa	tgcctttgct	360
ctgggcttcc	tgagcaccag	cagtgggtgc	tctggagaag	atgaagtaga	gcccttacac	420
gatggagttg	aagaggcaga	gaaaaagatg	gaagaagaag	gtgtgagtgt	gagtgaatat	480
gaggcaacag	gagcacaagg	accagcagg	gtagaagagg	ctgagggaca	cacagagggtg	540
acagaagcag	agggatccca	ggggactgct	gaggctgacg	ggccaggagc	atcttcagggtg	600
gatgaggatg	cctctggcag	ggcagcaagt	ccagagtcgg	cctccagcac	ccctgagtct	660
ctccaggcca	ggcgacatca	tcagtttctt	gagccagccc	cagcgctgg	tgctgcagtc	720
ttatcttcag	agcctgcaga	gcctctgttg	gtcaggcatc	cccctaggcc	ccggaccacc	780
ggccccaggc	cccggcaaga	tccccacaag	gctggactga	gccactatgt	gaaactcttt	840
agcttctatg	ccaagatgcc	catggagagg	aaggctcttg	agatgggtgga	gaagtgccta	900
gataaatatt	tccagcatct	ttgtgatgat	ctggagggtat	ttgctgctca	tgctggccgc	960
aagactgtga	agccagagga	cctggagctg	ctgatgcggc	ggcagggcct	ggctactgac	1020
caagtctcac	tgcacgtgct	agtggagcgg	cacctgcccc	tggagtaccg	gcagctgctc	1080
atccccctgtg	catacagtgg	caactctgtc	ttccctgccc	agtagtgccc	aggcttcaac	1140
actttccctg	tcccacctgg	ggactcttgc	ccccacatat	ttctccaggt	ctcctcccca	1200
cccccccagc	atcaataaag	tgtcataaac	agaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1260
attggggggg	ggcccc					1276

<210> 41

<211> 2083

<212> DNA

<213> Homo sapiens

<400> 41

gccctttacc	cccaacccca	ggccactggg	cccttcccac	accacttggg	gagctgagaa	60
gaggaggctg	gagtaaggga	ggacttgatc	atccaagaaa	tactttttat	tgctgggagt	120
cttctgaacc	tcaccaaact	gaggccagag	ctgagctcct	gggggagtta	attcagagggt	180
gagaggccag	cacctccctc	ctccatygtc	cgctgtgtgc	cttaaactcc	atctcatgtc	240
cctccccatc	ccctggcttt	ccctccctcc	ttgccccatc	ctggggccagc	cagcaggggt	300
cctcctctgg	ctcttcagac	ctttcagcca	gtgctgtcag	tgccccctggg	aggggaagggc	360
atccctgagg	caccogaatg	gtccctcagg	gtgcagggag	gcagaagcct	ggccacagag	420
gagcctccta	aggcagcagc	tgcagcaagc	gcaccctctc	cccactctcc	ccacgccaga	480
gcggttcca	gagcagatgc	tgtttccatc	ctcctcgtea	aaaccattct	cgctgctgag	540
cttgacaatc	tgggcaaggc	ttgtggggcg	cttgacaaac	agaatctgcc	ctgtgccgcc	600
tggttccgtg	gcctccagca	tgagcctgca	ggcagggcgc	tgcggggaacc	cagttgtgct	660
gccccagccc	atgcctccgg	gtctgctgtg	catgaatgag	tgctcacttg	tcccgggttt	720
aggacgtggt	caagtgaaca	gcagggctca	actgtgctta	cttagccag	ttcaaacaga	780
acaaaggaaa	aatatagaaa	gcaacatctg	ttgatcattt	agggtttttt	ttaaaccacc	840
atgtcacttt	gagtccttca	tgggtttttg	aacagcattt	atcaagaaga	aaatgtgggc	900
tttttccct	ctcccggtt	ttgtttgtcc	tgtagataga	gggaggaaag	ccgtgcagtg	960
gcaggcgga	ccccctctgg	tggcgggacc	ccctcttgcg	gtggtcttgc	ggggccagcc	1020
gggacctgtc	actttattat	ttaaggagtg	tgtgtgtaga	gtcgctggct	tattaacagt	1080
attgtgtgtg	gggtgggttt	ttagtttgtt	ccttcttttt	gaagtccctt	catttcaatc	1140
cttgactctc	tctccccctc	ccttgcccag	ctctgttgaa	tgctgctgtg	cgctgtgtgag	1200
ggcgcctctg	cacacagggc	ccttgggttg	tgtgaactga	aattctccct	gtatttgtga	1260
gactcgcagg	agtccccatc	tgtagcacag	gcaatgccag	tgccatgctg	cagcctcaga	1320
aaccaggcct	ctcactccag	cagcaggcag	aaccgtgtct	gtggtcgggt	gctgtccaca	1380
gctctgtctg	ccttgtttct	gggcttgagc	tggatagagg	tgggtctctc	tcacctccc	1440
tgaattcaga	acagaccctg	tgcctggccc	cagtgtgccc	aggcaattcc	ccaggccctc	1500
attgggagcc	cttgggtgtc	tgagcagcag	ggcccaggca	gcacatgagc	agtgccagg	1560
ggctccctgc	gtgaggacgg	caagggtgca	tgtatgtcta	acttattgat	ggcaggcagc	1620
ccctgtgcc	ccctaagcct	ggccctgggt	attgctgagc	tctgtgctca	gtgctgcggc	1680
ctggccgtgg	ctcgtctgtt	cctttggggg	gcccggggcg	gttgtgggaa	tcagtcttca	1740
cagacagacg	tgagccaggc	ggaggactcg	ttccttgacg	aggtcagtc	tcacctgcag	1800

gtgtcgggggt	ggrgggggggc	aaggaggggc	aggcacacac	catgtctgac	ctgaaccgga	1860
ttctggggag	catcttcccg	ctccggcccc	acgacctcca	cagggttaca	ttgtaatata	1920
tatgccccag	ctaacctgtc	tgatggtggc	atcttctctgc	agacatttca	aacatgtaac	1980
ttttatatga	aaaaaaaaataa	acacagatga	aagctgcccc	aaaaaaaaaaaa	aaaaaaaaaaaa	2040
aaaaaaaaaaaa	aaaaaaaaaaaa	aaaaaaaaaaaa	aaaaaaaaaaaa	agg		2083

```
<210> 42
<211> 1016
<212> DNA
<213> Homo sapiens
```

<400>	42					
taattcgcca	gagccagcct	gggtgcctgt	atgcgctcga	ggcggggggcg	cgggttgccg	60
acggaggcgc	gggaggcggt	tctgcgcggc	gggggccgta	cccgcggcgg	agcaggagg	120
cgagaatgga	tcaatggtgt	cacggagcac	atcgctgacg	ctgatttgtt	tccttttcca	180
cagatttgtt	aaagccccag	gaaaaatggt	ggaaaattca	ccgtcgccat	tgccagaaag	240
agcgatttat	ggctttgttc	ttttcttaag	ctcccaattt	ggcttcaaaa	atctgaaggg	300
atctcgtgtt	tgctgagtgt	tccgtgtgcc	agcactagcc	taggaggttt	tagtctctac	360
aaatatattt	acagcaccag	acgcgatggc	aaagtggata	aagcctggtc	cctgccctta	420
aggaggtcgt	ggtcttgttg	aggagacaga	tggtacttta	cctcgtgtgg	gcctttattc	480
ctgaatcttg	gctaaactct	ttaggtttaa	cctattggcc	tcaaaaatat	tgggcagttg	540
cattacctgt	ctacctcttt	attgctatag	taattggcta	cgtgctcttg	tttgggatta	600
acatgatgag	tacctctcca	ctcgactcca	tccatacaat	cacagataac	tatgcaaaaa	660
atcaacagca	gaagaaatac	caagaggagg	ccattccagc	cttaagagat	atttctatta	720
gtgaagtaaa	ccaaatgttc	tttcttgcag	ccaaagaact	ttacaccaaa	aactgaactg	780
tgtgtaacca	tagtaacacc	aagcacgtat	ttattttata	gtttttgcc	ttataatttt	840
gaccataaat	taatttgacc	atctctctta	ttaatagaga	agtaaaaaat	gtaagttgac	900
cttctcttag	attatgttca	atgaatatgt	taaagtgtca	agtattgtta	atgaatagaa	960
taaatacaat	attgcattcc	cataaaaaaa	aaaaaaaaaa	aaaaaaaaac	tcgtag	1016

```
<210> 43
<211> 2197
<212> DNA
<213> Homo sapiens
```

[illegible]

agagagcctg	cagaagggct	tgggagtgcc	acaccccatc	tctgctgatt	gaatgtccct	1080
ccaggcacca	ggatctcatc	atttcccat	cagaggggtg	ggccaggcct	aacaagacca	1140
tgggtgcttc	tagaaacagg	gttgaagttc	ccagattccc	tgagaggaga	atgtgtatag	1200
gagggtttgg	ctgagtcctt	cagcgttaag	tggaggaaag	cttgggggag	ccccaatagc	1260
tggacagacc	tcagcctccc	ctcgaagaca	cctcaattca	cagactctca	gcccacacaa	1320
tgccccagt	tccccagctc	cgctggagca	gctgcagggc	acttggtatc	caacttctgc	1380
accctctgtc	cagagtctag	ggcagtcctc	cactggccca	gcactccagt	ttcctttccc	1440
tgcctcttgt	ccaatggagt	gggaggccag	gtgagtggag	cagaggtcct	gaagcccttg	1500
accctggggg	gcctgggtag	tgtaggatct	cgctgggctg	ggcctggat	tcagggtcta	1560
ttcctgggag	gacagtctca	gttatgggat	aaggccccct	gggggtctcc	atttctttcc	1620
aacagtttca	tgttcactac	tggactctta	cgggctcagt	atctctccct	tagccatgag	1680
ctggctcagg	catcccttcc	cttccctgga	gctgccctgc	ctttctcaag	tatttattta	1740
tttattgcat	ggttctctgg	aacatgtggc	acaagtaatg	ggatgaggag	gaattggggg	1800
tgggggtctt	ctacctagga	ctcttccctg	gagtcatggg	ctgcctggga	cccaggaccc	1860
atgagggggc	tgagagggtt	ctacactcga	ggagcagggg	tccagagagg	caggctgggg	1920
aggcaaggga	cccctcctag	gcccgccttc	ttgccgagcc	aagcagctta	gctggggctg	1980
tgcagccagg	ggcttaccca	ggccagtggg	ggtgccacag	ccctggggag	ccagacaggc	2040
tttggtatcg	tatcgctctt	gtgtcctttt	aagagaggag	agttcagtac	cccgtgcttt	2100
ctttacactg	gagaggaact	aaaaggatct	ctgtgtctat	ggagaattgt	caataaaaag	2160
gcctcaagct	tmaaaaaaaaa	aaaaaaaaaaa	ctcgtag			2197

<210> 44

<211> 1999

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (965)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (973)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1110)

<223> n equals a,t,g, or c

<400> 44

ggcagagacc	caaccacaca	cctgggggaat	tgctggcctg	acttctgacc	cctgactcct	60
catacccttc	ctccagagca	tgacatttga	ccaccaactg	aaacctgacc	tctgacccca	120
gaccactggc	ccttcccccg	ccctgtgggt	acttcataaa	ggttactagc	ttctcccctg	180
gccttgagac	ccacacgatg	gccctgctgg	ctctggccag	tgcctgccc	tctgccctgc	240
tggccctggc	tgtcttcagg	gtgcccgcct	gggcctgtct	cctctgcttc	acaacctact	300
ctgagcgcct	ccgcctctgc	cagatgtttg	ttgggatg	gagcccaagc	ttgaagagt	360
tgaggaggcc	ttcacggccg	ccttccagg	cctctctgac	accgaaatca	gtgaggagac	420
catccacact	tcatcagtgt	cctgggggag	gtgcagagg	agggcaggag	aggcccagag	480
ggtcaggctg	agggacagac	agagagaaac	agtcagagga	gaaaggctca	aagaccatga	540
gaacaacaga	gacttaggga	cagagagaca	cagacagggg	asgacagcag	ggcaaagact	600
cagagagggg	aggatggaga	gtcagagagg	ggaagatgga	gactcagaga	gggggaggat	660
ggagactcag	agagagagga	agatggagac	tcggaaagat	ggagactcag	gagtatggag	720

agtcagagag	gggaggatgg	acactcggga	ggatggagag	tcaggaggat	ggagactcat	780
agaaagggga	ggatggagag	tcaggagagg	ttggagactg	gagagggaat	agagacccag	840
agaggggagg	atggagactc	agaggggtga	agatggagac	tcaaagagga	tggaaccca	900
ggagagagga	ggacagagat	gaggcagaga	ctaggggaag	caggatagcg	actggtcggg	960
ggcanagact	canggaggat	agagacttgg	gagggactca	ggaagcatag	cgactgtggg	1020
gcaaagagtc	agagagggga	ggatacagac	ttggggagggc	agagactcag	aaacagaatg	1080
ttcgcattag	ggacatggtg	ttgcggggan	ctgcctcccc	cagccccctgc	tccctccctc	1140
accgccagac	tatgatgaga	gaagccacct	gcatgacacc	ttcaccacaga	tgaccatgc	1200
cctgcaggag	ctggctgctg	cccagggatc	ctttgagggt	gccttccctg	atgctgcgga	1260
gaaaatgaag	aaggtcttta	cacagcttaa	agaagcccag	gcttgcatcc	ctccctgcga	1320
aggtctccag	gagttcgccc	ggcgtttctt	ctgcagcggg	tgctactcta	gggtctgcga	1380
cctcccgtg	gactgcccag	ttcaggatgt	gacagtgcct	cggggcgacc	aggctatgtt	1440
ttcttgcac	gtaaacttcc	agctgccaaa	ggaggagatc	acctattcct	ggaagtgcgc	1500
aggaggaggt	ctccggactc	aggacttgct	ctatttccga	gatatgccgc	gggccgaagg	1560
atacctggcg	cggatccggc	cggctcagct	cacgcaccgc	gggacgttct	cctgcgtgat	1620
caagcaagac	cagcgcctcc	tgccccggct	ctacttcttt	cttaacgtga	cgggccgccc	1680
ccgcggggcg	agacagagtt	gcaggcctcg	ttccgggaag	tgctgcgctg	ggcgccgagg	1740
gatgccgagc	tgatcgagcc	ctggaggccc	agcctgggcg	agctgctggc	caggcccag	1800
gctctgacgc	ccagcaatct	gttcttgctt	gcagtcctcg	gggccctcgc	atcagcgagt	1860
gcgacagtgt	tggcgtggat	gttctttcga	tggtactgca	gtggcaacta	acaaaggat	1920
ctttctctct	tccctatcct	atttccatcc	tgaaaataaa	gaatatattt	caactctaaa	1980
aaaaaaaaa	aaaaaaaaa					1999

<210> 45

<211> 1519

<212> DNA

<213> Homo sapiens

<400> 45

cggcacgagg	taaattctgc	cttcaccacg	tatatctttc	caatgtagga	tgatttattt	60
ttcattacat	ttgttctaag	attttgtagt	gattactcta	gtgtttgtca	tgtaaagtgt	120
agtttatcaa	aatcaggctc	agttctccag	taatatgtgg	ttaaatttca	gtgatgtaca	180
cacatatattg	tccctatag	ctctattatg	tttttgcctt	tctggggtag	ttgtttgcac	240
atgtaacaac	tcagtgttcc	acattcaaca	atatattcct	ataattatta	cttttccact	300
ggtagtcatt	tagttcagtt	tttatgggtg	tatttataaa	tataatacat	gtatgttaaa	360
tttttctatg	ttgtaggcct	aacaatccat	tactacttat	tactttacac	aattgacttg	420
taaatccata	acaaggagaa	aggtgaagaa	acacatatcc	agtttgtctt	ttccacttat	480
atagtcttgc	atgggtgctc	ctgctttttc	ctgtggattt	tgacagactc	aataattttt	540
tttttttttg	agatggagtc	ttcctctggt	gtcccaggct	ggagtgcggt	ggctctatct	600
tggccactgc	agcctccacc	tgccgggttc	aaatgattgt	cctgcctcag	ccccccaagt	660
agctgggact	acaggcgtgt	gccaccacac	ccggctaatt	tttgattttt	tttttttttt	720
tgtagagaca	gggttttgcc	atgtttgcca	gggtgctctc	aaactcctga	cctctagtga	780
tccaccagcc	tcggcctccc	aaagtgtcga	gattacagac	gcgagccacc	gcacctggca	840
ctttgggtctt	gtagggctgg	tgtgccagga	aaaattctct	caatgttcat	atttttaagc	900
ctaggaaaaat	atttgttttg	tctttcattt	tgaacatgaa	cattgtttgga	ttctgggttaa	960
ggtgtgtttt	ggagcagagc	atgatgaggg	actgggtgag	gggcttccca	gtgaaaggag	1020
gaacagaacc	tagcaaaagc	aaatatgtct	gtttcactcc	aatcacttat	tacaataacc	1080
tctattactt	aatatcaaaa	aaaaagcaat	gatcaatatg	ttgaaaggga	tggagaagc	1140
aagtatgatg	tttgaccata	atagcattca	ttgcttggga	aactaaagac	aaaacaactg	1200
gaaaactatt	aacactgttg	gccagggtgtg	gtggctcatg	cctgtcatcc	cagcactttg	1260
ggaggctggg	gtggatggat	cgcttgagcc	caggagttcg	agaccagcct	gggcaacatg	1320
gcgaaacctc	atctctacaa	aaaatacaaa	aaattacccg	ggtctgggtg	tgtgttctctg	1380
tggtcccagc	tactcgggag	gctgagatgg	aaggattgct	tgagcctggg	aagtcgatgc	1440
tgcatgtgagc	caggattgca	ccactgcact	ctagcctgag	tgacagagtg	agaccctgtc	1500

taaaaaaaaa aaaaaaaaaa

1519

<210> 46

<211> 1189

<212> DNA

<213> Homo sapiens

<400> 46

ggcacgagat	ttaatacaaa	gtttgctttg	agacttttca	gcatatgac	ttttttccat	60
aaacttgtag	agtgcacaa	acattttgaa	taccatgac	gatgatgtcc	catgcttoga	120
ggaaaaccaa	acactttccg	cctctcttgc	aaaatccatt	cctcatgctg	accctcctca	180
cgatggctgt	gtcagcccag	ccccttccct	tctccaggcc	cagataactc	ttccacaaac	240
aagatgagag	ccactcggga	aaagagccat	agtcaactgg	gagggcctac	atctggatgg	300
cgggtgaaaa	acttgagggt	ttggggttca	aagtcagccc	atcccacctg	gcaaaatcct	360
cctggaagga	ggaccttcaa	gagcgcac	cctgaatgtc	atgaagaagt	atctctgaat	420
gtatccagga	gaggaactgc	ataaccaaag	gggtgaccag	ccctcagatg	tgcttattgg	480
attccagtac	aaacgccacc	aaagccagcc	cactgctctc	ctacaaggaa	ggaaagatct	540
gcacgtgtaa	aacatggggc	agccttggaa	catggtgttt	tttggagtgt	cctttctcac	600
agttttccat	ctccccactt	ctttgatcag	tcatgtgtcc	gtgacctcgt	tccatgacat	660
caggatagct	gtgtttgcac	accatgctgc	atgttcattt	ggagccagga	ggggttctca	720
gtggagcctg	gcttagggaa	caggagcgca	tggaagaatg	ccaacattag	cgttgggtct	780
ctcttgtcag	gaatgaagga	tgcttgcaca	catgcacccc	ctcactctca	cacttgcaca	840
catacacaca	cacacacacg	aaatgggttg	tttgtcaaaa	ctcactgtag	tacataaagc	900
ttgcactctg	cgctctatat	ctagcagcat	ggggtacgtt	tggcagttca	ctccattagg	960
gggtaataaa	tttatgacca	ttcatctgtt	tttatgaatt	tttttatcta	gacaataatt	1020
gtaaataaag	aactcaccat	ctctgttcat	ttaatactat	gcaatgggta	tgctttcaat	1080
cgctggctct	tctgactcgt	gcagtgtggt	tctgaaatgt	ttgtgggtta	aaaaaaaaag	1140
caaaaaacac	tcaacagaac	atagtaaata	taaaaaaaaa	aaaaaaaaaa		1189

<210> 47

<211> 2584

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1389)

<223> n equals a,t,g, or c

<400> 47

accacgcgt	ccgcgggcac	cgcccgacat	ggcggcagcg	gtggcggctg	cgctggcgcg	60
gcttttggcg	gcctttctgc	tcctcgcggc	ccaggtggcc	tgtgagtacg	gcatgggtgca	120
cgtggtctcc	caggccgggg	gccccgaagg	caaagactac	tgcatcctct	acaaccgcga	180
gtgggcccac	cttccgcacg	acctcagcaa	ggcatctttc	ctgcagctgc	gcaactggac	240
ggcctccctg	ctctgctccg	cagccgacct	ccccgcccgt	ggcttcagca	accagatccc	300
gctggtggcg	cgggggaaact	gcaccttcta	tgagaaaagt	aggctggccc	agggcagcgg	360
acacgcgggc	tgctcatcgt	cagcaggag	argctgggtc	ccccgggggg	taataagacg	420
catatgatga	gattggcatt	cccgtggccc	tgctcagcta	caaagacatg	ctggacatct	480
tcacgcgttt	cgccgcacg	gtgaggcg	cgctgtatgc	gcctaaggag	ccggtgctgg	540
actacaacat	ggatcatc	ttcatcatgg	ctgtgggsac	cgctcgccatc	ggcggctact	600
gggcccggg	tcgggacgtg	aagaaaaggt	acatgaagca	caagcgcgac	gatgggccc	660
agaagcagga	ggacgaggcg	gtggacgtga	cgccgggtgat	gacctgcgtg	tttgtggtga	720
tgtgctgctc	catgctgggtg	ctgctctact	ayttctacga	cctcctcgtg	trcgtggtca	780

```

tcgggatctt ctgcctggcc tccgccaccg gcctctacag ctgcctggcg ccctgtgtgc      840
ggcggctgcc cttcggcaag tgcaggatcc ccaacaacag cctgccctac ttccacaagc      900
gcccgcaggc ccgtatgctg ctccctggcg tcttctgcgt ggcgtcagc gtgggtgtggg      960
gcgtcttccg caacgargac cagtgggcct gggtccctcca ggatgccctg ggcacgcct      1020
tctgcctcta catgctgaag accatccgtc tgcccacctt caaggcctgc acgctgctgc      1080
tgctgggtgct gttcctctac gacatcttct tcgtgttcat cagcccttc ctgaccaaga      1140
gtgggagcag catcatggtg gaggtggcca ctgggccctc ggactcagcc acccgtgaga      1200
agctgcccac ggtcctgaag gtgcccaggc tgaactcctc acctctggcc ctgtgtgacc      1260
ggcccttctc cctcctgggt ttcggagaca ttttggtgcc agggctgctg gtggcctact      1320
gccacagggt tgacatccag gtacagtcct ccagggtata cttcgtggcc tgcaccatcg      1380
cctatggynt tggcctcctt gtgacattcg tggcactggc cctgatgcag cgtggccagc      1440
ccgtctcctt ctacctggtg ccctgcacgc tgggtgacgag ctgcgtgtg gcgtctgtgc      1500
gcygkgaact gggcgtgttc tggacgggca ggcgctttgc gaaagtccta cctccatctc      1560
cgtggggccc agcaccagcc gacggcccgc agcctcccaa agactctgcc acgccactct      1620
ccccgcagcc gccagcgaa gaaccagcca catccccctg gcctgctgag cagtcccaa      1680
aatcacgcac gtccgaggag atgggggctg gagccatgct gggascctgg gagcccagct      1740
gaatccgagg gccgggacca ggccagcgt ccccggtaac ccagcctggc gcctcggcct      1800
aggggagggg tgagacgctc gctgccgtgc ccgccacacc aagatgttgg ggctgcctgg      1860
cgccactgg agacagacag acagacgcyt gtcccccggg accgaggcct gtgcctccc      1920
caccgcccc aacatggtgc ttatccttgc cgagaccct gcagtccgtg cccgcgcca      1980
gccagctgc cccggctgca cgctgctgc tcccagctcg cccggctgcc acaagctctc      2040
tgcggtcca tcctccccgc aggaggagg gtccgtcctc gcaggccytg cccggcctct      2100
ctgcagacc tcaagcgtcg tctgcatgag tgagcaggcg tgggtggact ctggccgagg      2160
ccacacttg tgctcaccag ctgcttcggc cttcaggtga cctccctccc caggcatcc      2220
tgctctccgg gtggaagagc agctttctgt ctcccagaag gcacgcttt tccctctga      2280
gcagatcgga gccctggga ggtttggaag ctgcctccaa gcctaggaca cggaccggtg      2340
gccggggcgg cctctggccc ctgacgctgg ctgagacagg cccgtggggc ggggttttgg      2400
ggcgtgaaca aggtggcag taagtggaca agctgctccc ctggctaagg ccctgccctg      2460
ccctcagcca gaggtgcctg gccatgcctg cacactcctc cccattttaa taaatggctg      2520
caacttcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaagggcgg      2580
ccgc

```

<210> 48

<211> 56

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (56)

<223> Xaa equals stop translation

<400> 48

```

Met Ile Lys His Ala Leu Ile Arg Pro Phe Ile Val Phe Ser Leu Leu
 1             5             10             15

```

```

Leu Arg Leu Cys Ser Glu Asn Leu Phe Cys Pro Asn Thr Gln Phe Ile
      20             25             30

```

```

Val Leu Ser Cys Phe Gln Ser Val Val Lys Ser Leu Leu Ser Ile Leu
      35             40             45

```

```

Asn Leu Ser Tyr Cys Ile Phe Xaa
      50             55

```

<210> 49
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals stop translation

<400> 49
 Met Asn Ser Cys Leu Phe Leu Cys Ile Leu Ile Leu Glu Ser Ala Met
 1 5 10 15
 Val Val Leu Met Lys Val His Phe Ile Val Ala Phe Glu Leu Thr Ala
 20 25 30
 Lys Ala Ile Asn Gln Lys Gln Lys Xaa
 35 40

<210> 50
 <211> 94
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (94)
 <223> Xaa equals stop translation

<400> 50
 Met Ala Arg Lys Ser Phe Ala Leu Leu Met Phe Val Trp Gln Met Ser
 1 5 10 15
 Leu Ser Leu Pro Ile Lys Gly Phe Ile Leu Arg Val Ala Asn Trp Leu
 20 25 30
 Phe Lys Pro His Leu Asn Ser Val Cys Leu Gly Trp Gln Asn His Thr
 35 40 45
 Arg Phe Cys Trp Ala Asn Leu Pro Gly Gly Val Leu Leu Glu Glu Ser
 50 55 60
 Ala Thr Ala Glu Asp Thr Leu Ser Trp Pro Leu Ala Leu Gln Thr Ile
 65 70 75 80
 Val Glu Glu Gly Val Trp Gly His Gln Pro Leu Pro Gly Xaa
 85 90

<210> 51
 <211> 84

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (84)

<223> Xaa equals stop translation

<400> 51

Met Leu Ser Leu Phe Phe Cys Phe Trp Lys Pro Ser Phe Leu Val Ser
 1 5 10 15

Arg Leu Val Ile Trp Leu Gly Leu Val Cys Gly Gly Arg Ser Leu Ser
 20 25 30

Trp Val Ala Leu Gly Glu Asp Tyr Leu Gly Thr Pro Ile Leu Ile Pro
 35 40 45

Asn Ile His Gln Thr Cys Pro His Pro Pro Leu Trp Glu Leu Val Pro
 50 55 60

Glu His Pro Cys Arg Leu Val Leu Ile Phe Ser Leu Cys Glu His Thr
 65 70 75 80

His Ile Arg Xaa

<210> 52

<211> 66

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (66)

<223> Xaa equals stop translation

<400> 52

Met Leu Ser Pro Lys Ser Pro Arg Met Leu Leu Pro Cys Leu Leu Gln
 1 5 10 15

Pro Leu Val Val Ala Asn Ile Pro Arg Val Pro Trp Leu Ala Asp Glu
 20 25 30

Ser Leu Asn Pro Thr Pro Ile Ile Thr Trp Gln Ser Pro Cys Val Ala
 35 40 45

Gln Leu Cys Pro Asn Phe Pro Phe Pro Thr Arg Thr Leu Val Thr Gly
 50 55 60

Leu Xaa
 65

<210> 53
<211> 53
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (53)
<223> Xaa equals stop translation

<400> 53
Met His Cys His Ser Ala Leu Gly Pro Met Ser Thr Pro Val Leu Pro
1 5 10 15
Phe Ser Gly Ile Gly Leu Ala Phe Leu Cys Leu Cys Leu Ala Ala Ser
20 25 30
Met Val Asp Leu Lys Cys Leu Gly Met Asn Ser Thr Leu Leu Gln Pro
35 40 45
Ser Ile Lys Glu Xaa
50

<210> 54
<211> 541
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (469)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (541)
<223> Xaa equals stop translation

<400> 54
Met Ala Thr Ser Gly Ala Ala Ser Ala Xaa Leu Val Ile Gly Trp Cys
1 5 10 15
Ile Phe Gly Leu Leu Leu Leu Ala Ile Leu Ala Phe Cys Trp Ile Tyr
20 25 30
Val Arg Lys Tyr Gln Ser Arg Arg Glu Ser Glu Val Val Ser Thr Ile
35 40 45
Thr Ala Ile Phe Ser Leu Ala Ile Ala Leu Ile Thr Ser Ala Leu Leu

50 55 60
 Pro Val Asp Ile Phe Leu Val Ser Tyr Met Lys Asn Gln Asn Gly Thr
 65 70 75 80
 Phe Lys Asp Trp Ala Asn Ala Asn Val Ser Arg Gln Ile Glu Asp Thr
 85 90 95
 Val Leu Tyr Gly Tyr Tyr Thr Leu Tyr Ser Val Ile Leu Phe Cys Val
 100 105 110
 Phe Phe Trp Ile Pro Phe Val Tyr Phe Tyr Tyr Glu Glu Lys Asp Asp
 115 120 125
 Asp Asp Thr Ser Lys Cys Thr Gln Ile Lys Thr Ala Leu Lys Tyr Thr
 130 135 140
 Leu Gly Phe Val Val Ile Cys Ala Leu Leu Leu Leu Val Gly Ala Phe
 145 150 155 160
 Val Pro Leu Asn Val Pro Asn Asn Lys Asn Ser Thr Glu Trp Glu Lys
 165 170 175
 Val Lys Ser Leu Phe Glu Glu Leu Gly Ser Ser His Gly Leu Ala Ala
 180 185 190
 Leu Ser Phe Ser Ile Ser Ser Leu Thr Leu Ile Gly Met Leu Ala Ala
 195 200 205
 Ile Thr Tyr Thr Ala Tyr Gly Met Ser Ala Leu Pro Leu Asn Leu Ile
 210 215 220
 Lys Gly Thr Arg Ser Ala Ala Tyr Glu Arg Leu Glu Asn Thr Glu Asp
 225 230 235 240
 Ile Glu Glu Val Glu Gln His Ile Gln Thr Ile Lys Ser Lys Ser Lys
 245 250 255
 Asp Gly Arg Pro Leu Pro Ala Arg Asp Lys Arg Ala Leu Lys Gln Phe
 260 265 270
 Glu Glu Arg Leu Arg Thr Leu Lys Lys Arg Glu Arg His Leu Glu Phe
 275 280 285
 Ile Glu Asn Ser Trp Trp Thr Lys Phe Cys Gly Ala Leu Arg Pro Leu
 290 295 300
 Lys Ile Val Trp Gly Ile Phe Phe Ile Leu Val Ala Leu Leu Phe Val
 305 310 315 320
 Ile Ser Leu Phe Leu Ser Asn Leu Asp Lys Ala Leu His Ser Ala Gly
 325 330 335
 Ile Asp Ser Gly Phe Ile Ile Phe Gly Ala Asn Leu Ser Asn Pro Leu
 340 345 350

Asn Met Leu Leu Pro Leu Leu Gln Thr Val Phe Pro Leu Asp Tyr Ile
 355 360 365
 Leu Ile Thr Ile Ile Ile Met Tyr Phe Ile Phe Thr Ser Met Ala Gly
 370 375 380
 Ile Arg Asn Ile Gly Ile Trp Phe Phe Trp Ile Arg Leu Tyr Lys Ile
 385 390 395 400
 Arg Arg Gly Arg Thr Arg Pro Gln Ala Leu Leu Phe Leu Cys Met Ile
 405 410 415
 Leu Leu Leu Ile Val Leu His Thr Ser Tyr Met Ile Tyr Ser Leu Ala
 420 425 430
 Pro Gln Tyr Val Met Tyr Gly Ser Gln Asn Tyr Leu Ile Glu Thr Asn
 435 440 445
 Ile Thr Ser Asp Asn His Lys Gly Asn Ser Thr Leu Ser Val Pro Lys
 450 455 460
 Arg Cys Asp Ala Xaa Ala Pro Glu Asp Gln Cys Thr Val Thr Arg Thr
 465 470 475 480
 Tyr Leu Phe Leu His Lys Phe Trp Phe Phe Ser Ala Ala Tyr Tyr Phe
 485 490 495
 Gly Asn Trp Ala Phe Leu Gly Val Phe Leu Ile Gly Leu Ile Val Ser
 500 505 510
 Cys Cys Lys Gly Lys Lys Ser Val Ile Glu Gly Val Asp Glu Asp Ser
 515 520 525
 Asp Ile Ser Asp Asp Glu Pro Ser Val Tyr Ser Ala Xaa
 530 535 540

<210> 55

<211> 178

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (67)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (178)

<223> Xaa equals stop translation

<400> 55

Met Phe Gln Val Arg Pro Gly Trp Gln Leu Leu Leu Val Met Phe Ser

<400> 56
Met Ser Leu Ile Trp Glu Gln Gly Leu Gln Leu Cys Gly Phe Cys Leu
1 5 10 15

Phe Tyr Leu Val Phe Cys Phe Cys Ile Ser Ser Leu Arg Val Met Ala
 20 25 30
 Phe Ser Cys Xaa His Val Ala Cys Cys Lys Gly Tyr Asp Phe Val Leu
 35 40 45
 Phe Tyr Gly Cys Val Val Phe His Gly Val Tyr Gly Pro His Phe Leu
 50 55 60
 Tyr Pro Ile His His Ile Trp Ala Pro Arg Leu Ile Pro Cys Leu Cys
 65 70 75 80
 Tyr Cys Glu Xaa

<210> 57
 <211> 132
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (132)
 <223> Xaa equals stop translation

<400> 57
 Met Leu Trp Thr Leu Thr Phe Phe Leu Leu Gln Arg Ser Leu Thr Ser
 1 5 10 15
 Pro Trp Leu Phe Gly Leu Leu Phe Leu Gly Ser Ser Asn Thr Ala Val
 20 25 30
 Cys Cys Phe Leu Gly Gln Leu Ile Met Gly Pro Lys Gly Glu Arg Gly
 35 40 45
 Phe Pro Gly Pro Pro Gly Arg Cys Leu Cys Gly Pro Thr Met Asn Val
 50 55 60
 Asn Asn Pro Ser Tyr Gly Glu Ser Val Tyr Gly Pro Ser Ser Pro Arg
 65 70 75 80
 Val Pro Val Val Arg Leu Ser Gly Arg Ser Leu Gly Trp Leu Ser Val
 85 90 95
 Arg Thr Ser His Leu Ile Leu Met Gly Leu Cys Lys Ile Leu Ser Val
 100 105 110
 Lys Leu Thr Phe Phe His Asp Ser Glu Tyr Thr Leu Ile Ile Gly Asn
 115 120 125
 Trp Lys Ile Xaa
 130

<210> 58
 <211> 187
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (167)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 58
 Met Gly Phe Phe Leu Val Leu Val Met Glu Gln Ile Thr Leu Ala Tyr
 1 5 10 15
 Lys Glu Gln Ser Gly Pro Ser Pro Leu Glu Glu Thr Arg Ala Leu Leu
 20 25 30
 Gly Thr Val Asn Gly Gly Pro Gln His Trp His Asp Gly Pro Gly Val
 35 40 45
 Pro Gln Ala Ser Gly Ala Pro Ala Thr Pro Ser Ala Leu Arg Ala Cys
 50 55 60
 Val Leu Val Phe Ser Leu Ala Leu His Ser Val Phe Glu Gly Leu Ala
 65 70 75 80
 Val Gly Leu Gln Arg Asp Arg Ala Arg Ala Met Glu Leu Cys Leu Ala
 85 90 95
 Leu Leu Leu His Lys Gly Ile Leu Ala Val Ser Leu Ser Leu Arg Leu
 100 105 110
 Leu Gln Ser His Leu Arg Ala Gln Val Val Ala Gly Cys Gly Ile Leu
 115 120 125
 Phe Ser Cys Met Thr Pro Leu Gly Ile Gly Leu Gly Ala Ala Leu Ala
 130 135 140
 Glu Ser Ala Gly Pro Leu His Gln Leu Ala Gln Ser Val Leu Glu Gly
 145 150 155 160
 Met Ala Ala Gly Thr Phe Xaa Tyr Ile Thr Phe Leu Glu Ile Leu Leu
 165 170 175
 Phe His Pro Lys Phe Lys Gly Val Ser Arg Arg
 180 185

<210> 59
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE

<222> (41)

<223> Xaa equals stop translation

<400> 59

Met Thr Phe Ser Pro Leu Ser Ser Thr Phe Trp Trp Ser Ser Arg Phe
 1 5 10 15

His Cys Glu Met Leu Trp Phe Val Ser Leu Leu Val Thr Phe Thr Ala
 20 25 30

His Ser Val Glu Tyr Ser Gln Tyr Xaa
 35 40

<210> 60

<211> 339

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (339)

<223> Xaa equals stop translation

<400> 60

Met Tyr Gly Tyr Val Asp Thr Leu Leu Thr Met Leu Ala Met Leu Leu
 1 5 10 15

Lys Val Ala Met Asn Arg Ala Gln Val Cys Leu Ile Ser Ser Ser Lys
 20 25 30

Ser Gly Glu Arg His Leu Tyr Leu Ile Lys Val Ser Arg Asp Lys Ile
 35 40 45

Ser Asp Ser Asn Asp Gln Glu Ser Ala Asn Cys Asp Ala Lys Ala Ile
 50 55 60

Phe Ala Val Leu Thr Ser Val Leu Thr Lys Asp Asp Trp Trp Asn Leu
 65 70 75 80

Leu Leu Lys Ala Ile Tyr Ser Leu Cys Asp Leu Ser Arg Phe Gln Glu
 85 90 95

Ala Glu Leu Leu Val Asp Ser Ser Leu Glu Tyr Tyr Ser Phe Tyr Asp
 100 105 110

Asp Arg Gln Lys Arg Lys Glu Leu Glu Tyr Phe Gly Leu Ser Ala Ala
 115 120 125

Ile Leu Asp Lys Asn Phe Arg Lys Ala Tyr Asn Tyr Ile Arg Ile Met
 130 135 140

Val Met Glu Asn Val Asn Lys Pro Gln Leu Trp Asn Ile Phe Asn Gln
 145 150 155 160

Val Thr Met His Ser Gln Asp Val Arg His His Arg Phe Cys Leu Arg
 165 170 175
 Leu Met Leu Lys Asn Pro Glu Asn His Ala Leu Cys Val Leu Asn Gly
 180 185 190
 His Asn Ala Phe Val Ser Gly Ser Phe Lys His Ala Leu Gly Gln Tyr
 195 200 205
 Val Gln Ala Phe Arg Thr His Pro Asp Glu Pro Leu Tyr Ser Phe Cys
 210 215 220
 Ile Gly Leu Thr Phe Ile His Met Ala Ser Gln Lys Tyr Val Leu Arg
 225 230 235 240
 Arg His Ala Leu Ile Val Gln Gly Phe Ser Phe Leu Asn Arg Tyr Leu
 245 250 255
 Ser Leu Arg Gly Pro Cys Gln Glu Ser Phe Tyr Asn Leu Gly Arg Gly
 260 265 270
 Leu His Gln Leu Gly Leu Ile His Leu Ala Ile His Tyr Tyr Gln Lys
 275 280 285
 Ala Leu Glu Leu Pro Pro Leu Val Val Glu Gly Ile Glu Leu Asp Gln
 290 295 300
 Leu Asp Leu Arg Arg Asp Ile Ala Tyr Asn Leu Ser Leu Ile Tyr Gln
 305 310 315 320
 Ser Ser Gly Asn Thr Gly Met Ala Gln Thr Leu Leu Tyr Thr Tyr Cys
 325 330 335

Ser Ile Xaa

<210> 61
 <211> 48
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (48)
 <223> Xaa equals stop translation

<400> 61
 Met Leu Thr Val Lys Ile Leu Lys Cys Phe Leu Gly Trp Ala Val Val
 1 5 10 15
 Ala Gly Gly Leu Gly Arg Ser Gln Ala Arg Pro Ser Leu Leu Phe Asn
 20 25 30
 Arg Leu Ser Pro Ser Val Pro Gln Met Arg Ile Gln Gln Pro Trp Xaa

35

40

45

<210> 62

<211> 336

<212> PRT

<213> Homo sapiens

<400> 62

Met Ala Ala Ala Val Ala Ala Ala Leu Ala Arg Leu Leu Ala Ala Phe
 1 5 10 15

Leu Leu Leu Ala Ala Gln Val Ala Cys Glu Tyr Gly Met Val His Val
 20 25 30

Val Ser Gln Ala Gly Gly Pro Glu Gly Lys Asp Tyr Cys Ile Leu Tyr
 35 40 45

Asn Pro Gln Trp Ala His Leu Pro His Asp Leu Ser Lys Ala Ser Phe
 50 55 60

Leu Gln Leu Arg Asn Trp Thr Ala Ser Leu Leu Cys Ser Ala Ala Asp
 65 70 75 80

Leu Pro Ala Arg Gly Phe Ser Asn Gln Ile Pro Leu Val Ala Arg Gly
 85 90 95

Asn Cys Thr Phe Tyr Glu Lys Val Arg Leu Ala Gln Gly Ser Gly Ala
 100 105 110

Arg Gly Leu Leu Ile Val Ser Arg Glu Arg Leu Val Pro Pro Gly Gly
 115 120 125

Asn Lys Thr Gln Tyr Asp Glu Ile Gly Ile Pro Val Ala Leu Leu Ser
 130 135 140

Tyr Lys Asp Met Leu Asp Ile Phe Thr Arg Phe Gly Arg Thr Val Arg
 145 150 155 160

Ala Ala Leu Tyr Ala Pro Lys Glu Pro Val Leu Asp Tyr Asn Met Val
 165 170 175

Ile Ile Phe Ile Met Ala Val Gly Thr Val Ala Ile Gly Gly Tyr Trp
 180 185 190

Ala Gly Ser Arg Asp Val Lys Lys Arg Tyr Met Lys His Lys Arg Asp
 195 200 205

Asp Gly Pro Glu Lys Gln Glu Asp Glu Ala Val Asp Val Thr Pro Val
 210 215 220

Met Thr Cys Val Phe Val Val Met Cys Cys Ser Met Leu Val Leu Leu

225 230 235 240
 Tyr Tyr Phe Tyr Asp Leu Leu Val Cys Val Val Ile Gly Ile Phe Cys
 245 250 255
 Leu Ala Ser Ala Thr Gly Leu Tyr Ser Cys Leu Ala Pro Cys Val Arg
 260 265 270
 Arg Leu Pro Phe Gly Lys Cys Arg Ile Pro Asn Asn Ser Leu Pro Tyr
 275 280 285
 Phe His Lys Arg Pro Gln Ala Arg Met Leu Leu Leu Ala Leu Phe Cys
 290 295 300
 Val Ala Val Ser Val Val Trp Gly Val Phe Arg Asn Glu Asp Ser Gly
 305 310 315 320
 Pro Gly Ser Ser Arg Met Pro Trp Ala Ser Pro Ser Ala Ser Thr Cys
 325 330 335

<210> 63
 <211> 85
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (85)
 <223> Xaa equals stop translation

<400> 63
 Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly Ala Leu Leu Gly
 1 5 10 15
 Thr Ala Trp Ala Arg Arg Ser Gln Asp Leu His Cys Gly Ala Cys Arg
 20 25 30
 Ala Leu Val Asp Glu Leu Glu Trp Glu Ile Ala Gln Val Asp Pro Lys
 35 40 45
 Lys Thr Ile Gln Met Gly Ser Phe Arg Ile Asn Pro Asp Gly Ser Gln
 50 55 60
 Ser Val Val Glu Val Thr Val Thr Val Pro Pro Asn Lys Val Ala His
 65 70 75 80
 Ser Gly Phe Gly Xaa
 85

<210> 64

<211> 63
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (63)
<223> Xaa equals stop translation

<400> 64
Met Val Ala Val Thr Gly Gly Val Gly Val Ala Ala Ala Leu Cys Leu
1 5 10 15
Cys Ser Leu Leu Leu Trp Pro Thr Arg Leu Arg Arg Ser Arg Gly Gly
20 25 30
Glu His Arg Thr Pro Ser Glu Gly Glu Gly Ile Ser Thr Ala Pro Pro
35 40 45
Pro Cys Trp Asn Glu Thr Gln Pro Gln Gly Gly Ala Lys Leu Xaa
50 55 60

<210> 65
<211> 50
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (50)
<223> Xaa equals stop translation

<400> 65
Met Arg Leu Cys Ser Phe Thr Lys Val Pro Met Asn Leu Phe Leu Asn
1 5 10 15
Val Ile Leu Leu Lys Phe Tyr Asn Phe Leu Phe Ser Leu Ile Leu Gly
20 25 30
Lys Ser Cys Leu Ala Ser Leu Gly Leu Cys Lys Asn Asn Lys Cys Leu
35 40 45
Ser Xaa
50

<210> 66
<211> 402
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (402)

<223> Xaa equals stop translation

<400> 66

```

Met Val Ala Leu Arg Gly Ala Ser Ala Leu Leu Val Leu Phe Leu Ala
 1             5             10             15
Ala Phe Leu Pro Pro Pro Gln Cys Thr Gln Asp Pro Ala Met Val His
 20             25             30
Tyr Ile Tyr Gln Arg Phe Arg Val Leu Glu Gln Gly Leu Glu Lys Cys
 35             40             45
Thr Gln Ala Thr Arg Ala Tyr Ile Gln Glu Phe Gln Glu Phe Ser Lys
 50             55             60
Asn Ile Ser Val Met Leu Gly Arg Cys Gln Thr Tyr Thr Ser Glu Tyr
 65             70             75             80
Lys Ser Ala Val Gly Asn Leu Ala Leu Arg Val Glu Arg Ala Gln Arg
 85             90             95
Glu Ile Asp Tyr Ile Gln Tyr Leu Arg Glu Ala Asp Glu Cys Ile Glu
100            105            110
Ser Glu Asp Lys Thr Leu Ala Glu Met Leu Leu Gln Glu Ala Glu Glu
115            120            125
Glu Lys Lys Ile Arg Thr Leu Leu Asn Ala Ser Cys Asp Asn Met Leu
130            135            140
Met Gly Ile Lys Ser Leu Lys Ile Val Lys Lys Met Met Asp Thr His
145            150            155            160
Gly Ser Trp Met Lys Asp Ala Val Tyr Asn Ser Pro Lys Val Tyr Leu
165            170            175
Leu Ile Gly Ser Arg Asn Asn Thr Val Trp Glu Phe Ala Asn Ile Arg
180            185            190
Ala Phe Met Glu Asp Asn Thr Lys Pro Ala Pro Arg Lys Gln Ile Leu
195            200            205
Thr Leu Ser Trp Gln Gly Thr Gly Gln Val Ile Tyr Lys Gly Phe Leu
210            215            220
Phe Phe His Asn Gln Ala Thr Ser Asn Glu Ile Ile Lys Tyr Asn Leu
225            230            235            240
Gln Lys Arg Thr Val Glu Asp Arg Met Leu Leu Pro Gly Gly Val Gly
245            250            255
Arg Ala Leu Val Tyr Gln His Ser Pro Ser Thr Tyr Ile Asp Leu Ala
260            265            270
Val Asp Glu His Gly Leu Trp Ala Ile His Ser Gly Pro Gly Thr His

```


275 280 285
 Ser His Leu Val Leu Thr Lys Ile Glu Pro Gly Thr Leu Gly Val Glu
 290 295 300
 His Ser Trp Asp Thr Pro Cys Arg Ser Gln Asp Ala Glu Ala Ser Phe
 305 310 315 320
 Leu Leu Cys Gly Val Leu Tyr Val Val Tyr Ser Thr Gly Gly Gln Gly
 325 330 335
 Pro His Arg Ile Thr Cys Ile Tyr Asp Pro Leu Gly Thr Ile Ser Glu
 340 345 350
 Glu Asp Leu Pro Asn Leu Phe Phe Pro Lys Arg Pro Arg Ser His Ser
 355 360 365
 Met Ile His Tyr Asn Pro Arg Asp Lys Gln Leu Tyr Ala Trp Asn Glu
 370 375 380
 Gly Asn Gln Ile Ile Tyr Lys Leu Gln Thr Lys Arg Lys Leu Thr Leu
 385 390 395 400

Lys Xaa

<210> 67
 <211> 58
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (58)
 <223> Xaa equals stop translation

<400> 67
 Met Val Ser Leu Leu Ser Ser Tyr Leu Leu Leu Leu Glu Leu Leu Ser
 1 5 10 15
 Lys Arg Ser Leu Phe Leu Gln Trp Tyr Leu Phe Phe Gly Leu Gln Cys
 20 25 30
 Cys Ser Ser Phe Leu Cys Arg Lys Asn Glu Ser Gln Cys Phe Thr Arg
 35 40 45

Leu Lys Glu Arg Ser Ala Gly Ser Val Xaa
 50 55

<210> 68
 <211> 73
 <212> PRT
 <213> Homo sapiens

<220>
<221> SITE
<222> (73)
<223> Xaa equals stop translation

<400> 68
Met Leu Arg Pro Ala Leu Pro Trp Leu Tyr Leu Gly Leu Cys Ser Leu
1 5 10 15
Leu Val Gly Glu Ala Glu Ala Pro Ser Pro Val Asp Pro Leu Glu Arg
20 25 30
Ser Arg Pro Tyr Ala Val Leu Arg Gly Gln Asn Leu Val Leu Met Gly
35 40 45
Thr Ile Phe Ser Ile Leu Leu Val Thr Val Ile Leu Met Ala Phe Cys
50 55 60
Val Tyr Lys Pro Ile Arg Arg Arg Xaa
65 70

<210> 69
<211> 51
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (51)
<223> Xaa equals stop translation

<400> 69
Met Leu Thr Tyr Leu Pro Arg Trp Cys Phe Leu Ser Leu Pro Pro Pro
1 5 10 15
Cys Cys Gly Ala Ala Ser Cys Thr Met Met His Ile Gln Ile Ile Leu
20 25 30
Asn Thr His Ile Leu Ile Glu Arg Phe Leu Gly Phe Leu Leu Asn Gln
35 40 45
Val Tyr Xaa
50

<210> 70
<211> 182
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (182)

<223> Xaa equals stop translation

<400> 70

```

Met Thr Ser Arg Arg Ser Ser Thr Leu Ser Met Thr Ser Ser Leu Leu
 1           5           10           15

Ser Leu Gly Cys Ala Leu Thr Ser Ala Phe Pro Ala Ser Thr Met Ser
      20           25           30

Trp Val Pro Leu Leu Gln Met Leu Asp Gln Ser Pro Arg Arg Val Met
      35           40           45

Arg Lys Ser Val Ser Gln Leu Cys Pro Leu Leu Arg Pro His Pro Pro
      50           55           60

Leu Ser Ser Lys His Pro Leu Val Leu Pro Leu Gln Leu Pro Pro Thr
      65           70           75           80

Phe Leu His Leu Leu Pro Gly Pro Gly Cys Pro Gly Gln Thr Val Ala
      85           90           95

Tyr Trp Leu Leu Glu Phe Leu Ser Arg Ala Thr Leu Lys Leu Tyr Pro
      100          105          110

Gly Asp Arg Pro Leu Trp Leu Gln Pro Thr Arg Leu Asn Phe Lys Asp
      115          120          125

His Trp Thr Ile Phe Ser Val Ala Ser Ala Ala Leu Phe Cys Val His
      130          135          140

Arg Met Ala Thr Asp Arg His Ala Ser Phe Pro Thr His Trp Lys Ala
      145          150          155          160

His Arg Gln Gly Glu Arg Gly His Arg Arg Cys Gln His Cys Arg Tyr
      165          170          175

Ser Lys Asp Leu Lys Xaa
      180

```

<210> 71

<211> 49

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (49)

<223> Xaa equals stop translation

<400> 71

```

Met His Met Gly Leu Thr Thr Cys Lys Cys His Trp Lys Met Ala Tyr
 1           5           10           15

Leu Arg Phe Leu Ile Leu Trp Ser Phe Pro Leu Ser Ser Ala Val Ser

```

20 25 30

Gly Ala Lys Arg Val Thr Asp Leu Leu Asn Gly Lys His Trp Lys Pro
 35 40 45

Xaa

<210> 72
 <211> 54
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (54)
 <223> Xaa equals stop translation

<400> 72
 Met Val Gln Phe Glu Val Ile Phe Leu Leu Phe Gly Leu Cys Phe Ser
 1 5 10 15
 Ser Ser Ser Ser Arg Leu Val Gly Ser Gln Val Glu Asn Phe Ser Pro
 20 25 30
 Thr Pro Cys Ile Phe Gln Ala Phe Arg Cys Ser Ser Leu Ala Ile Ile
 35 40 45
 Ser Met Ser Leu Ser Xaa
 50

<210> 73
 <211> 75
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (75)
 <223> Xaa equals stop translation

<400> 73
 Met Ser Val Val Pro Val Met Ile Pro Phe Leu Leu Leu Leu Phe Phe
 1 5 10 15
 Phe Ser Leu Ser Ser Thr His His Pro His Leu Leu Tyr Phe Ser Ile
 20 25 30
 Phe Ile Phe Ser Gly Ser Leu Leu Val Arg Ile Leu Ser Cys Arg Lys
 35 40 45
 Glu Ser Ser His Gln Val Leu Ser Arg Lys Cys Phe Ile Lys Gly
 50 55 60

His Arg Gln His Arg Gln Leu Thr Lys Val Xaa
 65 70 75

<210> 74

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (65)

<223> Xaa equals stop translation

<400> 74

Met Pro Leu Phe Leu Phe Val Ala His Leu Ile Ser Leu Leu Leu Ala
 1 5 10 15

Phe Arg Arg Pro Pro Ala Ser Gln Ile Thr Pro Arg Ala Trp Thr Thr
 20 25 30

Glu Ile Ala Ser Cys Glu Ser Val Glu Met Val Lys Ala Leu Ser Ser
 35 40 45

Leu Arg Ser Arg Ala Gln Val Asn Ala Asp Phe Pro Gly His Leu Cys
 50 55 60

Xaa

65

<210> 75

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 75

Met Ser Ser Val Lys Cys Pro Tyr Met Trp Cys Phe Trp Ala Phe Pro
 1 5 10 15

Leu Phe Gln Leu Ser Val Phe Ile Pro Val Ser Lys Ser His Ser Ile
 20 25 30

Asn Tyr Tyr Asn Phe Ile Val Ser Leu Asn Ile Xaa
 35 40

<210> 76

<211> 53

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (53)

<223> Xaa equals stop translation

<400> 76

Met Ile Leu Phe Met Cys Phe Leu Val Tyr Cys Leu Ser Ser Val Glu
 1 5 10 15

Trp Lys Ser His Arg Tyr Phe Val Phe Phe Ser Pro Cys Pro Phe Leu
 20 25 30

Tyr Pro Gln Leu Leu Glu His Ser Leu Glu His Ser Lys Cys Ser Val
 35 40 45

Leu Phe Met Glu Xaa
 50

<210> 77

<211> 320

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (320)

<223> Xaa equals stop translation

<400> 77

Met Ser Trp Cys Cys Leu Trp Leu Cys Leu Ser Ser Val Gly Arg Thr
 1 5 10 15

Gly Ser Ala Gly Pro Ser Leu Pro Phe Ser Glu Leu Cys Ser Leu Gly
 20 25 30

Leu Leu Arg Leu Arg Pro Val Phe Ser Pro Leu His Ser Gly Pro Gly
 35 40 45

Lys Pro Ala Gln Phe Leu Ala Gly Glu Ala Glu Glu Val Asn Ala Phe
 50 55 60

Ala Leu Gly Phe Leu Ser Thr Ser Ser Gly Val Ser Gly Glu Asp Glu
 65 70 75 80

Val Glu Pro Leu His Asp Gly Val Glu Glu Ala Glu Lys Lys Met Glu
 85 90 95

Glu Glu Gly Val Ser Val Ser Glu Met Glu Ala Thr Gly Ala Gln Gly
 100 105 110

Pro Ser Arg Val Glu Glu Ala Glu Gly His Thr Glu Val Thr Glu Ala

115	120	125
Glu Gly Ser Gln Gly Thr Ala Glu Ala Asp Gly Pro Gly Ala Ser Ser		
130	135	140
Gly Asp Glu Asp Ala Ser Gly Arg Ala Ala Ser Pro Glu Ser Ala Ser		
145	150	155
Ser Thr Pro Glu Ser Leu Gln Ala Arg Arg His His Gln Phe Leu Glu		
165	170	175
Pro Ala Pro Ala Pro Gly Ala Ala Val Leu Ser Ser Glu Pro Ala Glu		
180	185	190
Pro Leu Leu Val Arg His Pro Pro Arg Pro Arg Thr Thr Gly Pro Arg		
195	200	205
Pro Arg Gln Asp Pro His Lys Ala Gly Leu Ser His Tyr Val Lys Leu		
210	215	220
Phe Ser Phe Tyr Ala Lys Met Pro Met Glu Arg Lys Ala Leu Glu Met		
225	230	235
Val Glu Lys Cys Leu Asp Lys Tyr Phe Gln His Leu Cys Asp Asp Leu		
245	250	255
Glu Val Phe Ala Ala His Ala Gly Arg Lys Thr Val Lys Pro Glu Asp		
260	265	270
Leu Glu Leu Leu Met Arg Arg Gln Gly Leu Val Thr Asp Gln Val Ser		
275	280	285
Leu His Val Leu Val Glu Arg His Leu Pro Leu Glu Tyr Arg Gln Leu		
290	295	300
Leu Ile Pro Cys Ala Tyr Ser Gly Asn Ser Val Phe Pro Ala Gln Xaa		
305	310	315
		320

<210> 78

<211> 172

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (172)

<223> Xaa equals stop translation

<400> 78

Met Ser Leu Pro Ile Pro Trp Leu Ser Leu Pro Pro Cys Pro Ile Leu
1 5 10 15

Gly Gln Pro Ala Gly Leu Leu Leu Trp Leu Phe Arg Pro Phe Ser Gln
 20 25 30
 Cys Cys Gln Cys Pro Trp Glu Gly Arg Ala Ser Leu Arg His Pro Asn
 35 40 45
 Gly Pro Ser Gly Cys Arg Glu Ala Glu Ala Trp Pro Gln Arg Ser Leu
 50 55 60
 Leu Arg Gln Gln Leu Gln Gln Ala His Pro Leu Pro Thr Leu Pro Thr
 65 70 75 80
 Pro Glu Arg Leu Pro Glu Gln Met Leu Phe Pro Ser Ser Ser Ser Lys
 85 90 95
 Pro Phe Ser Leu Leu Ser Leu Thr Ile Trp Ala Arg Leu Val Gly Arg
 100 105 110
 Leu Thr Asn Arg Ile Cys Pro Val Pro Pro Gly Ser Val Ala Ser Ser
 115 120 125
 Met Ser Leu Gln Ala Gly Arg Cys Gly Asn Pro Val Val Leu Pro Gln
 130 135 140
 Pro Met Pro Pro Gly Leu Leu Cys Met Asn Glu Cys Ser Leu Val Pro
 145 150 155 160
 Gly Leu Gly Arg Gly Gln Val Asn Ser Arg Val Xaa
 165 170

<210> 79
 <211> 61
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (61)
 <223> Xaa equals stop translation

<400> 79
 Met Val Ser Arg Ser Thr Ser Leu Thr Leu Ile Val Phe Leu Phe His
 1 5 10 15
 Arg Leu Ser Lys Ala Pro Gly Lys Met Val Glu Asn Ser Pro Ser Pro
 20 25 30
 Leu Pro Glu Arg Ala Ile Tyr Gly Phe Val Leu Phe Leu Ser Ser Gln
 35 40 45
 Phe Gly Phe Lys Asn Leu Lys Gly Ser Arg Val Cys Xaa
 50 55 60

<210> 80
 <211> 101
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (20)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (37)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (101)
 <223> Xaa equals stop translation

<400> 80
 Met Leu Pro Ser Ala Trp Gly Pro Leu Gln Val Ala Ser Phe Phe Leu
 1 5 10 15
 Leu Ser Phe Xaa Phe Cys Phe Leu Ser Ser Ser Pro His Leu Gly Arg
 20 25 30
 Gln Glu Thr His Xaa Val Val Leu Glu Asp Asp Glu Gly Ala Pro Cys
 35 40 45
 Pro Ala Glu Asp Glu Leu Ala Leu Gln Asp Asn Gly Phe Leu Ser Lys
 50 55 60
 Asn Glu Val Leu Arg Thr Arg Cys Leu Gly Ser Arg Ser Gly Ser Ala
 65 70 75 80
 Ser Ala Thr Pro Pro Thr Thr Ser Gly Thr Ala Arg Ala Ala Arg Pro
 85 90 95
 Pro Ser Gln Cys Xaa
 100

<210> 81
 <211> 98
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (98)
 <223> Xaa equals stop translation

<400> 81

Met Ala Leu Leu Ala Leu Ala Ser Ala Val Pro Ser Ala Leu Leu Ala
 1 5 10 15
 Leu Ala Val Phe Arg Val Pro Ala Trp Ala Cys Leu Leu Cys Phe Thr
 20 25 30
 Thr Tyr Ser Glu Arg Leu Arg Ile Cys Gln Met Phe Val Gly Met Arg
 35 40 45
 Ser Pro Ser Leu Lys Ser Val Arg Arg Pro Ser Arg Pro Pro Ser Arg
 50 55 60
 Ala Ser Leu Thr Pro Lys Ser Val Arg Arg Pro Ser Thr Leu His Gln
 65 70 75 80
 Cys Pro Gly Glu Gly Ala Glu Gly Gly Gln Glu Arg Pro Arg Gly Ser
 85 90 95
 Gly Xaa

<210> 82
 <211> 53
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (53)
 <223> Xaa equals stop translation

<400> 82
 Met Trp Leu Asn Phe Ser Asp Val His Thr Tyr Leu Ser Ser Ile Ala
 1 5 10 15
 Leu Leu Cys Phe Cys Leu Ser Gly Val Leu Cys Cys Ile Cys Asn Asn
 20 25 30
 Ser Val Phe His Ile Gln Gln Tyr Ile Leu Ile Ile Ile Thr Phe Pro
 35 40 45
 Leu Val Val Ile Xaa
 50

<210> 83
 <211> 41
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (41)
 <223> Xaa equals stop translation

<400> 83

Met Ser His Ala Ser Arg Lys Thr Lys His Phe Pro Pro Leu Leu Gln
 1 5 10 15

Asn Pro Phe Leu Met Leu Thr Leu Leu Thr Met Ala Val Ser Ala Gln
 20 25 30

Pro Leu Pro Phe Ser Arg Pro Arg Xaa
 35 40

<210> 84

<211> 133

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (122)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (133)

<223> Xaa equals stop translation

<400> 84

Met Ala Ala Ala Val Ala Ala Ala Leu Ala Arg Leu Leu Ala Ala Phe
 1 5 10 15

Leu Leu Leu Ala Ala Gln Val Ala Cys Glu Tyr Gly Met Val His Val
 20 25 30

Val Ser Gln Ala Gly Gly Pro Glu Gly Lys Asp Tyr Cys Ile Leu Tyr
 35 40 45

Asn Pro Gln Trp Ala His Leu Pro His Asp Leu Ser Lys Ala Ser Phe
 50 55 60

Leu Gln Leu Arg Asn Trp Thr Ala Ser Leu Leu Cys Ser Ala Ala Asp
 65 70 75 80

Leu Pro Ala Arg Gly Phe Ser Asn Gln Ile Pro Leu Val Ala Arg Gly
 85 90 95

Asn Cys Thr Phe Tyr Glu Lys Val Arg Leu Ala Gln Gly Ser Gly His
 100 105 110

Ala Gly Cys Ser Ser Ser Ala Gly Arg Xaa Trp Ser Pro Arg Gly Val
 115 120 125

Ile Arg Arg Ile Xaa
 130

<210> 85
<211> 11
<212> PRT
<213> Homo sapiens

<400> 85
His Ser Ser Leu Pro His Phe Ser Ser Arg Ile
1 5 10

<210> 86
<211> 22
<212> PRT
<213> Homo sapiens

<400> 86
Arg Asp Ser Asn Gly Arg Gly Asp Ser Ser Leu Leu Lys Phe Val Cys
1 5 10 15

Pro Val Pro Leu Lys Lys
20

<210> 87
<211> 12
<212> PRT
<213> Homo sapiens

<400> 87
Ile Pro Glu Tyr Thr Phe Arg Arg Arg Trp Phe His
1 5 10

<210> 88
<211> 17
<212> PRT
<213> Homo sapiens

<400> 88
Leu Cys Val Ser Met Lys Ile Glu Trp Gly Arg Glu Ser Cys Glu Lys
1 5 10 15

Lys

<210> 89
<211> 25
<212> PRT
<213> Homo sapiens

<400> 89
Arg Leu Lys Thr Thr Arg Ala Tyr Ser Ser Gln Phe Trp Arg Pro Glu
1 5 10 15

Val Gln Asn Gln Gly Val Arg Lys Val
20 25

<210> 90
<211> 165
<212> PRT
<213> Homo sapiens

<400> 90
Leu Thr Leu Cys Leu Pro Arg Ser Leu Tyr Ala Leu Pro Gln Cys Pro
1 5 10 15
Gly Pro His Val His Pro Cys Pro Ala Leu Leu Trp Asp Arg Ala Gly
20 25 30
Leu Pro Leu Pro Leu Pro Gly Cys Ile His Gly Arg Ser Gln Val Pro
35 40 45
Trp His Glu Leu His Ser Pro Ala Ala Phe Asn Gln Gly Met Met Gly
50 55 60
Met Cys Thr Tyr Pro Thr Pro Pro Leu Gly Arg Val Met Leu Arg Cys
65 70 75 80
Gly Phe Leu Thr Val Pro Arg Leu Ser Gln Glu Ala Trp Val Trp Val
85 90 95
Pro Thr Val Gly Ala Gly Val Ile Ser Tyr Leu Arg Arg Pro Pro Phe
100 105 110
Leu Pro Val Leu Cys Ala Pro Thr Pro Thr Leu Glu Leu Pro Arg Phe
115 120 125
Ser Val Phe Val Lys Glu Leu Thr Leu Cys Cys Leu Pro Leu Ser Gln
130 135 140
Cys Pro Cys His Ser Cys Glu Pro Ala Ala Gly Glu Val Gly Ala Asp
145 150 155 160
Leu Cys Val Ala Gly
165

<210> 91
<211> 41
<212> PRT
<213> Homo sapiens

<400> 91
Leu Thr Leu Cys Leu Pro Arg Ser Leu Tyr Ala Leu Pro Gln Cys Pro
1 5 10 15
Gly Pro His Val His Pro Cys Pro Ala Leu Leu Trp Asp Arg Ala Gly

20 25 30
 Leu Pro Leu Pro Leu Pro Gly Cys Ile
 35 40

 <210> 92
 <211> 38
 <212> PRT
 <213> Homo sapiens

 <400> 92
 His Gly Arg Ser Gln Val Pro Trp His Glu Leu His Ser Pro Ala Ala
 1 5 10 15
 Phe Asn Gln Gly Met Met Gly Met Cys Thr Tyr Pro Thr Pro Pro Leu
 20 25 30
 Gly Arg Val Met Leu Arg
 35

 <210> 93
 <211> 41
 <212> PRT
 <213> Homo sapiens

 <400> 93
 Cys Gly Phe Leu Thr Val Pro Arg Leu Ser Gln Glu Ala Trp Val Trp
 1 5 10 15
 Val Pro Thr Val Gly Ala Gly Val Ile Ser Tyr Leu Arg Arg Pro Pro
 20 25 30
 Phe Leu Pro Val Leu Cys Ala Pro Thr
 35 40

 <210> 94
 <211> 45
 <212> PRT
 <213> Homo sapiens

 <400> 94
 Pro Thr Leu Glu Leu Pro Arg Phe Ser Val Phe Val Lys Glu Leu Thr
 1 5 10 15
 Leu Cys Cys Leu Pro Leu Ser Gln Cys Pro Cys His Ser Cys Glu Pro
 20 25 30
 Ala Ala Gly Glu Val Gly Ala Asp Leu Cys Val Ala Gly
 35 40 45

<210> 95

<211> 38
<212> PRT
<213> Homo sapiens

<400> 95

Ile Arg His Glu Thr Phe Arg Val Arg Gly Cys Ser Ile Ser Arg Ala
1 5 10 15

Leu Ser Pro Phe Pro Leu Pro Phe Pro His Pro Gly Arg Ser Gly Trp
20 25 30

Ser Gly Pro Glu Ala Lys
35

<210> 96
<211> 145
<212> PRT
<213> Homo sapiens

<400> 96

Pro Asp Ser Arg Pro Glu Ala Arg Gly Asp His Val Val Arg Pro Ser
1 5 10 15

Arg Gly Leu Arg Val Thr Gly Ala Thr Arg Ser Ile Met Gly Pro Trp
20 25 30

Gly Glu Pro Glu Leu Leu Val Trp Arg Pro Glu Ala Val Ala Ser Glu
35 40 45

Pro Pro Val Pro Val Gly Leu Glu Val Lys Leu Gly Ala Leu Val Leu
50 55 60

Leu Leu Val Leu Thr Leu Leu Cys Ser Leu Val Pro Ile Cys Val Leu
65 70 75 80

Arg Arg Pro Gly Ala Asn His Glu Gly Ser Ala Ser Arg Gln Lys Ala
85 90 95

Leu Ser Leu Val Ser Cys Phe Ala Gly Gly Val Phe Leu Ala Thr Cys
100 105 110

Leu Leu Asp Leu Leu Pro Asp Tyr Leu Ala Ala Ile Asp Glu Ala Leu
115 120 125

Ala Ala Leu His Val Thr Leu Gln Phe Pro Leu Gln Glu Phe Ile Leu
130 135 140

Ala
145

<210> 97
<211> 35
<212> PRT

<213> Homo sapiens

<400> 97

Pro Asp Ser Arg Pro Glu Ala Arg Gly Asp His Val Val Arg Pro Ser
1 5 10 15
Arg Gly Leu Arg Val Thr Gly Ala Thr Arg Ser Ile Met Gly Pro Trp
20 25 30
Gly Glu Pro
35

<210> 98

<211> 37

<212> PRT

<213> Homo sapiens

<400> 98

Glu Leu Leu Val Trp Arg Pro Glu Ala Val Ala Ser Glu Pro Pro Val
1 5 10 15
Pro Val Gly Leu Glu Val Lys Leu Gly Ala Leu Val Leu Leu Leu Val
20 25 30
Leu Thr Leu Leu Cys
35

<210> 99

<211> 36

<212> PRT

<213> Homo sapiens

<400> 99

Ser Leu Val Pro Ile Cys Val Leu Arg Arg Pro Gly Ala Asn His Glu
1 5 10 15
Gly Ser Ala Ser Arg Gln Lys Ala Leu Ser Leu Val Ser Cys Phe Ala
20 25 30
Gly Gly Val Phe
35

<210> 100

<211> 37

<212> PRT

<213> Homo sapiens

<400> 100

Leu Ala Thr Cys Leu Leu Asp Leu Leu Pro Asp Tyr Leu Ala Ala Ile
1 5 10 15
Asp Glu Ala Leu Ala Ala Leu His Val Thr Leu Gln Phe Pro Leu Gln



```

<210> 103
<211> 96
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids

```

<400> 103

Asp Phe Met Glu Thr Phe Pro Asp Phe Cys Leu Pro Leu Ala Pro His
1 5 10 15

Tyr Leu Gly Lys Ala Ala Leu Trp Ala Met Cys Pro Gly Arg Ala Trp
20 25 30

Ala Gly Cys Gly Pro Val Leu Arg Thr Ser His Leu Gly Pro His Ser
35 40 45

Ala Leu Pro Ser Trp Cys Asn Ile Cys Xaa Gln Ala Ile Val Gly Ala
50 55 60

Gly Arg Gln Arg Gly Leu Ser Glu Asp Pro Thr Cys Ala Ser His Trp
65 70 75 80

Asp Thr Lys Thr Gly Leu Val Pro Ser Cys Gly Ala Gly Lys Gly Ile
85 90 95

<210> 104

<211> 44

<212> PRT

<213> Homo sapiens

<400> 104

Asp Phe Met Glu Thr Phe Pro Asp Phe Cys Leu Pro Leu Ala Pro His
1 5 10 15

Tyr Leu Gly Lys Ala Ala Leu Trp Ala Met Cys Pro Gly Arg Ala Trp
20 25 30

Ala Gly Cys Gly Pro Val Leu Arg Thr Ser His Leu
35 40

<210> 105

<211> 52

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 105

Gly Pro His Ser Ala Leu Pro Ser Trp Cys Asn Ile Cys Xaa Gln Ala
1 5 10 15

Ile Val Gly Ala Gly Arg Gln Arg Gly Leu Ser Glu Asp Pro Thr Cys

20 25 30
 Ala Ser His Trp Asp Thr Lys Thr Gly Leu Val Pro Ser Cys Gly Ala
 35 40 45
 Gly Lys Gly Ile
 50
 <210> 106
 <211> 280
 <212> PRT
 <213> Homo sapiens
 <400> 106
 Arg Leu Pro Gln Arg Gly Gln Trp Ala Trp Val Leu Gln Asp Ala Leu
 1 5 10 15
 Gly Ile Ala Phe Cys Leu Tyr Met Leu Lys Thr Ile Arg Leu Pro Thr
 20 25 30
 Phe Lys Ala Cys Thr Leu Leu Leu Leu Val Leu Phe Leu Tyr Asp Ile
 35 40 45
 Phe Phe Val Phe Ile Thr Pro Phe Leu Thr Lys Ser Gly Ser Ser Ile
 50 55 60
 Met Val Glu Val Ala Thr Gly Pro Ser Asp Ser Ala Thr Arg Glu Lys
 65 70 75 80
 Leu Pro Met Val Leu Lys Val Pro Arg Leu Asn Ser Ser Pro Leu Ala
 85 90 95
 Leu Cys Asp Arg Pro Phe Ser Leu Leu Gly Phe Gly Asp Ile Leu Val
 100 105 110
 Pro Gly Leu Leu Val Ala Tyr Cys His Arg Phe Asp Ile Gln Val Gln
 115 120 125
 Ser Ser Arg Val Tyr Phe Val Ala Cys Thr Ile Ala Tyr Gly Val Gly
 130 135 140
 Leu Leu Val Thr Phe Val Ala Leu Ala Leu Met Gln Arg Gly Gln Pro
 145 150 155 160
 Ala Leu Leu Tyr Leu Val Pro Cys Thr Leu Val Thr Ser Cys Ala Val
 165 170 175
 Ala Leu Trp Arg Arg Glu Leu Gly Val Phe Trp Thr Gly Ser Gly Phe
 180 185 190
 Ala Lys Val Leu Pro Pro Ser Pro Trp Ala Pro Ala Pro Ala Asp Gly
 195 200 205
 Pro Gln Pro Pro Lys Asp Ser Ala Thr Pro Leu Ser Pro Gln Pro Pro

210

215

220

Ser Glu Glu Pro Ala Thr Ser Pro Trp Pro Ala Glu Gln Ser Pro Lys
 225 230 235 240

Ser Arg Thr Ser Glu Glu Met Gly Ala Gly Ala Pro Met Arg Glu Pro
 245 250 255

Gly Ser Pro Ala Glu Ser Glu Gly Arg Asp Gln Ala Gln Pro Ser Pro
 260 265 270

Val Thr Gln Pro Gly Ala Ser Ala
 275 280

<210> 107

<211> 43

<212> PRT

<213> Homo sapiens

<400> 107

Arg Leu Pro Gln Arg Gly Gln Trp Ala Trp Val Leu Gln Asp Ala Leu
 1 5 10 15

Gly Ile Ala Phe Cys Leu Tyr Met Leu Lys Thr Ile Arg Leu Pro Thr
 20 25 30

Phe Lys Ala Cys Thr Leu Leu Leu Leu Val Leu
 35 40

<210> 108

<211> 44

<212> PRT

<213> Homo sapiens

<400> 108

Phe Leu Tyr Asp Ile Phe Phe Val Phe Ile Thr Pro Phe Leu Thr Lys
 1 5 10 15

Ser Gly Ser Ser Ile Met Val Glu Val Ala Thr Gly Pro Ser Asp Ser
 20 25 30

Ala Thr Arg Glu Lys Leu Pro Met Val Leu Lys Val
 35 40

<210> 109

<211> 44

<212> PRT

<213> Homo sapiens

<400> 109

Pro Arg Leu Asn Ser Ser Pro Leu Ala Leu Cys Asp Arg Pro Phe Ser
 1 5 10 15

Leu Leu Gly Phe Gly Asp Ile Leu Val Pro Gly Leu Leu Val Ala Tyr
20 25 30

Cys His Arg Phe Asp Ile Gln Val Gln Ser Ser Arg
35 40

<210> 110
<211> 43
<212> PRT
<213> Homo sapiens

<400> 110
Val Tyr Phe Val Ala Cys Thr Ile Ala Tyr Gly Val Gly Leu Leu Val
1 5 10 15

Thr Phe Val Ala Leu Ala Leu Met Gln Arg Gly Gln Pro Ala Leu Leu
20 25 30

Tyr Leu Val Pro Cys Thr Leu Val Thr Ser Cys
35 40

<210> 111
<211> 40
<212> PRT
<213> Homo sapiens

<400> 111
Ala Val Ala Leu Trp Arg Arg Glu Leu Gly Val Phe Trp Thr Gly Ser
1 5 10 15

Gly Phe Ala Lys Val Leu Pro Pro Ser Pro Trp Ala Pro Ala Pro Ala
20 25 30

Asp Gly Pro Gln Pro Pro Lys Asp
35 40

<210> 112
<211> 41
<212> PRT
<213> Homo sapiens

<400> 112
Ser Ala Thr Pro Leu Ser Pro Gln Pro Pro Ser Glu Glu Pro Ala Thr
1 5 10 15

Ser Pro Trp Pro Ala Glu Gln Ser Pro Lys Ser Arg Thr Ser Glu Glu
20 25 30

Met Gly Ala Gly Ala Pro Met Arg Glu
35 40

<210> 113
<211> 25
<212> PRT
<213> Homo sapiens

<400> 113
Pro Gly Ser Pro Ala Glu Ser Glu Gly Arg Asp Gln Ala Gln Pro Ser
1 5 10 15

Pro Val Thr Gln Pro Gly Ala Ser Ala
20 25

<210> 114
<211> 26
<212> PRT
<213> Homo sapiens

<400> 114
Glu Ser Ser Gly Leu Pro Ala Leu Gly Pro Arg Arg Arg Pro Trp Glu
1 5 10 15

Gln Arg Trp Ser Asp Pro Ile Thr Leu Lys
20 25

<210> 115
<211> 61
<212> PRT
<213> Homo sapiens

<400> 115
Leu Thr Leu Ala Leu Asp Glu Ile Arg Leu Leu Lys Lys Asp Leu Gly
1 5 10 15

Leu Ile Glu Met Lys Lys Thr Asp Ser Glu Lys Arg Phe Gly Ser Val
20 25 30

Ser Phe Gly Arg Ser Cys Arg Leu Ile Pro His Ala Leu Ala Ser Trp
35 40 45

Leu Gln Thr Leu Ile Leu Cys Phe Cys Cys Arg Ile Cys
50 55 60

<210> 116
<211> 32
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 116

Gly Arg Pro Thr Arg Pro Val Met Ala Ile Gln Ser Leu His Pro Cys
1 5 10 15

Pro Ser Glu Leu Cys Cys Arg Ala Cys Val Xaa Phe Tyr His Trp Ala
20 25 30

<210> 117

<211> 29

<212> PRT

<213> Homo sapiens

<400> 117

Asn Ser Lys Asn Thr Arg Asn Glu Arg Ser Phe Leu Lys Leu Phe Arg
1 5 10 15

Asn Ile His Asp Ile Pro Leu Thr Val Leu Glu Asn Lys
20 25

<210> 118

<211> 20

<212> PRT

<213> Homo sapiens

<400> 118

Pro Arg Val Arg Gly Glu Gly Asn Arg Cys Trp Thr Gln Gly Ala Leu
1 5 10 15

Cys His Arg Met
20

<210> 119

<211> 27

<212> PRT

<213> Homo sapiens

<400> 119

Phe Pro Cys Ile Cys Leu Ser Gly Leu Leu Asp Leu Leu Ile Trp Arg
1 5 10 15

Pro Phe Ser Glu Glu Leu Thr Lys Thr Phe Gly
20 25

<210> 120

<211> 24

<212> PRT

<213> Homo sapiens

<220>
<221> SITE
<222> (8)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 120
Lys Asp Thr Cys Thr Arg Met Xaa Ile Ala Ala Leu Phe Thr Ile Ala
1 5 10 15

Lys Ile Trp Asn Gln Pro Lys Xaa
20

<210> 121
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (26)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 121
Arg His Met His Thr Tyr Val Tyr Cys Gly Thr Ile His Asn Ser Lys
1 5 10 15

Asp Leu Glu Pro Thr Gln Met Xaa Asp Xaa Ile Lys Lys Met Trp His
20 25 30

Leu Tyr Thr Thr Lys Tyr Tyr Ala Ala Ile Lys Lys Asp
35 40 45

<210> 122
<211> 14
<212> PRT
<213> Homo sapiens

<400> 122
Arg Lys Cys Gly Thr Tyr Ile Pro Arg Asn Thr Met Gln Pro
1 5 10

<210> 123
 <211> 40
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (9)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 123
 Lys Arg Thr Glu Phe Met Ser Phe Xaa Gly Thr Trp Met Lys Leu Glu
 1 5 10 15

Ala Ile Ile Leu Ser Lys Leu Thr Gln Glu Glu Lys Thr Lys His. Leu
 20 25 30

Met Phe Ser Leu Ile Ser Gly Ser
 35 40

<210> 124
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 124
 Pro Lys Ser Asp Thr Ser Pro Ala Ser Ser Arg
 1 5 10

<210> 125
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 125
 Pro Lys Ser Asp Thr Ser Pro Ala Ser Ser Arg Leu Cys Trp Asp
 1 5 10 15

<210> 126
 <211> 270
 <212> PRT
 <213> Homo sapiens

<400> 126
 Tyr Val Pro Ser Phe Leu Pro Lys Ala Thr Gly Ser Ile Pro Ser Arg
 1 5 10 15

Lys Gly Gly Val Gly Ser Glu Lys Pro Glu Val Pro Leu Gln Thr Tyr
 20 25 30

Lys Glu Ile Val His Cys Cys Glu Glu Val Leu Thr Leu Ala Thr
 35 40 45

Glu Gln Thr Tyr Ala Val Glu Gly Glu Thr Pro Ile Asn Arg Leu Ser
 50 55 60
 Leu Leu Leu Ser Gly Arg Val Arg Val Ser Gln Asp Gly Gln Phe Leu
 65 70 75 80
 His Tyr Ile Phe Pro Tyr Gln Phe Met Asp Ser Pro Glu Trp Glu Ser
 85 90 95
 Leu Gln Pro Ser Glu Glu Gly Val Phe Gln Val Thr Leu Thr Ala Glu
 100 105 110
 Thr Ser Cys Ser Tyr Ile Ser Trp Pro Arg Lys Ser Leu His Leu Leu
 115 120 125
 Leu Thr Lys Glu Arg Tyr Ile Ser Cys Leu Phe Ser Ala Leu Leu Gly
 130 135 140
 Tyr Asp Ile Ser Glu Lys Leu Tyr Thr Leu Asn Asp Lys Leu Phe Ala
 145 150 155 160
 Lys Phe Gly Leu Arg Phe Asp Ile Arg Leu Pro Ser Leu Tyr His Val
 165 170 175
 Leu Gly Pro Thr Ala Ala Asp Ala Gly Pro Glu Ser Glu Lys Gly Asp
 180 185 190
 Glu Glu Val Cys Glu Pro Ala Val Ser Pro Pro Gln Ala Thr Pro Thr
 195 200 205
 Ser Leu Gln Gln Thr Pro Pro Cys Ser Thr Pro Pro Ala Thr Thr Asn
 210 215 220
 Phe Pro Ala Pro Pro Thr Arg Ala Arg Leu Ser Arg Pro Asp Ser Gly
 225 230 235 240
 Ile Leu Ala Ser Arg Ile Pro Leu Gln Ser Tyr Ser Gln Val Ile Ser
 245 250 255
 Arg Gly Gln Ala Pro Leu Ala Pro Thr His Thr Pro Glu Leu
 260 265 270

<210> 127

<211> 21

<212> PRT

<213> Homo sapiens

<400> 127

Ala Thr Gly Ser Ile Pro Ser Arg Lys Gly Gly Val Gly Ser Glu Lys
 1 5 10 15

Pro Glu Val Pro Leu
 20

<210> 128
<211> 25
<212> PRT
<213> Homo sapiens

<400> 128
Ile Val His Cys Cys Glu Glu Gln Val Leu Thr Leu Ala Thr Glu Gln
1 5 10 15
Thr Tyr Ala Val Glu Gly Glu Thr Pro
20 25

<210> 129
<211> 23
<212> PRT
<213> Homo sapiens

<400> 129
Gln Asp Gly Gln Phe Leu His Tyr Ile Phe Pro Tyr Gln Phe Met Asp
1 5 10 15
Ser Pro Glu Trp Glu Ser Leu
20

<210> 130
<211> 23
<212> PRT
<213> Homo sapiens

<400> 130
Thr Leu Thr Ala Glu Thr Ser Cys Ser Tyr Ile Ser Trp Pro Arg Lys
1 5 10 15
Ser Leu His Leu Leu Leu Thr
20

<210> 131
<211> 25
<212> PRT
<213> Homo sapiens

<400> 131
Asp Ile Ser Glu Lys Leu Tyr Thr Leu Asn Asp Lys Leu Phe Ala Lys
1 5 10 15
Phe Gly Leu Arg Phe Asp Ile Arg Leu
20 25

<210> 132

<211> 26
<212> PRT
<213> Homo sapiens

<400> 132
Ser Leu Tyr His Val Leu Gly Pro Thr Ala Ala Asp Ala Gly Pro Glu
1 5 10 15

Ser Glu Lys Gly Asp Glu Glu Val Cys Glu
20 25

<210> 133
<211> 28
<212> PRT
<213> Homo sapiens

<400> 133
Thr Thr Asn Phe Pro Ala Pro Pro Thr Arg Ala Arg Leu Ser Arg Pro
1 5 10 15

Asp Ser Gly Ile Leu Ala Ser Arg Ile Pro Leu Gln
20 25

<210> 134
<211> 10
<212> PRT
<213> Homo sapiens

<400> 134
Tyr Phe Ser His Gly Ile Cys Ser His Ala
1 5 10

<210> 135
<211> 55
<212> PRT
<213> Homo sapiens

<400> 135
Asn Ser Glu Asp Ile Ser Gln Thr Arg Gln Glu Leu Gly Leu Cys Ile
1 5 10 15

Ser Gln Arg Cys Leu Ser Asp Arg Lys Lys Ser Arg Arg Ser Gly Val
20 25 30

Trp Val Arg Ala Cys Thr Met Gln Phe Met Lys His Val Phe Pro Arg
35 40 45

Leu Ile Ser Pro Arg Arg Pro
50 55

<210> 136

<211> 55

<212> PRT

<213> Homo sapiens

<400> 136

Pro Thr Arg His Phe Cys Gly Thr Ser Ser Cys Leu Thr Gly Thr Ala
1 5 10 15

Val Arg Cys Arg Ala Pro Ala Pro Val Trp Ser Val Arg Cys Pro His
20 25 30

Cys Phe Arg Ser Ser Asp Ala Trp Val Asp Pro Gly Ile Pro Asp Arg
35 40 45

Tyr Leu Gln Ala Tyr Leu Leu
50 55

<210> 137

<211> 246

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (8)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 137

Gly Glu Ala Met Asp Ala Glu Xaa Ala Val Ala Pro Pro Gly Cys Ser
1 5 10 15

His Leu Gly Ser Phe Lys Val Asp Asn Trp Lys Gln Asn Leu Arg Ala
20 25 30

Ile Tyr Gln Cys Phe Val Trp Ser Gly Thr Ala Glu Ala Arg Lys Arg
35 40 45

Lys Ala Lys Ser Cys Ile Cys His Val Cys Gly Val His Leu Asn Arg
50 55 60

Leu His Ser Cys Leu Tyr Cys Val Phe Phe Gly Cys Phe Thr Lys Lys
65 70 75 80

His Ile His Glu His Ala Lys Ala Lys Arg His Asn Leu Ala Ile Asp
85 90 95

Leu Met Tyr Gly Gly Ile Tyr Cys Phe Leu Cys Gln Asp Tyr Ile Tyr
100 105 110

Asp Lys Asp Met Glu Ile Ile Ala Lys Glu Glu Gln Arg Lys Ala Trp
115 120 125

Lys Met Gln Gly Val Gly Glu Lys Phe Ser Thr Trp Glu Pro Thr Lys
130 135 140

Arg Glu Leu Glu Leu Leu Lys His Asn Pro Lys Arg Arg Lys Ile Thr
145 150 155 160

Ser Asn Cys Thr Ile Gly Leu Arg Gly Leu Ile Asn Leu Gly Asn Thr
165 170 175

Cys Phe Met Asn Cys Ile Val Gln Ala Leu Thr His Thr Pro Leu Leu
180 185 190

Arg Asp Phe Phe Leu Ser Asp Arg His Arg Cys Glu Met Gln Ser Pro
195 200 205

Ser Ser Cys Leu Val Cys Glu Met Ser Ser Leu Phe Gln Glu Phe Gly
210 215 220

Arg Val Gly Arg Pro Gly Asn Ser Gly Pro Val Pro Ala Gly Val Pro
225 230 235 240

Ser Ile Val Ser Pro Glu
245

<210> 138
<211> 24
<212> PRT
<213> Homo sapiens

<400> 138
Val Ala Pro Pro Gly Cys Ser His Leu Gly Ser Phe Lys Val Asp Asn
1 5 10 15

Trp Lys Gln Asn Leu Arg Ala Ile
20

<210> 139
<211> 23
<212> PRT
<213> Homo sapiens

<400> 139
Thr Ala Glu Ala Arg Lys Arg Lys Ala Lys Ser Cys Ile Cys His Val
1 5 10 15

Cys Gly Val His Leu Asn Arg
20

<210> 140
<211> 23
<212> PRT
<213> Homo sapiens

<400> 140

Phe Thr Lys Lys His Ile His Glu His Ala Lys Ala Lys Arg His Asn
1 5 10 15

Leu Ala Ile Asp Leu Met Tyr
20

<210> 141
<211> 21
<212> PRT
<213> Homo sapiens

<400> 141
Tyr Asp Lys Asp Met Glu Ile Ile Ala Lys Glu Glu Gln Arg Lys Ala
1 5 10 15

Trp Lys Met Gln Gly
20

<210> 142
<211> 28
<212> PRT
<213> Homo sapiens

<400> 142
Glu Leu Leu Lys His Asn Pro Lys Arg Arg Lys Ile Thr Ser Asn Cys
1 5 10 15

Thr Ile Gly Leu Arg Gly Leu Ile Asn Leu Gly Asn
20 25

<210> 143
<211> 26
<212> PRT
<213> Homo sapiens

<400> 143
Gly Asn Thr Cys Phe Met Asn Cys Ile Val Gln Ala Leu Thr His Thr
1 5 10 15

Pro Leu Leu Arg Asp Phe Phe Leu Ser Asp
20 25

<210> 144
<211> 20
<212> PRT
<213> Homo sapiens

<400> 144
Glu Phe Gly Arg Val Gly Arg Pro Gly Asn Ser Gly Pro Val Pro Ala
1 5 10 15

Gly Val Pro Ser
20

<210> 145
<211> 7
<212> PRT
<213> Homo sapiens

<400> 145
Ala Phe Pro Trp Pro Thr Ser
1 5

<210> 146
<211> 23
<212> PRT
<213> Homo sapiens

<400> 146
Glu Ser Asn Phe Phe Tyr Pro Tyr Asp Ser Gln Leu Ala Leu Leu Ser
1 5 10 15

Ser Val Thr Cys Ser Ala Ser
20

<210> 147
<211> 83
<212> PRT
<213> Homo sapiens

<400> 147
Lys Leu Lys Met Phe Ala Phe Tyr Val Gln Val Leu Asn Gln Ser Lys
1 5 10 15

Ser Ile Phe Val Tyr Ser Arg Asn Leu Ile Phe Phe Ile His Met Ile
20 25 30

Val Ser Trp Pro Ser Phe Leu Gln Leu Pro Ala Val His Gln Cys His
35 40 45

Gln Ser Ser Val His Ile Cys Gly Val Ser Gly Leu Phe Pro Ser Ser
50 55 60

Asn Tyr Gln Cys Leu Ser Leu Cys Gln Asn His Thr Val Leu Ile Ile
65 70 75 80

Thr Thr Leu

<210> 148
<211> 48
<212> PRT

<213> Homo sapiens

<400> 148

Ser Ile Leu Asn Val Ile Pro Asn Leu Ser Lys Gln Ser Phe Glu Glu
1 5 10 15
Phe Asp Arg Leu Ile Leu Lys Tyr Met Gln Lys Ser Lys Ser Lys Arg
20 25 30
Ile Ala Lys Ile Leu Leu Ser Asn Lys Lys Thr Cys Pro Thr Lys Tyr
35 40 45

<210> 149

<211> 36

<212> PRT

<213> Homo sapiens

<400> 149

Leu Pro Gln Ile Leu Arg Trp Leu Lys Tyr His Gln Ser Val Trp Gly
1 5 10 15
Lys Gln Thr Pro Val Thr Leu His Tyr Leu Thr Leu Asp Leu Ile Gln
20 25 30
Glu Phe Thr Pro
35

<210> 150

<211> 33

<212> PRT

<213> Homo sapiens

<400> 150

Ile Phe Val Tyr Ser Arg Asn Leu Ile Phe Phe Ile His Met Ile Val
1 5 10 15
Ser Trp Pro Ser Phe Leu Gln Leu Pro Ala Val His Gln Cys His Gln
20 25 30

Ser

<210> 151

<211> 184

<212> PRT

<213> Homo sapiens

<400> 151

Pro Thr Gly Asn Asp Leu Val Tyr Val Phe Pro Cys Leu Leu Ser Val

75

1 5 10 15
 Phe Ser Arg Met Glu Glu Pro Ser Val Phe Cys Leu Phe Phe Pro Leu
 20 25 30
 Ser Ile Leu Ile Ser Ser Ala Ser Arg Thr Phe Pro Gly Thr Gln Gln
 35 40 45
 Val Phe Ser Ile Val His Gly Val Thr Asp Val Ser Ala Lys Lys Val
 50 55 60
 Gln Ser Gln Gly Arg Met Thr Ser Thr Gly Leu Asp Phe Asn Leu Leu
 65 70 75 80
 Pro Ala Trp Phe Pro Ser Pro Thr Ser Leu Gln Pro Thr Glu Asp Leu
 85 90 95
 Phe Gln Thr Gly Ser Leu Ser Arg Ser Phe Phe Cys Ser Lys Ala Phe
 100 105 110
 Ser Ser Ser Pro Leu Ser Pro Gly Gly Ser Pro Asn Ala Leu Thr Ser
 115 120 125
 Val Lys Glu His Leu Val Ser Pro Ala Phe Leu Ala Ser His Ser Cys
 130 135 140
 Thr Ala Glu Ser Phe Pro Arg Val Asp Val Ile His Ala Val Pro Ile
 145 150 155 160
 Ala Trp Ile Pro Ala Pro Leu His Pro Ile Gln Leu Ile Asn Ser Trp
 165 170 175
 Phe Phe Phe Phe Phe Phe Phe
 180

<210> 152
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 152
 Asp Leu Val Tyr Val Phe Pro Cys Leu Leu Ser Val Phe Ser Arg Met
 1 5 10 15

Glu Glu Pro Ser Val Phe Cys Leu
 20

<210> 153
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 153

Ile Ser Ser Ala Ser Arg Thr Phe Pro Gly Thr Gln Gln Val Phe Ser
1 5 10 15

Ile Val His Gly Val Thr Asp Val
20

<210> 154

<211> 20

<212> PRT

<213> Homo sapiens

<400> 154

Phe Asn Leu Leu Pro Ala Trp Phe Pro Ser Pro Thr Ser Leu Gln Pro
1 5 10 15

Thr Glu Asp Leu
20

<210> 155

<211> 25

<212> PRT

<213> Homo sapiens

<400> 155

Phe Cys Ser Lys Ala Phe Ser Ser Ser Pro Leu Ser Pro Gly Gly Ser
1 5 10 15

Pro Asn Ala Leu Thr Ser Val Lys Glu
20 25

<210> 156

<211> 23

<212> PRT

<213> Homo sapiens

<400> 156

Thr Ala Glu Ser Phe Pro Arg Val Asp Val Ile His Ala Val Pro Ile
1 5 10 15

Ala Trp Ile Pro Ala Pro Leu
20

<210> 157

<211> 34

<212> PRT

<213> Homo sapiens

<400> 157

Phe Ser Phe Leu Lys Pro Leu Cys Ala Pro Arg Ala Pro Trp Leu Trp
1 5 10 15

Leu Pro Pro Ser Ser Lys Ser Arg Val His Val Gly Pro Gly Asp Phe
 20 25 30

Arg Ser

<210> 158

<211> 122

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (108)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 158

Val Cys Gly Thr Gly Gly Leu Glu Pro Asn Leu Ala Trp Val Arg Val
 1 5 10 15

Asp Asn Gly Ser Phe Pro Ser Ser Ser Pro Ser Val Pro Leu Glu His
 20 25 30

Pro Gly Cys Gly Cys Leu Leu His Pro Arg Ala Glu Ser Met Leu Gly
 35 40 45

Gln Glu Thr Ser Asp Pro Cys Pro Gly Ala Ala Ser Gly Phe Val Phe
 50 55 60

Pro Gln Trp Ala Gly Leu Gly Leu Leu Val His Leu Tyr Pro Ser Leu
 65 70 75 80

Ser Tyr Ala Ala Leu Ala Cys Cys Val Ser Gly Leu Tyr Ser Leu Pro
 85 90 95

Phe Thr Gln Ala Leu Gly Asn Gln Pro Ser Phe Xaa Gln Glu Arg Gln
 100 105 110

Arg Arg Ser Met Pro Leu Leu Trp Ala Ser
 115 120

<210> 159

<211> 8

<212> PRT

<213> Homo sapiens

<400> 159

His Ala Gly Arg Lys Thr Val Lys
 1 5

<210> 160

<211> 61

<212> PRT

<213> Homo sapiens

<400> 160

Ser Phe Tyr Ala Lys Met Pro Met Glu Arg Lys Ala Leu Glu Met Val
1 5 10 15

Glu Lys Cys Leu Asp Lys Tyr Phe Gln His Leu Cys Asp Asp Leu Glu
20 25 30

Val Phe Ala Ala His Ala Gly Arg Lys Thr Val Lys Pro Glu Asp Leu
35 40 45

Glu Leu Leu Met Arg Arg Gln Gly Leu Val Thr Asp Gln
50 55 60

<210> 161

<211> 19

<212> PRT

<213> Homo sapiens

<400> 161

Pro Met Glu Arg Lys Ala Leu Glu Met Val Glu Lys Cys Leu Asp Lys
1 5 10 15

Tyr Phe Gln

<210> 162

<211> 22

<212> PRT

<213> Homo sapiens

<400> 162

Glu Val Phe Ala Ala His Ala Gly Arg Lys Thr Val Lys Pro Glu Asp
1 5 10 15

Leu Glu Leu Leu Met Arg
20

<210> 163

<211> 31

<212> PRT

<213> Homo sapiens

<400> 163

Ser Phe Pro Ser Ser Ser Pro Ser Val Pro Leu Glu His Pro Gly Cys
1 5 10 15

Gly Cys Leu Leu His Pro Arg Ala Glu Ser Met Leu Gly Gln Glu
20 25 30

<210> 164
<211> 27
<212> PRT
<213> Homo sapiens

<400> 164
Tyr Pro Ser Leu Ser Tyr Ala Ala Leu Ala Cys Cys Val Ser Gly Leu
1 5 10 15

Tyr Ser Leu Pro Phe Thr Gln Ala Leu Gly Asn
20 25

<210> 165
<211> 27
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 165
Ala Pro Gly Gly Val Asn Ser Glu Gly Arg Gly Gln His Leu Pro Pro
1 5 10 15

Pro Xaa Leu Ala Val Cys Leu Lys Leu His Leu
20 25

<210> 166
<211> 44
<212> PRT
<213> Homo sapiens

<400> 166
Asn Ser Ala Glu Pro Ala Trp Val Pro Val Cys Ala Arg Gly Gly Gly
1 5 10 15

Ala Gly Cys Gly Arg Arg Arg Gly Arg Arg Phe Cys Ala Ala Gly Ala
20 25 30

Val Pro Ala Ala Glu Arg Gly Gly Glu Asn Gly Ser
35 40

<210> 167
<211> 124
<212> PRT
<213> Homo sapiens

<400> 167
Ser Leu Val Pro Ala Leu Lys Glu Val Val Val Leu Trp Arg Arg Gln

80

1 5 10 15
Met Val Leu Tyr Leu Val Trp Ala Phe Ile Pro Glu Ser Trp Leu Asn
20 25 30
Ser Leu Gly Leu Thr Tyr Trp Pro Gln Lys Tyr Trp Ala Val Ala Leu
35 40 45
Pro Val Tyr Leu Leu Ile Ala Ile Val Ile Gly Tyr Val Leu Leu Phe
50 55 60
Gly Ile Asn Met Met Ser Thr Ser Pro Leu Asp Ser Ile His Thr Ile
65 70 75 80
Thr Asp Asn Tyr Ala Lys Asn Gln Gln Gln Lys Lys Tyr Gln Glu Glu
85 90 95
Ala Ile Pro Ala Leu Arg Asp Ile Ser Ile Ser Glu Val Asn Gln Met
100 105 110
Phe Phe Leu Ala Ala Lys Glu Leu Tyr Thr Lys Asn
115 120

<210> 168
<211> 28
<212> PRT
<213> Homo sapiens

<400> 168
Met Val Leu Tyr Leu Val Trp Ala Phe Ile Pro Glu Ser Trp Leu Asn
1 5 10 15
Ser Leu Gly Leu Thr Tyr Trp Pro Gln Lys Tyr Trp
20 25

<210> 169
<211> 25
<212> PRT
<213> Homo sapiens

<400> 169
Tyr Trp Ala Val Ala Leu Pro Val Tyr Leu Leu Ile Ala Ile Val Ile
1 5 10 15
Gly Tyr Val Leu Leu Phe Gly Ile Asn
20 25

<210> 170
<211> 22
<212> PRT
<213> Homo sapiens

<400> 170

Gln Gln Gln Lys Lys Tyr Gln Glu Glu Ala Ile Pro Ala Leu Arg Asp
1 5 10 15

Ile Ser Ile Ser Glu Val
20

<210> 171

<211> 32

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (26)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 171

Leu Ser Pro Arg Leu Phe Asp Ala Gly Ile Leu Leu Trp Gly Ala Ser
1 5 10 15

Val Asn Val Thr Ile Trp Glu Val Arg Xaa Ala Gln Ser Ser Ala Ser
20 25 30

<210> 172

<211> 32

<212> PRT

<213> Homo sapiens

<400> 172

Asn Leu Thr Ser Asp Pro Arg Pro Leu Ala Leu Pro Pro Pro Cys Gly
1 5 10 15

Asp Phe Ile Lys Val Thr Ser Phe Ser Pro Gly Leu Glu Thr His Thr
20 25 30

<210> 173

<211> 135

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (14)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 173

Glu Gln Gln Arg Leu Arg Asp Arg Glu Thr Gln Thr Gly Xaa Asp Ser
 1 5 10 15
 Arg Ala Lys Thr Gln Arg Gly Glu Asp Gly Glu Ser Glu Arg Gly Arg
 20 25 30
 Trp Arg Leu Arg Glu Gly Glu Asp Gly Asp Ser Glu Arg Glu Glu Asp
 35 40 45
 Gly Asp Ser Glu Arg Trp Arg Leu Arg Ser Met Glu Ser Gln Arg Gly
 50 55 60
 Glu Asp Gly His Ser Gly Gly Trp Arg Val Arg Arg Met Glu Thr His
 65 70 75 80
 Arg Lys Gly Arg Met Glu Ser Gln Glu Arg Leu Glu Thr Gly Glu Gly
 85 90 95
 Ile Glu Thr Gln Arg Gly Glu Asp Gly Asp Ser Glu Gly Gly Arg Trp
 100 105 110
 Arg Leu Lys Glu Asp Gly Asn Pro Gly Glu Arg Arg Thr Glu Met Arg
 115 120 125
 Gln Arg Leu Gly Glu Ala Gly
 130 135

<210> 174

<211> 220

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (7)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 174

Gly His Gly Val Ala Gly Xaa Cys Leu Pro Gln Pro Leu Leu Pro Pro
 1 5 10 15
 Ser Pro Pro Asp Tyr Asp Glu Arg Ser His Leu His Asp Thr Phe Thr
 20 25 30
 Gln Met Thr His Ala Leu Gln Glu Leu Ala Ala Ala Gln Gly Ser Phe
 35 40 45
 Glu Val Ala Phe Pro Asp Ala Ala Glu Lys Met Lys Lys Val Phe Thr
 50 55 60
 Gln Leu Lys Glu Ala Gln Ala Cys Ile Pro Pro Cys Glu Gly Leu Gln
 65 70 75 80

Met Leu Val Tyr Gln Asn Gln Ala Gln Phe Ser Ser Asn
1 5 10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/03939

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07H 21/00; C12N 1/15, 1/21, 5/10, 15/12, 15/63
US CL :435/252.3, 254.11, 320.1, 325, 440; 536/23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/252.3, 254.11, 320.1, 325, 440; 536/23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

GenBank, EMBL, SwissProt, Pir, Genesearch
search terms: SEQ ID NOs: 11-20, 48-57

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. W32308, HILLIER et al., 'The WashU-Merck EST Project', complete record, 11 October 1996.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA774284, HILLIER et al., 'WashU-NCI human EST Project', complete record, 29 January 1998.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA613279, NCI-CGAP, 'National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index', complete record, 16 October 1997.	1, 7-10

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 MAY 1999

Date of mailing of the international search report

02 JUN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized Officer

SCOTT D. PRIEBE

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/03939

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA643974, NCI-CGAP, 'National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index', complete record, 27 October 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. T85021, HILLIER et al., 'The WashU-Merck EST Project', complete record, 17 March 1995.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA427866, HILLIER et al., 'WashU-Merck EST Project 1997', complete record, 16 October 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA446322, HILLIER et al., 'WashU-Merck EST Project 1997', complete record, 03 June 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA496985, HILLIER et al., 'WashU-Merck EST Project 1997', complete record, 12 August 1997.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. AA001029, HILLIER et al., 'The WashU-Merck EST Project', complete record, 29 November 1996.	1, 7-10
X	Database GenBank, US National Library of Medicine, (Bethesda, MD, USA), No. T70779, HILLIER et al., 'The WashU-Merck EST Project', complete record, 15 March 1995.	1, 7-10

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/03939

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10, 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups I-VIII, claim(s) 1-10 and 21, drawn to a polynucleotide, vector comprising same, first claimed method of use, i.e. using polynucleotide to make a cell, and the cell made by the process. Claims 1-10 and 21 recite 37 independent polynucleotides (SEQ ID NO: 11-47 or encoding SEQ ID NO: 48-84). Group I consists of the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 48-57). Each of groups II-VIII consists of up to four of the remaining 27 polynucleotides, in order.

Groups IX-XLV, claim(s) 11, 12, 14-16 and 17 (first part), drawn to a polypeptide, a method of making the polypeptide and first claimed method of use, i.e. in treatment. These claims recite 37 independent polypeptides, each of groups IX-XLV consists of a single polypeptide as set forth in SEQ ID NOs 48-84, respectively.

Groups XLVI-LXXXII, claim(s) 13 and 19, drawn to an antibody to a polypeptide and the first claimed method of using same. These claims recite 37 independent antibodies to 37 independent polypeptides, each of groups XLVI-LXXXII consists an antibody against a single polypeptide as set forth in SEQ ID NOs 48-84, respectively.

Groups LXXXIII-XC, claim(s) 17(second part), drawn to an additional method of using a polynucleotide. Group LXXXIII consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 48-57). Each of groups LXXXIV-XC pertains to up to four of the remaining 27 polynucleotides, in order.

Groups XCI-XCVIII, claim(s) 18, drawn to a second additional method of using a polynucleotide. Group XCI consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 48-57). Each of groups XCII-XCVIII pertains to up to four of the remaining 27 polynucleotides, in order.

Groups IC-CXXXV, claim(s) 20, drawn to an additional method of using the polypeptide. These claims recite 37 independent methods of using 37 independent polypeptides, each of groups IC-CXXXV consists a method of using a single polypeptide as set forth in SEQ ID NOs 48-84, respectively.

Groups CXXXVI-CXLIII, claim 22, drawn to a third additional method of using a polynucleotide. Group CXXXVI consists of methods reciting the first ten polynucleotides (SEQ ID NOs 11-20 or encoding SEQ ID NOs 48-57). Each of groups CXXXVII-V pertains to up to four of the remaining 27 polynucleotides, in order.

Claim 23 is unsearchable and cannot be grouped as it is drawn to unknown and unspecified compounds.

The inventions listed as Groups I-CXLIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Each of the corresponding polynucleotides, polypeptides and antibodies are independent products, with different uses and being structurally, biochemically and biologically different products. In additional or alternate methods of use are claimed for individual polynucleotides and polypeptides. 37 CFR 1.475(b) does not provide for unity of invention of more than 1 product or more than one method of using a product as a combination of invention having unity of invention. However, with respect to groups drawn to independent polynucleotides or alternate methods of using same recited in the alternative, in accordance with 1192 O.G. 68 (19 November 1966) applicant is entitled to an initial search of inventions pertaining to the first ten independent polynucleotides recited, and may elect to pay an additional fee for each search of up to four additional independent polynucleotides. For additional method of using each of the independent polynucleotides, applicant may further elect to pay an additional fee for an additional search involving the first ten polynucleotides and each additional search involving up to four additional polynucleotides. With respect to groups pertaining to independent polypeptides or antibodies to the independent polypeptides, each product or method of use is an additional invention. An additional fee must be paid for search of each additional invention relating to polypeptides or antibodies against same. With respect to the relationship between the claimed polynucleotides and the claimed polypeptides, there is no one-to-one correspondence, i.e. no corresponding scope, between claims drawn to polynucleotides and their use and those drawn to polypeptides, antibodies and their use. Consequently, there is no special technical feature linking the polynucleotides and the polypeptides or antibodies claimed.

Only Group I, the first ten polynucleotides of SEQ ID NOs 11-20 or encoding SEQ ID NOs 48-57, was searched.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>65</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>February 12, 1998</u>	Accession Number <u>209626</u>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
EUROPE In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p style="text-align: center;">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> This sheet was received with the international application PERRY HACKLEY INTERNATIONAL DIVISION Authority <u>03-045-6517</u> PERRY HACKLEY@USPTO.GOV </div>	<p style="text-align: center;">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer: </div>
--	---

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

THIS PAGE BLANK (USPTO)